

00014935152-24-04589410-Q Glucotrack, Inc. 202411142024111461550161550161550 0 000149352-24-045894 10-Q 46 20240930 20241114 20241114 Glucotrack, Inc. 0001506983 3841 980668934 DE 1231 10-Q 34 001-41141 241462551 301 RT 17 NORTH SUITE 800 RUTHERFORD NJ 07070

Glucotrack, Inc. 20220328 Integrity Applications, Inc. 20101203 10-Q 1 form10-q.htm false Q3 -12-31 0001506983 P5Y P10Y P10Y 0001506983 2024-01-01 2024-09-30 0001506983 2024-11-03 0001506983 2024-09-30 0001506983 2023-12-31 0001506983 2024-07-01 2024-09-30 0001506983 2023-07-01 2023-09-30 0001506983 2023-01-01 2023-09-30 0001506983 us-gaap:CommonStockMember 2022-12-31 0001506983 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001506983 GCTK:ReceiptsOnAccountOfSharesMember 2022-12-31 0001506983 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001506983 us-gaap:RetainedEarningsMember 2022-12-31 0001506983 2022-12-31 0001506983 us-gaap:CommonStockMember 2023-06-30 0001506983 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001506983 GCTK:ReceiptsOnAccountOfSharesMember 2023-06-30 0001506983 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001506983 us-gaap:RetainedEarningsMember 2023-06-30 0001506983 2023-06-30 0001506983 us-gaap:CommonStockMember 2023-12-31 0001506983 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001506983 GCTK:ReceiptsOnAccountOfSharesMember 2023-12-31 0001506983 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001506983 us-gaap:RetainedEarningsMember 2023-12-31 0001506983 us-gaap:CommonStockMember 2024-06-30 0001506983 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001506983 GCTK:ReceiptsOnAccountOfSharesMember 2024-06-30 0001506983 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001506983 us-gaap:RetainedEarningsMember 2024-06-30 0001506983 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001506983 GCTK:ReceiptsOnAccountOfSharesMember 2024-07-01 2024-09-30 0001506983 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001506983 GCTK:ReceiptsOnAccountOfSharesMember 2024-07-01 2024-09-30 0001506983 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0001506983 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001506983 us-gaap:CommonStockMember 2023-09-30 0001506983 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001506983 GCTK:ReceiptsOnAccountOfSharesMember 2023-09-30 0001506983 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001506983 us-gaap:RetainedEarningsMember 2023-09-30 0001506983 us-gaap:CommonStockMember 2024-09-30 0001506983 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001506983 GCTK:ReceiptsOnAccountOfSharesMember 2024-09-30 0001506983 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001506983 us-gaap:RetainedEarningsMember 2024-09-30 0001506983 us-gaap:IPOMember 2023-01-01 2023-12-31 0001506983 us-gaap:PrivatePlacementMember 2024-01-01 2024-09-30 0001506983 us-gaap:WarrantMember 2024-01-01 2024-09-30 0001506983 GCTK:PrefundedWarrantsMember 2024-07-01 2024-09-30 0001506983 GCTK:PrefundedWarrantsMember 2023-07-01 2023-09-30 0001506983 GCTK:PrefundedWarrantsMember 2024-01-01 2024-09-30 0001506983 GCTK:AugustTwentyThreeWarrantOneMember 2024-08-23 0001506983 GCTK:AugustTwentyThreeWarrantTwoMember 2024-08-23 0001506983 GCTK:AugustTwentyThreeWarrantThreeMember 2024-08-23 0001506983 GCTK:PerformanceMilestoneMember 2024-07-01 2024-09-30 0001506983 GCTK:PerformanceMilestoneMember 2023-07-01 2023-09-30 0001506983 GCTK:PerformanceMilestoneMember 2024-01-01 2024-09-30 0001506983 GCTK:PerformanceMilestoneMember 2023-01-01 2023-09-30 0001506983 GCTK:ExchangeAgreementMember 2024-02-13 2024-02-13 0001506983 us-gaap:LeaseAgreementsMember 2024-02-19 2024-02-19 0001506983 us-gaap:LeaseAgreementsMember 2024-02-19 0001506983 2024-02-19 0001506983 us-gaap:PrivatePlacementMember 2024-04-22 2024-04-22 0001506983 us-gaap:PrivatePlacementMember 2024-04-22 2001506983 2024-04-30 2024-04-30 0001506983 GCTK:UnsecuredPromissoryNotesMember 2024-06-27 0001506983 2024-06-27 0001506983 2024-06-27 0001506983 us-gaap:ConvertibleNotesPayableMember 2024-07-18 0001506983 us-gaap:ConvertibleNotesPayableMember 2024-07-18 0001506983 GCTK:ConvertiblePromissoryNotesMember 2024-07-30 2024-07-30 0001506983 GCTK:FirstWarrantMember 2024-07-30 2024-07-30 0001506983 GCTK:SecondWarrantMember 2024-07-30 2024-07-30 0001506983 GCTK:ThirdWarrantMember 2024-07-30 2024-07-30 0001506983 GCTK:ThirdWarrantMember 2024-07-30 2024-07-30 0001506983 GCTK:JuneTwentySevenNotesMember 2024-08-23 2024-08-23 0001506983 GCTK:JuneTwentySevenNotesMember 2024-08-23 2001506983 us-gaap:SubsequentEventMember 2024-10-15 2024-10-15 0001506983 GCTK:AugustTwentyThreeWarrantOneMember 2024-08-23 2024-08-23 0001506983 GCTK:AugustTwentyThreeWarrantTwoMember 2024-08-23 2001506983 GCTK:AugustTwentyThreeWarrantThreeMember 2024-08-23 0001506983 GCTK:JulyThirteenNotesMember 2024-01-01 2024-09-30 0001506983 GCTK:LessThanOneYearMember 2024-09-30 0001506983 GCTK:BetweenOneYearToTwoYearsMember 2024-09-30 0001506983 GCTK:MoreThanTwoYearsMember 2024-09-30 0001506983 GCTK:JuneTwentySevenWarrantsMember 2023-12-31 0001506983 GCTK:JuneTwentySevenWarrantsMember 2024-09-30 0001506983 GCTK:JulyEighteenNotesMember 2024-09-30 0001506983 GCTK:JulyThirtyNotesMember 2024-01-01 2024-09-30 0001506983 GCTK:JulyThirtyNotesMember 2024-09-30 0001506983 GCTK:IsraelInnovationAuthorityMember 2004-03-04 0001506983 GCTK:IsraelInnovationAuthorityMember srt:MinimumMember 2004-03-04 2004-03-04 0001506983 GCTK:IsraelInnovationAuthorityMember srt:MaximumMember 2004-03-04 2004-03-04 0001506983 GCTK:IsraelInnovationAuthorityMember 2004-03-04 0001506983 GCTK:IsraelInnovationAuthorityMember 2024-09-30 0001506983 GCTK:IntellectualPropertyPurchaseAgreementMember us-gaap:CommonStockMember 2022-10-07 2022-10-07 0001506983 GCTK:IntellectualPropertyPurchaseAgreementMember us-gaap:CommonStockMember srt:MinimumMember 2022-10-07 2022-10-07 0001506983 GCTK:IntellectualPropertyPurchaseAgreementMember us-gaap:CommonStockMember srt:MinimumMember 2022-10-07 2022-10-07 0001506983 GCTK:TrueUpSharesMember 2022-10-07 0001506983 2023-06-01 2023-06-20 0001506983 2024-05-01 2024-05-31 0001506983 us-gaap:SubsequentEventMember 2024-11-12 2024-11-12 0001506983 us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2024-11-12 0001506983 us-gaap:SubsequentEventMember GCTK:PrefundedWarrantsMember 2024-11-12 0001506983 us-gaap:SubsequentEventMember GCTK:SeriesACommonWarrantMember 2024-11-12 0001506983 us-gaap:SubsequentEventMember GCTK:SeriesBCommonWarrantMember 2024-11-12 0001506983 us-gaap:SubsequentEventMember GCTK:SeriesCCommonWarrantMember 2024-11-12 0001

transation adjustment) 17A(6) 11A(17) AAAAAAAAAAAAAAA Comprehensiv loss for the period\$5,104.4 \$2,217.4 \$12,514.4 \$4,668A AAAAAAAAA
Basic and diluted net loss per common stock\$(0.91)\$ (0.49)\$ (2.39)\$ (1.38) AAAAAAAAAAAAAAA Weighted average number of common stock
used in computing basic and diluted loss per common stock\$5,594,880A \$4,593,733A \$4,355,806A \$4,006,527A The accompanying notes are an integral part of these
condensed interim consolidated financial statements. 5 A GLUCOTRACK INC. CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (in thousands
of US Dollars except share data) (unaudited) AAAAAAAAAAAAAAA In thousands of US Dollars (except share data) A Common Stock Additional A
Receipts Accumulated OtherA Total Stockholders' Numbers of SharesA AmountA Paid-in CapitalA on account of sharesA Comprehensive IncomeA
Accumulated DeficitA Equity (Deficit) AAAAAAAAAAAAAAA Balance as of January 1, 2023A AAAA 3,099,982A \$3A \$103,107A \$4A \$17A
\$(101,901)A \$1,230A Loss for the periodA -A -A -A -A -A -A -A (4,685)A (4,685) Other comprehensive incomeA -A -A -A -A -A 17A A -A A 17A
Stock-based compensationA -A A -A A 260A AAAAAAAAA -A A -A A 260A Deemed dividend resulted from trigger of down round protection feature of certain warrants grantedA -
A A -A A 855A A -A A -A (855)A -A Issuance of Common Stock and pre-funded warrants upon completion of public offering, net of offering expensesA 1,075,294A A 1A A
\$8,729A A -A A -A A 8,730A Issuance of restricted shares as compensation towards directorsA 2,998A A -(*)A A 9A A (4)A A -A A -A A 5A Balance as of
September 30, 2023A 4,178,274A \$4A \$112,960A -\$A \$34A \$(107,441)A \$5,557A AAAAAAAAAAAAAAA AAAAAAAAAAAAAAA Balance at July 1, 2023A
4,178,274A \$4A \$112,929A -\$A \$28A \$(105,218)A \$7,743A Loss for the periodA -A A -A A -A A -A A -A (2,223)A (2,223) Other comprehensive incomeA -
A A -A A -A A 6A A -A A 6A Stock-based compensationA -A A -A A 31A A -A A -A A 31A Balance as of September 30, 2023A 4,178,274A \$4A
\$112,960A -\$A \$34A \$(107,441)A \$5,557A AAAAAAAAAAAAAAA AAAAAAAAAAAAAAA AAAAAAAAAAAAAAA Balance as of January 1, 2024A 4,178,274A \$4A \$112,982A
\$48A \$16A \$(109,853)A \$3,197A Loss for the periodA -A A -A A -A A -A A -A (12,503)A AAAAAAAAAAAAAAA (12,503) Other comprehensive incomeA -A A -A A -A A -
A A -A A (11)A A -A A (11) Stock-based compensationA -A A -A A 239A A -A A -A A 239A Issuance of restricted shares as compensation towards directorsA
\$8,861A A -(*)A A 126A A (48)A A -A A -A 78A Restricted shares to be issued as compensation towards directorsA -A A -A A -A A 100A A -A A -A A 100A
Exercise of prefunded warrants into shares (Note 3A) A 395,294A A -(*)A A -A A -A A -A Exchange of warrants into shares (Note 3B) A 718,641A A 1A A (1)A
A -A A -A A -A Issuance of Common Stock upon private placement transaction (Note 3D) A 79,366A A -(*)A A 500A A -A A -A A 500A Issuance of detachable
warrants through private placement transactions (Note 3F and Note 3H) A -A A -A 2,635A A -A A -A 2,635A Issuance of shares and warrants as settlement of financial
liabilities (Note 3I and Note 3J) A 293,590A A 1A A 1,742A A -A A -A A -A 1,743A Issuance of restricted shares as payment for a previous achievement of milestone pursuant
to purchase agreement (Note 4B) A 20,000A A -A A -A A -A A -A A -A Balance as of September 30, 2024A 5,772,026A \$6A \$118,223A \$100A \$5A
\$(122,356)A (4,022) AAAAAAAAAAAAAAA AAAAAAAAAAAAAAA AAAAAAAAAAAAAAA Balance as of July 1, 2024A 5,478,436A \$5A \$113,903A \$50A \$22A \$(117,269)A (\$3,289)
Balance A 5,478,436A \$5A \$113,903A \$50A \$22A \$(117,269)A (\$3,289) Loss for the periodA -A A -A A -A A -A A -A (5,087)A (5,087) Other comprehensive
incomeA -A A -A A -A A -A (17)A A -A A (17) Stock-based compensationA -A A -A A 11A A -A A -A A 11A Restricted shares to be issued as compensation
towards directorsA -A A -A A -A A 50A A -A A -A 50A Issuance of detachable warrants through private placement transactions (Note 3F and Note 3H) A -A A -A
2,567A A -A A -A A 2,567A Issuance of shares and warrants as settlement of financial liabilities (Note 3I and Note 3J) A 293,590A A 1A A 1,742A A -A A -A A -A
A 1,743A Balance as of September 30, 2024A 5,772,026A \$6A \$118,223A \$100A \$5A \$(122,356)A (4,022) BalanceA 5,772,026A \$6A \$118,223A \$100A
\$5A \$(122,356)A (4,022) A (*) Represents amount lower than \$1. A The accompanying notes are an integral part of these condensed interim consolidated financial statements. 6 A
GLUCOTRACK INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands of US Dollars) (Unaudited) A A 2024A 2023A A Nine-month period ended
September 30,A A 2024A 2023A A A CASH FLOWS FROM OPERATING ACTIVITIESA AAAAAAAAA Loss for the periodA \$(12,503)A \$(4,685) Adjustments to reconcile net loss to
net cash used in operating activities:A AAAAAAAAA DepreciationA 22A A 21A Stock-based compensationA 239A A 260A Issuance of restricted shares as compensation towards
directorsA 178A A 5A Linkage difference on principal of loans from stockholdersA 1A A 4A Revaluation expenses incurred from settlement of financial liabilities (Note 3I and Note
3J) A 1,505A A -A Revaluation expenses related to derivative financial liabilities (Note 3H) A 2A A -A Discount amortization and interest expenses related to promissory notes (Note
3F, Note 3G and Note 3H) A 330A A -A Changes in assets and liabilities:A AAAAAAAAA Other current assetsA 80A A (216) Accounts payableA 1,129A A 598A Other current
liabilitiesA 26A A (134) Net cash used in operating activitiesA (8,991)A (4,147) AAAAAAAAA CASH FLOWS FROM INVESTING ACTIVITIES:A AAAAAAAAA Purchase of
property and equipmentA (104)A A -A Net cash used in investing activitiesA (104)A A -A AAAAAAAAA CASH FLOWS FROM FINANCING ACTIVITIES:A AAAAAAAAA Proceeds
received from private placement transaction (Note 3D) A 500A A -A Issuance of promissory notes and detachable warrants through private placement transaction (Note 3F) A 100A A -
A Issuance of convertible promissory notes and bifurcated conversion feature through private placement transaction (Note 3G) A 360A A -A Issuance of convertible promissory note,
bifurcated conversion and redemption features and detachable warrants through private placement transaction (Note 3H) A 4,000A A -A Net proceeds received from underwritten U.S.
public offeringA -A A 8,730A Net cash provided by financing activitiesA 4,960A A 8,730A AAAAAAAAA Effect of exchange rate changes on cash and cash equivalents, and
restricted cashA (11)A (17) AAAAAAAAA Change in cash and cash equivalents, and restricted cashA (4,146)A 4,566A AAAAAAAAA Cash and cash equivalents, and
restricted cash at beginning of the periodA 4,502A A 2,331A AAAAAAAAA Cash and cash equivalents, and restricted cash, end of periodA 356A \$6,897A AAAAAAAAA
Supplemental disclosure of cash flow activities:A AAAAAAAAA (a) Net cash (received) paid during the year for:A AAAAAAAAA InterestA \$(37)A \$-
A A AAAAAAAAA (b) Non-cash investment and financing activities:A AAAAAAAAA Deemed dividend upon trigger of down round protectionA -\$A 855A
Recognition of right for use asset against a lease liability (Note 3C) \$79A \$-A Issuance of shares and warrants as settlement of financial liabilities (Note 3I and Note 3J) \$238A \$-A
The accompanying notes are an integral part of these condensed interim consolidated financial statements. 7 A GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED
FINANCIAL STATEMENTS (UNAUDITED) (in thousands of US Dollars, except share and per share data) A NOTE 1 - GENERAL A Glucotrack Inc. (the "Company") was incorporated on
May 18, 2010 under the laws of the State of Delaware. The Company is a medical device company, focused on development of an Implantable Continuous Glucose Monitor (CGM) for persons
with Type 1 diabetes and insulin-dependent Type 2 diabetes (the "Glucotrack CBGM Product"). A B. Liquidity and capital resources A To date, the Company has not yet
commercialized the Glucotrack CBGM Product. Further development and commercialization efforts are expected to require substantial additional expenditure. Therefore, the Company is
dependent upon external sources for financing its operations. As of September 30, 2024, the Company has incurred an accumulated deficit of \$122,356. In addition, the Company has generated
operating losses and negative operating cash flow for all reported periods. As of September 30, 2024, the balance of cash and cash equivalents amounted to \$346, together with the net
proceeds in total amount of \$8,873 which expected to be received upon closing of a public offering through registration statements on Form S-1 (see also Note 6 below) on November 14, 2024.
A A During the year ended December 31, 2023, the Company raised net proceeds of \$8,730 through completion of underwritten public offering. Moreover, during the period of nine months
ended September 30, 2024, the Company entered into (i) exchange agreement with certain shareholders under which warrants with down round protection feature have been exchanged into
shares of common stock in order to facilitate its equity structure (see also Note 3B below), (ii) private placement agreement under which the Company raised proceeds of \$500 (see also Note 3D
below), (iii) unsecured promissory notes and warrant agreements under which the Company raised proceeds of \$100 (see also Note 3F below), (iv) unsecured promissory notes under which the
Company raised proceeds of \$360 (see also Note 3G below), (v) secured promissory note and warrant agreements under which the Company raised proceeds of \$4,000 (see also Note 3H below)
and (vi) conversion agreements under which certain financial liabilities have been settled for issuance of shares of common stock and warrants of the Company (see also Note 3I and Note 3J
below). A The Company plans to finance its operations through the sale of equity securities (including shelf registration statement on Form S-3 was declared effective on October 3, 2023 by the
Securities and Exchange Commission (SEC) which allows the Company to register up to \$30,000 of certain equity and/or debt securities of the Company through prospectus supplement) and/or
debt securities. There can be no assurance that the Company will succeed in obtaining the necessary financing or generating sufficient revenue from sale of its Glucotrack CBGM Product in
order to continue its operations as a going concern. A Management has considered the significance of such conditions in relation to the Company's ability to meet its current obligations and
to achieve its business targets and determined that these conditions raise substantial doubt about the Company's ability to continue as a going concern. A The condensed interim
consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. A 8 A GLUCOTRACK INC. NOTES TO CONDENSED
CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (in thousands of US Dollars) A NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES A Basis of Presentation A The
accompanying unaudited condensed interim consolidated financial statements and related notes should be read in conjunction with the Company's consolidated financial statements and
related notes included in the Company's annual report on Form 10-K for the fiscal year ended December 31, 2023, as was filed with the Securities and Exchange Commission ("SEC") on
March 28, 2024. The unaudited condensed interim consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC related to interim financial
statements. As permitted under those rules, certain information and footnote disclosures normally required or included in financial statements prepared in accordance with U.S. GAAP have
been condensed or omitted. The financial information contained herein is unaudited; however, management believes all adjustments have been made that are considered necessary to present
fairly the results of the Company's financial position and operating results for the interim periods. All such adjustments are of a normal recurring nature. A A The results for the period of
three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024 or for any other interim period or for any
future period. A B. Use of Estimates in the Preparation of Financial Statements A The preparation of the financial statements in conformity with U.S. GAAP requires management to make
estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements, and the
reported amounts of expenses during the reporting periods. Actual results could differ from

lease payments. The Company's 1% IBR is estimated to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic environments where the leased asset is located. The ROU asset also includes any lease payments made prior to commencement and is recorded net of any lease incentives received. Moreover, the ROU asset may also include initial direct costs, which are incremental costs of a lease that would not have been incurred if the lease had not been obtained. The Company uses the long-lived assets impairment guidance in ASC 360-10, "Property, Plant, and Equipment - Overall," to determine whether a ROU asset is impaired, and if so, the amount of the impairment loss to recognize. Certain leases include options to extend or terminate the lease. An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain that the Company will exercise that option. An option to terminate is considered unless it is reasonably certain that the Company will not exercise the option. A 11 A GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (in thousands of US Dollars) A NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.) A J. Basic and diluted loss per share A Basic loss per share is computed by dividing the loss for the period applicable (after considering the effect of deemed dividend related to trigger of down round protection feature) for Common Stockholders by the weighted average number of shares of Common Stock outstanding and shares of Common Stock to be issued upon achievement of certain performance milestones during the period and upon exercise of pre-funded warrants. In computing, diluted loss per share, basic earnings per share are adjusted to reflect the potential dilution that could occur upon the exercise of options or warrants issued or granted using the treasury stock method and using the if-converted method with respect to certain convertible promissory notes and bifurcated redemption feature accounted for as derivative financial liability, if the effect of each of such financial instruments is dilutive. In computing diluted loss per share, the average stock price for the period is used in determining the number of Common Stock assumed to be purchased from the proceeds to be received from the exercise of stock options or stock warrants. A Shares to be issued upon exercise of all options and warrants, convertible promissory notes and bifurcated redemption feature, have been excluded from the calculation of the diluted net loss per share for all the reported periods for which net loss was reported because the effect of the common shares issuable as result of the exercise or conversion of these instruments was anti-dilutive. A The net loss and the weighted average number of shares of Common Stock used in computing basic and diluted net loss per Common Stock for the period of three and nine months ended September 30, 2024 and 2023, is as follows: A SCHEDULE OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE A 2024 A 2023 A 2024 A 2023 A A US dollars (except share data) A US dollars (except share data) A Three-month period ended September 30, A Nine-month period ended September 30, A (Unaudited) A (Unaudited) A 2024 A 2023 A 2024 A 2023 A A Numerator: A Net loss A \$,087 A \$,223 A \$12,503 A \$4,685 A Deemed dividend related to trigger of down round protection feature A - A - A 855 A Net loss attributable to common stockholders A \$,087 A \$2,223 A \$12,503 A \$4,685 A \$5,540 A Denominator: A Shares of Common Stock used in computing basic and diluted net loss per common stock A 5,564,880 A 5,493,733 A 5,340,532 A 3,758,590 A Shares of Common Stock to be issued upon exercise of pre-funded warrants A - A - A A 241,266 A Shares of Common Stock to be issued upon achievement of performance milestones A 30,000 A - A 15,275 A 6,691 A Weighted average number of Common Stock outstanding used in computing basic and diluted net loss per share A 5,594,880 A 5,493,733 A 5,355,806 A 4,006,527 A Basic and diluted net loss per common stock A \$(0.91) A \$(2.39) A \$(1.38) A 12 A GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.) (in thousands of US Dollars) A NOTE 3 - SIGNIFICANT TRANSACTIONS A A. Exercise of pre-funded warrants A On January 3, 2024, 395,294 pre-funded warrants granted through underwritten public offering in April 2023 have been fully exercised into the same number of shares of Common Stock of the Company. A B. Exchange Agreement A On February 13, 2024, the Company entered into an Exchange Agreement with certain warrant holders (the "Holders"), pursuant to which the Company and the Holders agreed to exchange (the "Exchange") warrants with down round protection feature exercisable to common shares (the "Warrants") owned by the Holders for shares of Common Stock to be issued by the Company. On February 15, 2024, 718,641 shares of Common Stock have been issued in exchange for 876,391 Warrants (the "Shares"). A It was also agreed that the Holders will not, during the period (the "Lock-Up Period") (i) offer, pledge, announce the intention to sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any Shares, (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Shares of, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Shares or such other securities, in cash or otherwise, (iii) make any demand for or exercise any right with respect to, the registration of any Shares or any security convertible into or exercisable or exchangeable for shares of common stock, or (iv) publicly announce an intention to effect any transaction specific in clause (i), (ii) or (iii) above, provided that the Holder, during the Lock-Up Period, may (a) sell or contract to sell Shares at a price higher than \$0.50 per Share on any trading day up to 10% of the daily volume of Shares or (b) sell or contract to sell Shares at a price higher than \$0.80 per Share on any trading day with no volume limitation. A The Lock-Up Period shall expire at the earliest of (i) 365 days after the date hereof or (ii) until the Shares traded above \$1.00 per Share for five consecutive trading days. A The Company accounted for the Exchange of the aforesaid warrants with shares as deemed dividend which was calculated at the closing date by the management using the assistance of external appraiser as the excess of fair value of the share to be issued after taking into consideration a discount for lack of marketability at a rate of 16.81% over the Lock-Up Period over the fair value of the original equity instrument (i.e. warrants which included down round protection feature). However, since the fair value of the new equity instrument (common shares) was estimated as lesser than the fair value of the replaced equity instrument, deemed dividend was not recorded. A C. Lease Agreement A On February 19, 2024, the Company entered into Lease Agreement (the "Lease") with Tapsack Enterprises LLC dba Virginia Analytical (the "Landlord") under which it was agreed that the Company will lease from the Landlord a premises located in Front Royal, Virginia area for a monthly rental fee of \$2.5 over a period of 3-years commencing March 1, 2024 through February 28, 2027 (the "Initial Lease Period"). Security deposit of \$2.5 which represents payment of one month is held by the Landlord which will be returned to the Company at the end of the Initial Lease Period. A In addition, the Company has an option to renew the Initial Lease Period for another two additional periods of 3-years each following the Initial Lease Period (the "Option Term"), following advanced notice as defined in the Agreement. The monthly rental fee over the Option Term shall be the fair market rate determined as what is a comparable cost for similar property in Front Royal, Virginia area. A In accordance with the provision of ASC 842, Leases, at the commencement date of the Agreement, the Company recognized the right to use asset equals to lease liability in total amount of \$79. The lease liability was measured at the present value of the future lease payments, which are discounted based on an estimate of the incremental interest rate that the Company would be required to pay to borrow a similar amount for a similar period in order to obtain a similar amount on the initial recognition date of the lease. A As part of the leasing period, the Company considered only the Initial Lease Period as the realization of the option to extend the period was not considered as reasonably certain. A 13 A GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.) (in thousands of US Dollars) A NOTE 3 - SIGNIFICANT TRANSACTIONS (CONT.) A C. Lease Agreement (Cont.) A Operating lease: A A SCHEDULE OF OPERATING LEASE A September 30, 2024 A Operating right-of-use asset A 65 A Current operating lease liability A 25 A Non-Current operating lease liability A 40 A Maturity analysis of the Company's lease liability: A A SCHEDULE OF MATURITY ANALYSIS OF LEASE LIABILITY A September 30, 2024 A Less than one year A 30 A Between 1-2 years A 30 A More than 2 years A 13 A Total operating lease payments A 73 A Less: imputed interest A 8 A Present value of lease liabilities A 65 A Additional information on lease A The following is a summary of the weighted average remaining lease terms and discount rate for the lease: A A SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERMS AND DISCOUNT RATE A September 30, 2024 A Lease term (years) A 2.42 A Weighted average discount rate A 9.03 A D. Private Placement Agreement A On April 22, 2024, the Company entered into a private placement agreement under which the Company issued 79,366 shares of its common stock at a price of \$6.30 per share for aggregate gross proceeds of \$500 (the "Offering"). The Offering included participation of certain members of the Company's executive management, Board of Directors and existing shareholders. A E. Adoption of 2024 Equity Incentive Plan and Reverse Share Split A On April 26, 2024, the Company held its Annual Meeting of Shareholders (the "Annual Meeting") under which the Company's stockholders approved, inter alia, the following proposals: (i) adoption of the Company's 2024 Equity Incentive Plan and (ii) an amendment to Article IV of the Company's Certificate of Incorporation, to effect a reverse stock split of the Company's Common Stock at a ratio of between one-for-five and one-for-thirty, with such ratio to be determined at the sole discretion of the Board of Directors. Following the Annual Meeting, on April 30, 2024, the Company's Board of Directors approved a one-for-five reverse stock split of the Company's issued and outstanding shares of common stock (the "Reverse Stock Split"). On May 17, 2024, the Company filed a Certificate of Amendment to the Company's Certificate of Incorporation with the Secretary of State of the State of Delaware which effected the Reverse Stock Split. A For accounting purposes, all shares, options and warrants to purchase shares of common stock and loss per share amounts have been adjusted to give retroactive effect to the Reverse Share Split for all periods presented in these interim consolidated financial statements. Any fractional shares resulting from the Reverse Share Split were rounded up to the nearest whole share. A 14 A GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.) (in thousands of US Dollars) A NOTE 3 - SIGNIFICANT TRANSACTIONS (CONT.) A F. Note and Warrant Purchase Agreements A On June 27, 2024, the Company entered into note and warrant purchase agreements (the "Purchase Agreement") with certain investors (the "June 27 Investors"), providing for the private placement of unsecured promissory notes in the aggregate principal amount of \$100 (the "June 27 Notes") and each a "June 27 Note") and warrants to purchase up to an aggregate of 300,000 shares of the Company's Common Stock (the "June 27 Warrants"). A The June 27 Notes bear simple interest at a rate of 3% per annum and are due and payable in cash on the earlier of: (a) 12 months from the date of the June 27 Note; or (b) the date the Company raises third-party equity capital in an amount equal to or in excess of \$1,000 (the "Maturity Date"). The Company may prepay the June 27 Notes at any time prior to the Maturity Date without penalty. If an event of default occurs, the then-outstanding principal amount of the June 27 Notes plus any unpaid accrued interest will accelerate and become immediately payable in cash. A Each of June 27 Warrants has an exercise price of \$4.95 per share. The June 27 Warrants are immediately exercisable and have a 5-year term. A Upon initial recognition, the management allocated the gross cash proceeds received based on the relative fair value of the June 27 Notes and the detachable June 27 Warrants in total amount of \$15 and \$85, respectively. The fair value of the June 27 Note was determined based on a rating model using a debt discount rate of 28.65% which represented the Company's applicable rate of risk. The fair value of the June 27 Warrants was determined by using Black-Scholes pricing model taking into account, inter alia, expected stock price volatility of 245% and risk-free interest rate of 4.52%. The amount allocated to June 27 Warrants was classified as a component of permanent equity (as their terms permit the holders to receive a fixed number of shares of common stock upon exercise for a fixed exercise price). A The June 27 Notes are accounted for as a financial liability measured at amortized cost. In subsequent periods, the Company recognized a discount and interest expense over the economic life of the June 27 Notes based on the effective interest rate method. A The following tabular presentation reflects the reconciliation of the carrying amount of the June 27 Notes during the period of nine months ended September 30, 2024: A A SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JUNE 27 NOTES A A Nine-month period ended September 30, 2024 A A (Unaudited) A Open balance \$- A Total proceeds received A 100 A Total proceeds allocated to June 27 Warrants at initial recognition A (85) A Discount amortization and interest expenses related to June 27 Notes (Note 5 below) A 16 A Partial conversion June 27 Notes and accrued Interest (Note 3I and Note 3J below) A (26) A Ending balance A 5 A During the period commencing the issuance date through September 30, 2024, none of the June 27 Warrants have been exercised. A 15 A GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.) (in thousands of US Dollars) A NOTE 3 - SIGNIFICANT TRANSACTIONS (CONT.) A G. Convertible Promissory Notes A On July 18, 2024, the Company entered into a series of convertible promissory notes with three directors, and one member of the Company's executive management (the "July 18 Investors"), providing for the private placement of unsecured convertible promissory notes in the aggregate principal amount of \$360 (the "July 18 Notes") and each a "July 18 Note". A The July 18 Notes bear simple interest at a rate of 8% per annum. Interest on the outstanding principal will accrue and, unless converted earlier as set forth below, be due and payable on (i) the 12-month anniversary of the date hereof, or (ii) the closing date of a Qualified Financing, as defined herein (the "Maturity Date"). A Except regarding the conversion of the July 18 Notes as discussed below, the Company may not prepay the July 18 Notes without the written consent of the July 18 Investors. If not sooner repaid, all outstanding principal and accrued but unpaid interest on the July 18 Notes (the "July 18 Note Balance"), as of the close of business on the day immediately preceding the date of the closing of the next issuance and sale of capital stock of the Company, in a single transaction or series of related transactions, to investors resulting in gross proceeds to the Company of at least \$500 (excluding indebtedness converted in such financing) (a "Qualified Financing"), will automatically be converted into that number of shares of equity securities of the Company sold in the Qualified Financing equal to the number of shares calculated by dividing (X) the July 18 Note Balance by (Y) an amount equal to the price per share or other unit of equity securities issued in such Qualified Financing, and otherwise on the same terms as the security issued in the Qualified Financing, provided that the conversion price per share shall not be lower than \$1.56. A Upon the occurrence of an Event of Default (as defined below), each July 18 Investors may, by written notice to the Company, declare the July 18 Note to be

of the surviving corporation or its parent. Upon the occurrence of an Event of Default (defined below), the July 30 Note Holder may, at written notice to the Company, declare the Note to be due immediately and payable with respect to the July 30 Note balance. An "Event of Default" means (i) failure by the Company to pay the July 30 Note balance on the Maturity Date, (ii) the Company becomes subject to a judgement of more than \$50,000, (iii) voluntary bankruptcy, or (iv) involuntary bankruptcy. Upon the occurrence of an Event of Default specified in clause (iii) above, the July 30 Note balance shall automatically and immediately become due and payable, in all cases without any action on the part of the July 30 Holder. Each July 30 Warrant becomes exercisable 12 months after its issuance and has term of 10 years. The July 30 Warrants are exercisable for cash only and have no price-based antidilution. The first July 30 Warrant is for 2,133,334 shares at \$1.875 per share. The second July 30 Warrant is for 1,523,810 shares at \$2.625 per share. The third July 30 Warrant is for 1,185,186 shares at \$3.375 per share. At the initial date, the Company has issued two instruments that include (i) a financial instrument that is considered as "cashless exercise" which comprised of July 30 Note and two embedded derivative financial instruments (i.e., an embedded conversion feature and an embedded redemption feature to receive cash equals to 200% of July 30 Note balance upon Sale Transaction) and (ii) three series of detachable warrants. At the initial date, the Company is required to estimate the fair value of both two instruments and allocate the total gross proceeds received between them based on that relative fair value identified. The fair value of the embedded derivative financial instruments (i.e., the conversion right and the redemption right) should be bifurcated from the host instrument and remeasured on recurring basis at each reporting period under marked to market approach, the July 30 Note is accounted for under carrying amount whereby discount and interest expenses are recorded over the economic life of the July 30 Note based on the effective interest rate method and the July 30 Warrants are classified into equity without any further subsequent measurement.

A 17 A GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.) (in thousands of US Dollars)

NOTE 3 - SIGNIFICANT TRANSACTIONS (CONT.)

A H. Convertible Promissory Note and Warrant Agreements (Cont.)

A A Upon initial recognition, the management by using the assistance of an external appraiser allocated the gross cash proceeds received based on the relative fair value of the July 30 Note and the detachable July 30 Warrants in total amount of \$1,450 and \$2,550, respectively. The fair value of the convertible note was determined by using hybrid method that includes conversion scenario and liquidation scenario taking into account, inter alia, a debt discount rate of 28.65%. The fair value of the July 30 Warrants was determined by using Black-Scholes pricing model taking into account, inter alia, expected stock price volatility of 122.8% and risk-free interest rate of 4.78%. The amount allocated to July 30 Warrants was classified as a component of permanent equity (as their terms permit the holders to receive a fixed number of shares of common stock upon exercise for a fixed exercise price). A Furthermore, it was determined that the embedded conversion feature and embedded redemption feature are required to be bifurcated from the host loan instrument. The fair value of the bifurcated derivatives was determined by the management using the assistance of an external appraiser in a total amount of \$35 upon initial recognition and in subsequent periods as derivative liability at fair value through profit and loss. The remaining amount of \$1,415 was allocated to the host loan instrument which in subsequent periods is accounted for using the effective interest method over the term of the loan, until its stated maturity. A The following tabular presentation reflects the reconciliation of the carrying amount of the July 30 Note during the period of nine months ended September 30, 2024:

A SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JULY 30 NOTES

A Nine-month period ended September 30, 2024

A A (Unaudited)

A A Open balance

A \$-A Total proceeds received

A 4,000A Total proceeds allocated to July 30 Warrants at initial recognition

A (2,550) Total proceeds allocated to embedded redemption feature at initial recognition

A (35) Amortization of discount and interest expenses related to July 30 Note

(Note 5 below)

A 309A Ending balance

A \$1,724A The following tabular presentation reflects the reconciliation of the fair value of the embedded conversion feature and embedded redemption feature during the period of nine months ended September 30, 2024:

A SCHEDULE OF RECONCILIATION OF FAIR VALUE OF EMBEDDED CONVERSION FEATURE

A Nine-month period ended September 30, 2024

A A (Unaudited)

A A Open balance

A \$-A Proceeds allocated to embedded redemption feature at initial recognition

A 35A Revaluation expenses related to embedded redemption feature

(Note 5 below)

A 2A Ending balance

A \$37A On September 24, 2024, the Company held a special meeting of its stockholders under which shares of common stock issuable by the Company upon conversion of the July 30 Note and exercise of the July 30 Warrants has been approved. However, through September 30, 2024, July 30 Holder has not elected to trigger the conversion of July 30 Note or the exercise of the July 30 Warrants into shares of common stock.

A 18 A GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.) (in thousands of US Dollars)

NOTE 3 - SIGNIFICANT TRANSACTIONS (CONT.)

A I. August 23 Conversion

A A On August 23, 2024 (the "Commitment Date"), the Company and two of June 27 Investors entered into conversion agreement, under which the Company agreed to convert the principal nominal amount plus any accrued but unpaid interest pursuant to each of June 27 Notes, totalling approximately \$20 each (the "Debt"), held by the Investors to Common Stock at a conversion price of \$1.02 per share. On October 15, 2024, the Company issued 19,682 shares of common stock for each of the two of the June 27 Investors in respect of each respective Debt converted. A In satisfaction of the Debt, the Company also issued to each of the two June 27 Investors three warrants (each an "August 23 Warrant"). Each August 23 Warrant becomes exercisable on August 16, 2025 and has term of 10 years. The August 23 Warrants are exercisable for cash only and have no price-based antidilution. The first August 23 Warrant is for 10,707 shares of Common Stock and is exercisable at \$1.875 per share. The second August 23 Warrant is for 7,648 shares of Common Stock, exercisable at \$2.625 per share. The third August 23 Warrant is for 5,948 shares of Common Stock, exercisable at \$3.375 per share. A The above transaction was accounted for as settlements of financial liabilities under which the instruments issued or to be issued to the June 27 Investors (i.e., shares of common stock and August 23 Warrants) are eligible for equity classification and thus both have been recorded as part of the permanent equity based on the total fair value of \$238 at the Commitment Date. The difference between the fair value of these equity instruments and the carrying amount of each of the respective Debt at the Commitment Date amounted to \$11 was charged immediately to the finance expenses (see also Note 5 below).

A During the period commencing the issuance date through September 30, 2024, none of the August 23 Warrants have been exercised. A J. Sep 5 Conversion

A A On September 5, 2024 (the "Commitment Date"), the Company and one of June 27 Investors and July 18 Investors entered into a conversion agreement, under which the Company agreed to convert outstanding board fees amounted \$113 and the principal nominal amount plus any accrued but unpaid interest pursuant to June 27 Note and July 18 Note, totalling \$146 (referring together as a "Debt"), held by the Investor to Common Stock at a conversion price of \$1.02 per share. On October 15, 2024, the Company issued 254,226 shares of common stock for the June 27 Investor in respect of the Debt converted. A In satisfaction of the Debt, the Company also issued to June 27 Investor and July 18 Investor three warrants (each an "September 5 Warrant"). Each September 5 Warrant becomes exercisable on August 16, 2025 and has term of 10 years. The September 5 Warrants are exercisable for cash only and have no price-based antidilution. The first September 5 Warrant is for 138,299 shares of Common Stock and is exercisable at \$1.875 per share. The second September 5 Warrant is for 98,785 shares of Common Stock, exercisable at \$2.625 per share. The third September 5 Warrant is for 76,833 shares of Common Stock, exercisable at \$3.375 per share. A The above transaction was accounted for as settlements of financial liabilities under which the instruments issued or to be issued to the July 18 Investor (i.e., shares of common stock and September 5 Warrants) are eligible for equity classification and thus both have been recorded as part of permanent equity based on the total fair value of \$1,505 at the Commitment Date. The difference between the fair value of these equity instruments and the carrying amount of the Debt at the Commitment Date amounted to \$227 was charged immediately to the finance expenses (see also Note 5 below).

A During the period commencing the issuance date through September 30, 2024, none of the September 5 Warrants have been exercised. A 19 A GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.) (in thousands of US Dollars)

NOTE 4 - COMMITMENTS AND CONTINGENT LIABILITIES

A A In 2004, the Israeli Innovation Authority (IIA) provided Integrity Israel with a grant of approximately \$93 (NIS 420,000), for develop a non-invasive blood glucose monitor (the "Development Plan"). Integrity Israel is required to pay royalties to IIA at a rate ranging between 3-5% of the proceeds from sale of the Company's products arising from the Development Plan up to an amount equal to \$93, plus interest at LIBOR from the grant date. As to replacement of the LIBOR benchmark rate, even though the IIA has not declared the alternative benchmark rate to replace the LIBOR, the Company does not believe it will have a significant impact. As of September 30, 2024, the remaining contingent liability with respect to royalty payment on future sales equals approximately \$73, excluding interest. Such contingent obligation has no expiration date.

A B. On October 7, 2022 (the "Closing Date"), the Company entered into Intellectual Property Purchase Agreement (the "Agreement") with Paul Goode, which is the Company's Chief Executive Officer (the "Seller"), under which it was agreed that and subject to the terms and conditions of the Agreement, at the Closing Date, Seller sold and assigned to the Company, all of Seller's right, title and interest in and to the following assets, properties and rights (collectively, the "Purchased Assets"): (i) all rights, title, interests in all current and future intellectual property, including, but not limited to patents, trademarks, trade secrets, industry know-how and other IP rights relating to an implantable continuous glucose sensor (collectively, the "Conveyed Intellectual Property"); and (ii) all the goodwill relating to the Purchased Assets. A In consideration for the sale of the Purchased Assets to the Company, at the Closing Date, the Company paid to Seller cash in the amount of one dollar and obligated to issue up to 200,000 shares of Common Stock to be issued based upon specified performance milestones as set forth in the Agreement (the "Purchase Price"). In addition, if upon the final issuance, the aggregate 200,000 shares represent less than 1.5% of the then outstanding Common Stock of the Company, the final issuance will include such number of additional shares so that the total aggregate issuance equals 1.5% of the outstanding shares (the "True-Up Shares"). All shares of Common Stock of the Company that will be issued under the agreement shall be (i) restricted over a limited period as defined in the Agreement and (ii) subject to the lockup provisions. A When the Company acquires net assets that do not constitute a business, as defined under ASU 2017-01 Business Combinations (Topic 805) Clarifying the Definition of a Business (such when there is no substantive process in the acquired entity) the transaction is accounted for as asset acquisition and no goodwill is recognized. The acquired In-Process Research and Development intangible asset (the "IPR&D") to be used in research and development projects which have been determined not to have alternative future use at the acquisition date, is expensed immediately. A At the Closing Date, it was determined that the asset acquisition represents the purchase of IPR&D with no alternative future use. However, the achievement of each of the performance milestones is considered as a contingent event outside the Company's control and thus the contingent consideration which is equal to the fair value of the Purchase Price as measured at the Closing Date will be recognized when it becomes probable that each target will be achieved within the reasonable period. Such additional contingent consideration will be recognized in subsequent periods if and when the contingency (the achievement of targets) is resolved. A In June 2023, the Company achieved the first performance milestone out of the five performance milestones outlined in the Agreement executed between the Company and the Seller as of the Closing Date. As a result, upon the date of the fulfilment of the first performance milestone the Company was committed to issue 20,000 restricted shares to the Seller. Accordingly, the Company recorded an amount of \$131 as research and development expenses with a similar amount as an increase to additional paid-in capital. The first performance milestone shares were issued on February 6, 2024. A In May 2024, the Company achieved the second performance milestone out of the five performance milestones outlined in the Agreement executed between the Company and the Seller as of the Closing Date. As result, the Company is committed to issue 30,000 restricted shares to the Seller. Accordingly, the Company recorded stock-based compensation expenses amounted to \$192 which represents the quoted price of its Common Stock at the Closing Date, after taking into consideration a discount for lack of marketability in a rate of 30 % over the applicable restriction period. As of September 30, 2024, the second performance milestone shares were not yet issued. A As of September 30, 2024, the achievement of all other remaining performance milestones was not considered probable and thus no stock-based compensation expenses were recorded with respect to thereof. A 20 A GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.) (in thousands of US Dollars)

NOTE 5 - FINANCE (INCOME) EXPENSES, NET

A SCHEDULE OF FINANCE EXPENSES

A A A A A A A A A A A A Three-month period ended September 30,

A Nine-month period ended September 30,

A A 2024A A 2023A A 2024A A 2023A A UnauditedA A UnauditedA A A A A A A A A A Discount amortization and interest expenses related to July 30 Note

A 160A A 160A A Interest expenses related to July 18 Notes

A 5A A A 5A A A Discount amortization and interest expenses related to July 30 Note

A 309A A A 309A A A Revaluation expenses related to derivative financial liabilities

A 2A A A 2A A A Revaluation expenses incurred from settlement of financial liabilities

A 1,505A A A 1,505A A A Interest on bank deposits

A (7)A A (1)A A (38)A A (2) Exchange rate differentials, bank commissions and miscellaneous

A 18A A A 18A A A Finance (income) expenses, net

A 1,848A A (1)A A 1,822A A (2)A NOTE 6 - SUBSEQUENT EVENTS

A Management evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the condensed interim consolidated financial statements were available to be issued. Based upon this review, the Company did not

strategy, competitive strengths, goals, expansion and growth of our business and operations, plans, references to future success, projected performance and trends, and other such matters, are forward-looking statements. The words æœbelieve,æœ expect,æœ anticipate,æœ intend,æœ estimate,æœ plan,æœ may,æœ will,æœ could,æœ would,æœ should,æœ and other similar words and phrases, are intended to identify forward-looking statements. The forward-looking statements made in this Quarterly Report on Form 10-Q are based on certain historical trends, current conditions and expected future developments as well as other factors we believe are appropriate in the circumstances. These statements relate only to events as of the date on which the statements are made and we undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. All of the forward-looking statements made in this Quarterly Report on Form 10-Q are qualified by these cautionary statements and there can be no assurance that the actual results anticipated by us will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Whether actual results will conform to our expectations and predictions is subject to a number of risks and uncertainties that may cause actual results to differ materially. Risks and uncertainties, the occurrence of which could adversely affect our business, include the risks identified under the caption æœRisk Factorsæœ included in our annual report on Form 10-K for the year ended December 31, 2023. The following discussion should be read in conjunction with the condensed consolidated financial statements and the notes thereto included in Item 1 of this Quarterly Report on Form 10-Q. Å Overview Å We are a medical device company focused on the design, development and commercialization of novel technologies for use by people with diabetes. We are currently developing an Implantable CBGM for those with Type 1 diabetes and insulin-dependent Type 2 diabetes. Å The Company was founded with a mission to develop Glucotrack®, a non-invasive glucose monitoring device designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain, inconvenience, cost and difficulty of conventional (invasive) spot finger stick devices. The first generation Glucotrack, which successfully received CE Mark approval, obtained glucose measurements via a small sensor clipped onto oneæ™™s earlobe. A limited release beta test in Europe and the Middle East demonstrated the need for an updated product with improved accuracy and human factors. As the glucose monitoring landscape rapidly moved away from point-in-time measurement to continuous measurement since then, the Company recently determined that it would focus its efforts on developing its Implantable CBGM. As such, we have since withdrawn our CE Mark for Glucotrack and are no longer pursuing commercialization of this product or development of any further iterations. Å The Company is currently developing an Implantable CBGM for use by Type 1 diabetes patients as well as insulin-dependent Type 2 patients. Implant longevity is key to the success of such a device. We have continued to evolve our sensor chemistry following our successful in-vitro feasibility study demonstrating that a minimum two-year implant life is highly probable with the current sensor design. Recently we announced a 3-year longevity is feasible leveraging both in-vitro and in-silico test results. We have also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, good functionality, and safety. The Company has also successfully demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, good functionality, and safety. This latter approach is of importance for patients with painful diabetic neuropathy contemplating spinal cord stimulation therapy for their condition. The results of these animal trials were recently presented in poster form at the American Diabetes Association, the Diabetes Technology Society, and the DiabetesMine annual conferences. Å A regulatory submission has been made for a first in human study. This will be an acute study intended to demonstrate device performance and safety. All preparatory clinical activities are complete and the study is expected to initiate in Q4 2024, pending regulatory approval. In parallel, the Company is also preparing for a long-term clinical trial expected to begin in late Q2 2024. As part of this effort, the Company is working towards ISO13485 certification, an internationally agreed-upon standard of quality system requirements for the design, production, distribution, and sale of medical devices. The Company has successfully completed the first audit and is scheduled to complete the second audit in December 2024. A successful second audit results in certification of compliance to the standard, which is recognized and accepted by the FDA, the European Union, and many other geographies worldwide. Å We believe our technology, if successful, has the potential to be more accurate, more convenient and have a longer duration than other implantable glucose monitors that are either in the market or currently under development. Å 22 Å Å Our Senior Management team includes; CEO and President, Paul V. Goode PhD, who has a decorated career developing innovative medical technologies, including at Dexcom and MiniMed, CFO, James Cardwell, CPA who has over 16 years of experience as a Chief Financial Officer and Chief Operating Officer with a concentration in both SEC financial reporting and tax compliance, James P. Thrower PhD, Vice President of Engineering, a seasoned executive formerly of Sterling Medical Devices, Mindray DS USA and Dexcom, Inc., Mark Tapsak PhD, Vice President of Sensor Technology, a medical research scientist who brings over 25 years of experience in the diabetes industry, including previous senior roles at Dexcom and Medtronic, Drinda Benjamin, Vice President of Marketing, a medical device professional with over 20 years of experience in the medical device and diabetes industry with senior roles at Intuity Medical, Senseonics, Abbott Diabetes, and Medtronic Diabetes, Vincent Wong, Vice President of Quality, a medical device professional with 15 years of experience in quality system for implantable medical device manufacturing with senior roles at Cirtec Medical and TOMZ, and Sandie Martha, Vice President Clinical Operations, a medical device professional with over 20 years of experience in the medical device and diabetes industry with senior roles at Dexcom and GlySens. Å Andy Balo, formerly of Dexcom and St Jude Medical (now Abbott) and John Ballantyne, founder and formerly of Aldeveron have joined as independent board members. Several highly talented and accomplished executives joined the Company as senior advisors to the Board. These include Daniel McCaffrey MBA MA, a world-renowned behavioral scientist and digital health expert formerly at Samsung Health and Dexcom, Inc., and Dr. David C. Klonoff, world renowned endocrinologist and diabetes technology thought leader. We intend to continue to invest in our talent and to expand and strengthen all areas within the Company. Å Recent Events Å On April 22, 2024, we entered into a private placement agreement under which we issued 79,366 shares of our common stock at a price of \$6.3 per share for aggregate gross proceeds of \$500,000 to certain members of our executive management, Board of Directors and existing shareholders. Å On April 26, 2024, we held our Annual Meeting of Shareholders (the æœAnnual Meetingæœ) under which our stockholders approved, inter alia, the following proposals: (i) adoption of our 2024 Equity Incentive Plan; (ii) approved of an amendment to Article IV of our Certificate of Incorporation, as amended, to effect a reverse stock split of the Companyæ™™s Common Stock at a ratio of between one-for-five and one-for-thirty, with such ratio to be determined at the sole discretion of the Board of Directors. Following the Annual Meeting, on April 30, 2024, the Board of Directors approved a one-for-five reverse split of our issued and outstanding shares of Common Stock (the æœReverse Stock Splitæœ). On May 17, 2024, we filed a Certificate of Amendment to the Companyæ™™s Certificate of Incorporation with the Secretary of State of the State of Delaware which effected the Reverse Stock Split. Å On June 27, 2024, the Board of Directors approved us to enter into note and warrant purchase agreements with certain investors, providing for the private placement of unsecured promissory notes in the aggregate principal amount of \$100,000 (the æœNotesæœ) and warrants (the æœWarrantsæœ) to purchase up to an aggregate of 300,000 shares of our Common Stock. The closing of the private placement occurred on July 1, 2024. The Notes bear simple interest at the rate of 3% per annum and are due and payable in cash on the earlier of: (a) twelve months from the date of the Note; or (b) the date we raise third-party equity capital in an amount equal to or in excess of \$1,000,000 (the æœMaturity Dateæœ). We may prepay the Notes at any time prior to the Maturity Date without penalty. If an event of default occurs, the then-outstanding principal amount of the Notes plus any unpaid accrued interest will accelerate and become immediately payable in cash. Each Warrant has an exercise price of \$4.95 per share. The Warrants are immediately exercisable and have a five-year term. Å On July 18, 2024, we entered into a series of convertible promissory notes with certain investors which including three of our directors and one member of our executive management, providing for the private placement of unsecured convertible promissory notes in the aggregate principal amount of \$360,000 (the æœNotesæœ and each a æœNoteæœ). The Notes bear simple interest at the rate of 8% per annum and are due and payable in cash on the earlier of: (a) the twelve-month anniversary of Note, or (b) the date of closing of a Qualified Financing (as defined above). Interest will be computed on the basis of a 365-day year. Å On July 30, 2024, we entered into a convertible promissory note and three warrant agreements (the æœWarrantsæœ) with an existing investor (the æœHolderæœ), providing for the private placement of a secured convertible promissory note in the aggregate principal amount of \$4,000,000 (the æœNoteæœ). The Note was not convertible until and the approval at a meeting of our stockholders. The Note bears simple interest at the rate of 8% per annum and is due and payable in cash on the earlier of: (i) 12 months anniversary of Note, or (ii) the date of closing of a Sale Transaction (as defined above) (the æœMaturity Dateæœ). The Note is secured by a first-priority security interest on all our assets. Each Warrant becomes exercisable 12 months after its issuance and has term of 10 years. The Warrants are exercisable for cash only and have no price-based antidilution. The first Warrant is for 2,133,334 shares at \$1.875 per share. The second Warrant is for 1,523,810 shares at \$2.625 per share. The third Warrant is for 1,185,186 shares at \$3.375 per share. Å On August 23, 2024, two of the June 27 Investors entered into conversion agreements with us, pursuant to which we agreed to convert the principal amount, plus any accrued but unpaid interest pursuant to each of the June 27 Notes, totalling approximately \$20,076 each, held by the Investors to Common Stock at a conversion price of \$1.02 per share. On October 15, 2024, we issued 19,682 shares of common stock for each of the two of the June 27 Investors in respect of each respective debt converted. In satisfaction of the debt, we also issued to each of the two June 27 Investors three warrants (each an æœAugust 23 Warrantæœ). Each August 23 Warrant becomes exercisable on August 16, 2025 and has term of 10 years. The August 23 Warrants are exercisable for cash only and have no price-based antidilution. The first August 23 Warrant is for 10,707 shares of Common Stock and is exercisable at \$1.875 per share. The second August 23 Warrant is for 7,648 shares of Common Stock, exercisable at \$2.625 per share. The third August 23 Warrant is for 5,948 shares of Common Stock, exercisable at \$3.375 per share. Å On September 5, 2024, one of the June 27 Investors and July 18 Investors entered into a conversion agreement with us, pursuant to which we agreed to convert outstanding board fees and the principal amount, plus any accrued but unpaid interest pursuant to the June 27 Investoræ™™s June 27 Note, totalling \$259,300, held by the Investor to Common Stock at a conversion price of \$1.02 per share. On October 15, 2024, we issued 254,226 shares of common stock for the June 27 Investor in respect of the Debt converted. In satisfaction of the debt, we issued to the July 18 Investor three warrants (each an æœSeptember 5 Warrantæœ). Each September 5 Warrant becomes exercisable on August 16, 2025 and has term of 10 years. The September 5 Warrants are exercisable for cash only and have no price-based antidilution. The first September 5 Warrant is for 138,299 shares of Common Stock and is exercisable at \$1.875 per share. The second September 5 Warrant is for 98,785 shares of Common Stock, exercisable at \$2.625 per share. The third September 5 Warrant is for 76,833 shares of Common Stock, exercisable at \$3.375 per share. Å The summary of our significant accounting policies is included under Item 7 - Managementæ™™s Discussion and Analysis of Financial Condition and Results of Operations of our fiscal 2023 Form 10-K. An accounting policy is deemed to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, if different estimates reasonably could have been used, or if changes in the estimate that are reasonably possible could materially impact the financial statements. There have been no material changes to the critical accounting policies and estimates as filed in such report. Å 23 Å Å Liquidity and Capital Resources Å To date, we have not generated any revenues and have experienced net losses and negative cash flows from our activities. Å Since our incorporation, we have devoted substantially all our resources to research and product development and providing general and administrative support for these activities. Since our incorporation, we have incurred significant losses and negative cash flows from operations. During the nine months ended September 30, 2024, we incurred a net loss of approximately \$12.5 million and used \$9.0 million of cash in our operations. As of September 30, 2024, we had an accumulated deficit of approximately \$122.7 million. We expect to continue to incur significant and increasing losses and do not expect positive cash flows from operations for the foreseeable future, and our net losses may fluctuate significantly from period to period depending on the timing of and expenditures on our research and development activities. Å As of September 30, 2024, the balance of cash and cash equivalents of approximately \$346,000, together with the net proceeds in total amount of \$8,873 which expected to be received upon closing of a public offering through registration statements on Form S-1 on November 14, 2024, is insufficient for the Company to realize its business plans for the twelve-month period subsequent to the reporting period. Å Results of Operations Å The following discussion of our operating results explains material changes in our results of operations for the three and nine months ended September 30, 2024 compared with the same periods ended September 30, 2023. The discussion should be read in conjunction with the financial statements and related notes included elsewhere in this report. Å Consolidated Results of Operations for the Three Months Ended September 30, 2024 and 2023 Å Research and development expenses Å Research and development expenses were approximately \$2.1 million for the three-month period ended September 30, 2024, as compared to approximately \$1.7 million for the prior-year period. The increase is attributable to ramping up product development activities. Å Research and development expenses consist primarily of salaries and other personnel-related expenses, materials, animal trials, production labor and other expenses. We expect research and development expenses to increase in 2025 and beyond, primarily due to hiring additional personnel, as well clinical trials for the Glucotrack CBGM; however, we may adjust or allocate the level of our research and development expenses based on available financial resources and based on our commercial needs, including the FDA registration process, specific requirements from customers, development of new Glucotrack CBGM models and others. Å Marketing expenses Å Marketing expenses were approximately \$0.1 million for the three-month period ended September 30, 2024, as compared to \$0 for the prior-year period. This increase is primarily attributable to business development personnel and professional marketing services. Å General and administrative expenses Å General and administrative expenses were approximately \$1.1 million for the three-month period ended September 30, 2024, as compared to approximately \$0.5 million for the prior-year period. The increase is attributable to professional fees we accrued during the period. Å General and administrative expenses consist primarily of professional services, salaries, consulting fees, insurance, travel expenses and other related expenses for executive, finance and administrative personnel, including stock-based compensation expenses. Other general and administrative costs and expenses include facility-related costs not otherwise included in research and development costs and expenses, and professional fees for legal and accounting services. Å 24 Å Å Finance (income) expenses net Å Finance expenses, net was approximately \$1.9 million for the three-month period ended September 30, 2024, as compared to finance income of approximately \$0.001 million for the prior-year period. This increase was primarily due to \$1.5 million in revaluation expenses incurred from settlement of financial liabilities and \$0.3 million in discount amortization and interest expenses. Å Net Loss Å Net loss was approximately \$5.1 million for the three-month period ended September 30, 2024, as compared to approximately \$2.2 million for the prior-year period. The increase in net loss is attributable primarily to the increase in our operating expenses, as described above. Å Consolidated Results of Operations for the Nine Months Ended September 30, 2024 and 2023 Å Research and development expenses Å Research and development expenses were approximately \$7.8 million for the nine-month period ended September 30, 2024, as compared to approximately \$3.0 million for the prior-year period. The increase is attributable to professional fees we accrued during the period. Å Research and development expenses consist primarily of salaries and other personnel-related expenses, materials, animal trials and other expenses. We expect research and development expenses to increase in 2025 and beyond, primarily due to hiring additional personnel, as clinical trials for the Glucotrack CBGM; however, we may adjust or allocate the level of our research and development expenses based on available financial resources and based on our commercial needs, including the FDA registration process, specific requirements from customers, development of new Glucotrack CBGM models and others. Å Marketing expenses Å Marketing expenses were approximately \$0.3 million for the nine-month period ended September 30, 2024, as compared to \$0 for the prior-year period. This increase is primarily attributable to business development personnel and professional marketing services. Å General and administrative expenses Å General and administrative expenses were approximately \$2.6 million for the nine-month period ended September 30, 2024, as compared to approximately \$1.7 million for the prior-year period. The increase is attributable to professional fees we accrued during the period. Å General and administrative expenses consist primarily of professional services, salaries, consulting fees, insurance, travel expenses and other related expenses for executive, finance and administrative personnel, including stock-based compensation expenses. Other general and administrative costs and expenses include facility-related costs not otherwise included in research and development costs and expenses, and professional fees for legal and accounting services. Å Finance (income) expenses, net Å Finance expenses, net was approximately \$1.8 million for the nine-month period ended September 30, 2024, as compared to finance income, net of approximately \$0.002 million for the prior-year period. This increase was primarily due to \$1.5 million in revaluation expenses incurred from settlement of financial liabilities and \$0.3 million in discount amortization and interest expenses. Å Net Loss Å Net loss was approximately \$12.5 million for the nine-month period ended September 30, 2024, as compared to approximately \$4.7 million for the prior-year period. The increase in net loss is attributable primarily to the increase in our operating expenses, as described above. Å 25 Å Å Cash Flows for the Nine Months Ended September 30, 2024 and 2023 Å Operating Activities Å Net cash used in operating activities for the nine-month period ended September 30, 2024 was approximately \$9.0 million primarily due to the net loss of approximately \$12.5 million offset by non-cash charges of \$2.3 million and an increase in working capital excluding cash of \$1.2 million. Net cash used in operating activities for the nine-month periods ended September 30, 2023 was approximately \$4.1 million primarily due to the net loss of \$4.7 million. Å Investing Activities Å Net cash used in investing activities was \$0.1 million and \$0 for the nine-month periods ended

September 30, 2024 and 2023, respectively. Net cash used in investing activities primarily reflects the purchasing of fixed assets. Â Financing Activities Â Net cash provided by financing activities was approximately \$5.0 million and \$8.7 million for the nine-month periods ended September 30, 2024 and 2023, respectively. Net cash provided by financing activities primarily reflects the proceeds received from private placement transaction in 2024 versus net proceeds received upon completion of public offering. Â Off-Balance Sheet Arrangements Â As of September 30, 2024, we did not have any off-balance sheet arrangements as defined in Item 303(a)(4) of Regulation S-K. Â Critical Accounting Policies Â This Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations discuss our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (â€œU.S. GAAPâ€). In connection with the preparation of our financial statements, we are required to make assumptions and estimates about future events and apply judgments that affect the reported amounts of assets, liabilities, expenses and the related disclosures. We base our assumptions, estimates and judgments on historical experience, current trends and other factors that management believes to be relevant at the time our condensed consolidated financial statements are prepared. On a regular basis, management reviews the accounting policies, assumptions, estimates and judgments to ensure that our financial statements are presented fairly and in accordance with U.S. GAAP. However, because future events and their effects cannot be determined with certainty, actual results could differ from our assumptions and estimates, and such differences could be material. Â Going Concern Uncertainty Â The development of the implantable continuous glucose sensor product is expected to require substantial further expenditures. We remain dependent upon external sources for financing our operations. Since inception, we have incurred substantial accumulated losses and negative operating cash flow and have a significant accumulated deficit. We do not have any committed external source of funds or other support for our development efforts, and we cannot be certain that additional funding will be available on acceptable terms, or at all. Until we can generate sufficient revenue to finance our cash requirements, which we may never do, we expect to finance our future cash needs through a combination of public or private equity offerings, debt financings, collaborations, government funding, strategic alliances, licensing arrangements, and other marketing or distribution arrangements, any of which may include terms that may adversely affect our stockholdersâ€™ rights. If we are unable to raise additional capital in sufficient amounts or on acceptable terms, we may have to significantly delay, scale back or discontinue our development or commercialization initiatives. Any of the above events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our common stock to decline. We believe that our cash on hand as of September 30, 2024, together with the net proceeds expected to be received upon closing of a public offering through registration statements on Form S-1 on November 14, 2024, will not provide sufficient working capital to fund its current operations and animal trial program for the development of its Implantable CGM for a period of twelve-months subsequent to the reporting period. Â Item 3. Quantitative and Qualitative Disclosures About Market Risk. Â Not required for smaller reporting companies. Â 26 Â Â Item 4. Controls and Procedures. Â Evaluation of Disclosure Controls and Procedures Â Our management, with the participation of our Principal Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of September 30, 2024 (the â€œEvaluation Dateâ€). Based on such evaluation, those officers have concluded that, as of the Evaluation Date, our disclosure controls and procedures are ineffective in recording, processing, summarizing and reporting, on a timely basis, information required to be included in periodic filings under the Exchange Act and that such information is not accumulated and communicated to management, including our principal executive and financial officers, in a manner sufficient to allow timely decisions regarding required disclosure, due to the material weaknesses in internal control over financial reporting related to lack of sufficient internal accounting personnel, segregation of duties, and lack of sufficient internal controls (including IT general controls) that encompass the Company as a whole with respect to entity and transactions level controls in order to ensure complete documentation of complex and non-routine transactions and adequate financial reporting. Â Management has identified corrective actions to remediate such material weaknesses, which includes hiring additional employees and engaging in external financial reporting consultants. Management intends to implement procedures to remediate such material weaknesses during the fiscal year 2025; however, the implementation of these initiatives may not fully address any material weaknesses that we may have in our internal control over financial reporting. Â Changes in Internal Control over Financial Reporting Â There were no changes in our internal control over financial reporting during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Â 27 Â Â PART II - OTHER INFORMATION Â Item 1. Legal Proceedings Â From time to time in the ordinary course of business, the Company may be subject to various claims, charges, and litigation. At September 30, 2024, except as described in the preceding paragraph, the Company did not have any pending claims, charges or litigation that were expected to have a material adverse impact on its financial position, results of operations or cash flows. Â Item 1A. Risk Factors. Â You should carefully consider the factors discussed in Part I, Item 1A, â€œRisk Factorsâ€ in our Annual Report for the fiscal year ended December 31, 2023, which could materially affect our business, financial position, or future results of operations. The risks described in our Annual Report for the fiscal year ended December 31, 2023, are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial position, or future results of operations. We may disclose changes to such factors or disclose additional factors from time to time in our future filings with the SEC. The risk factor set forth below supplements and updates the risk factors previously disclosed and should be read together with the risk factors described in our Annual Report for the fiscal year ended December 31, 2023 and with any risk factors we may include in subsequent periodic filings with the SEC. Â We may fail to select or capitalize on the most scientifically, clinically or commercially promising or profitable product candidates. Â Given the current momentum for continuous glucose monitoring (â€œCGMâ€) in the diabetes market, we have announced our decision to reset our priorities, improve our commercial outlook and refine our business strategy to focus on our implantable CGM technology. Should our efforts to focus on CGM not be successful, we will need to further evaluate our business strategy and, as a result, our Board of Directors may decide that it is in the best interest of our stockholders to dissolve our Company and liquidate our assets or otherwise modify our strategy in the future. In this regard, we may, from time to time, focus our product development efforts on different product candidates or may delay, suspend or terminate the future development of a product candidate at any time for strategic, business, financial or other reasons. As a result of changes in our strategy, we have and may in the future change or refocus our existing product development, commercialization and manufacturing activities. This could require changes in our facilities and our personnel. Any product development changes that we implement may not be successful. In particular, we may fail to select or capitalize on the most scientifically, clinically or commercially promising or profitable product candidates. Our decisions to allocate our research and development, management and financial resources toward particular product candidates may not lead to the development of viable commercial products and may divert resources from better opportunities. Similarly, our decisions to delay or terminate product development programs may also prove to be incorrect and could cause us to miss valuable opportunities. Â 28 Â Â Our failure to maintain compliance with Nasdaqâ€™s continued listing requirements could result in the delisting of our Common Stock. Â Our common stock is currently listed for trading on The Nasdaq Stock Market LLC. We must satisfy the continued listing requirements of Nasdaq, to maintain the listing of our common stock on The Nasdaq Stock Market LLC. Â On May 26, 2023, we received notice from the Staff indicating that, based upon the closing bid price of our common stock for the prior 30 consecutive business days, we were not currently in compliance with the requirement to maintain a minimum bid price of \$1.00 per share for continued listing on Nasdaq as set forth in Nasdaq Listing Rule 5550(a)(2) (the â€œBid Price Ruleâ€). We had 180 days from May 26, 2023, or through November 22, 2023, to regain compliance with the Bid Price Rule. Â On November 24, 2023, we received a second letter from Nasdaq notifying the Company that it had been granted an additional 180 calendar days, or until May 20, 2024 (the â€œExtended Compliance Periodâ€), to regain compliance with the Minimum Bid Price Requirement in accordance with Nasdaq Listing Rule 5810(c)(3)(A). Â On May 21, 2024, we received a third letter from Nasdaq (the â€œLetterâ€) notifying us that it had not regained compliance with the Minimum Bid Price Requirement during the Extended Compliance Period. The Letter also notified us that our Form 10-Q for the period ended March 31, 2024, indicates that we no longer meet the \$2,500,000 minimum stockholdersâ€™ equity requirement for continued listing set forth under Listing Rule 5550(b)(1) (the â€œMinimum Stockholdersâ€™ Equity Requirementâ€). Pursuant to Listing Rule 5810(d)(2), the failure to comply with the Minimum Stockholdersâ€™ Equity Requirement has become an additional and separate basis for delisting. Â Because we were under review for failure to meet the Minimum Bid Price Requirement, we were not eligible to submit a plan to regain compliance. Accordingly, unless we would request an appeal of this determination by May 28, 2024, trading of our common stock would be suspended at the opening of business on May 30, 2024, and a Form 25-NSE would be filed with the Securities and Exchange Commission (the â€œSECâ€). We timely requested a hearing before a Nasdaq Hearings Panel (the â€œPanelâ€). The hearing request would result in a stay of any suspension or delisting action pending the hearing. On August 5, 2024, we received the decision of the Panel, and they granted us an extension to November 18, 2024 to regain compliance with the Minimum Stockholdersâ€™ Equity Requirement. Â On May 17, 2024, in order to regain compliance with the Minimum Bid Price Requirement, we filed a Certificate of Amendment to the Companyâ€™s Certificate of Incorporation with the Secretary of State of the State of Delaware which effected, as of 4:30 p.m. Eastern Time, on May 17, 2024, a one-for-five Reverse Stock Split of our issued and outstanding shares of Common Stock. Â In the event that we are unable to regain and sustain compliance with all applicable requirements for continued listing on the Nasdaq, our Common Stock may be delisted from Nasdaq. If our Common Stock were delisted from Nasdaq, trading of our common stock would most likely take place on an over-the-counter market established for unlisted securities, such as the OTCQB or the Pink Market maintained by OTC Markets Group Inc. An investor would likely find it less convenient to sell, or to obtain accurate quotations in seeking to buy, our common stock on an over-the-counter market, and many investors would likely not buy or sell our common stock due to difficulty in accessing over-the-counter markets, policies preventing them from trading in securities not listed on a national exchange or other reasons. In addition, as a delisted security, our common stock would be subject to SEC rules as a â€œpenny stock,â€ which impose additional disclosure requirements on broker-dealers. The regulations relating to penny stocks, coupled with the typically higher cost per trade to the investor of penny stocks due to factors such as broker commissions generally representing a higher percentage of the price of a penny stock than of a higher-priced stock, would further limit the ability of investors to trade in our common stock. In addition, delisting would materially and adversely affect our ability to raise capital on terms acceptable to us, or at all, and may result in the potential loss of confidence by investors, suppliers, customers and employees and fewer business development opportunities. For these reasons and others, delisting would adversely affect the liquidity, trading volume and price of our common stock, causing the value of an investment in us to decrease and having an adverse effect on our business, financial condition and results of operations, including our ability to attract and retain qualified employees and to raise capital. Â We rely on third parties to manufacture and supply our product. Â We do not own or operate manufacturing facilities for clinical or commercial production of Glucotrack CBGM, other than a prototype lab. We have no experience in medical device manufacturing and lack the resources and the capability to manufacture the Glucotrack CBGM on a commercial scale. Â If our manufacturing partners are unable to produce our products in the amounts, timing or pricing that we require, we may not be able to establish a contract and obtain a sufficient alternative supply from another supplier on a timely basis and in the quantities or pricing we require. We expect to depend on third-party contract manufacturers for the foreseeable future. Â Glucotrack CBGM does, and our future product candidates, if any, likely will require precise, high quality manufacturing. Any of our contract manufacturers will be subject to ongoing periodic unannounced inspections by the FDA and other non-U.S. regulatory authorities to ensure strict compliance with quality system regulations, including current good manufacturing practices and other applicable government regulations and corresponding standards. If our contract manufacturers fail to achieve and maintain high manufacturing standards in compliance with quality system regulations, we may experience manufacturing errors resulting in patient injury or death, product recalls or withdrawals, delays or interruptions of production or failures in product testing or delivery, delay or prevention of filing or approval of marketing applications for our products, cost overruns or other problems that could seriously harm our business. Â 29 Â Â Any performance failure on the part of our contract manufacturers could delay clinical development or regulatory clearance or approval of our product candidates or commercialization of our future product candidates, depriving us of potential product revenue and resulting in additional losses. In addition, our dependence on a third-party for manufacturing may adversely affect our future profit margins. Our ability to replace an existing manufacturer may be difficult because the number of potential manufacturers is limited, and the FDA must approve any replacement manufacturer before it can begin manufacturing our product candidates. Such approval would require additional non-clinical testing and compliance inspections. It may be difficult or impossible for us to identify and engage a replacement manufacturer on acceptable terms in a timely manner, or at all. Â Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. Â (a) Except as disclosed below, during the quarter ended September 30, 2024, there were no unregistered sales of our securities that were not reported in a Current Report on Form 8-K. Â On August 23, 2024, two investors entered into conversion agreements (the â€œConversion Agreementsâ€) with the Company, pursuant to which the Company agreed to convert the principal amount, plus any accrued but unpaid interest pursuant to two outstanding promissory notes, totalling \$20,076 each (the â€œDebtâ€), held by the Investors to Common Stock at a conversion price of \$1.02 per share. Â Also in satisfaction of the Debt and pursuant to the Conversion Agreement, the Company issued to each of the two Investors three warrants (each an â€œAugust 23 Warrantâ€). Each August 23 Warrant becomes exercisable on August 16, 2025, and has term of 10 years. The August 23 Warrants are exercisable for cash only and have no price-based antidilution. The first August 23 Warrant is for 10,707 shares of Common Stock and is exercisable at \$1.875 per share. The second August 23 Warrant is for 7,648 shares of Common Stock, exercisable at \$2.625 per share. The third August 23 Warrant is for 5,948 shares of Common Stock, exercisable at \$3.375 per share. Â The August 23 Warrants and the shares issued in satisfaction of the Debt were issued in reliance on the exemption from registration requirements thereof provided by Section 4(a)(2) of the Securities Act and Regulation D promulgated under the Securities Act. The Company relied on this exemption from registration based in part on representations made by the investors. Â (b) Not applicable. Â (c) None. Â Item 3. Defaults Upon Senior Securities Â None. Â Item 4. Mine Safety Disclosures Â None. Â Item 5. Other Information Â None. Â 30 Â Â Item 6. Exhibits. Â Exhibit No. Â Description Â Â 3.1 Â Certificate of Incorporation of Integrity Applications, Inc. (incorporated by reference to Exhibit 3.1 to the Companyâ€™s Registration Statement on Form S-1 filed with the SEC on August 22, 2011) 3.2 Â Certificate of Amendment to Certificate of Incorporation of Integrity Applications, Inc. (incorporated by reference to Exhibit 3.2 to the Companyâ€™s Registration Statement on Form S-1 filed with the SEC on August 22, 2011) 3.3 Â Bylaws of Integrity Applications, Inc. (incorporated by reference to Exhibit 3.3 to the Companyâ€™s Registration Statement on Form S-1 filed with the SEC on August 22, 2011) 3.4 Â Certificate of Amendment to Certificate of Incorporation of Integrity Applications, Inc. (incorporated by reference to Exhibit 99.1 to the Companyâ€™s Current Report on Form 8-K filed with the SEC on April 23, 2020) 3.5 Â Amendments to The Companyâ€™s Certificate of Incorporation (incorporated by reference to Exhibit 3.7 to the Companyâ€™s Annual Report on Form 10-K, filed with the SEC on March 31, 2022) 3.6 Â Certificate of Amendment to Amended and Restated Certificate of Incorporation, as filed with the Secretary of State of the State of Delaware on May 17, 2024 (incorporated by reference to Exhibit 3.1 to the Companyâ€™s Current Report on Form 8-K filed with SEC on May 20, 2024) 3.7 Â First Amendment to Bylaws (incorporated by reference to Exhibit 3.1 to the Companyâ€™s Current Report on Form 8-K filed with the SEC on June 20, 2024) 4.1 Â Form of Warrant (incorporated by reference to Exhibit 4.1 to the Companyâ€™s Current Report on Form 8-K filed with SEC on July 1, 2024) 4.2 Â Form of Warrant (incorporated by reference to Exhibit 10.2 to the Companyâ€™s Current Report on Form 8-K filed with SEC on July 31, 2024) 10.1 Â Form of Note and Warrant Purchase Agreement (incorporated by reference to Exhibit 10.1 to the Companyâ€™s Current Report on Form 8-K filed with SEC on July 1, 2024) 10.2 Â Form of Promissory Note (incorporated by reference to Exhibit 10.2 to the Companyâ€™s Current Report on Form 8-K filed with SEC on July 1, 2024) 10.3 Â Form of Promissory Note (incorporated by reference to Exhibit 10.1 to the Companyâ€™s Current Report on Form 8-K filed with SEC on July 22, 2024) 10.4 Â Form of Convertible Promissory Note (incorporated by reference to Exhibit 10.1 to the Companyâ€™s Current Report on Form 8-K filed with SEC on July 31, 2024) 31.1* Â Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 31.2* Â Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 32.1** Â Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 101.INS Â Inline XBRL Instance Document 101.SCH Â Inline XBRL Schema Document 101.CAL Â Inline XBRL Calculation Linkbase Document 101.LAB Â Inline XBRL Label Linkbase Document 101.PRE Â Inline XBRL Presentation Linkbase Document 101.DEF Â Inline XBRL Definition Linkbase Document 104 Â Cover Page Interactive Data File (embedded within the Inline XBRL document) Â * Filed herewith. ** Furnished herewith. Â 31 Â Â SIGNATURES Â Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Â Dated: November 14, 2024 Â Â GLUCOTRACK, INC. Â Â Â By: /s/ James Cardwell Â Name: James Cardwell Â Title Chief Financial Officer Â Â (Principal Financial Officer) Â 32 EX-31.2 ex31-1.htm Â Exhibit 31.1 Â CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Â 1, Paul Goode, certify that: Â 1. I have reviewed this quarterly report on Form 10-Q for the fiscal quarter ended September 30, 2024 of Glucotrack, Inc.; Â 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â 4. The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â (a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â (b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â (c) evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â (d) disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â 5. The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â (a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Date: November 14, 2024 By: /s/ Paul Goode Â Principal Executive Officer Â EX-31.2 3 ex31-2.htm Â Exhibit 31.2 Â CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 Â 1, James Cardwell, certify that: Â 1. I have reviewed this quarterly report on Form 10-Q for the fiscal quarter ended September 30, 2024 of Glucotrack, Inc.; Â 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Â 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; Â 4. The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: Â (a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; Â (b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; Â (c) evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and Â (d) disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and Â 5. The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): Â (a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and Â (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Â Date: November 14, 2024 By: /s/ James Cardwell Â James Cardwell Â Principal Financial Officer Â EX-32.1 4 ex32-1.htm Â Exhibit 32.1 Â CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Â In connection with the Quarterly Report on Form 10-Q of Glucotrack, Inc. (the â€œCompanyâ€) for the period ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), I, Paul Goode, Principal Executive Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge: Â (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and Â (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Â By: /s/ Paul Goode Â Paul Goode Â Principal Executive Officer Â Â Â Dated: November 14, 2024 Â Â EX-32.2 5 ex32-2.htm Â Exhibit 32.2 Â CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Â In connection with the Quarterly Report on Form 10-Q of Glucotrack, Inc. (the â€œCompanyâ€) for the period ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), I, James Cardwell, Principal Financial Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge: Â (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and Â (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Â By: /s/ James Cardwell Â James Cardwell Â Principal Financial Officer Â Â Â Dated: November 14, 2024 Â Â EX-101.SCH 6 gctk-20240930.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - GENERAL link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - SIGNIFICANT TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - FINANCE (INCOME) EXPENSES, NET link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - SIGNIFICANT TRANSACTIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - FINANCE (INCOME) EXPENSES, NET (Tables) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - GENERAL (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - SCHEDULE OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE (Details) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - SCHEDULE OF OPERATING LEASE (Details) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - SCHEDULE OF MATURITY ANALYSIS OF LEASE LIABILITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERMS AND DISCOUNT RATE (Details) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JUNE 27 NOTES (Details) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JULY 30 NOTES (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - SCHEDULE OF RECONCILIATION OF FAIR VALUE OF EMBEDDED CONVERSION FEATURE (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - SIGNIFICANT TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - SCHEDULE OF FINANCE EXPENSES (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 gctk-20240930 cal.xml XBRL CALCULATION FILE EX-101.DEF 8 gctk-20240930 def.xml XBRL DEFINITION FILE EX-101.LAB 9 gctk-20240930 lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Receipts on Account of Shares [Member] AOCI Attributable to Parent [Member] Retained Earnings [Member] Sale of Stock [Axis] IPO [Member] Private Placement [Member] Warrant [Member] Prefunded Warrants [Member] Performance Milestone [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Exchange Agreement [Member] Lease Agreements [Member] Debt Instrument [Axis] Unsecured Promissory Notes [Member] Short-Term Debt, Type [Axis] Convertible Notes Payable [Member] Convertible Promissory Notes [Member] Warrants Agreement [Member] First Warrant [Member] Second Warrant [Member] Third Warrant [Member] June Twenty Seven Notes [Member] Subsequent Event Type [Axis] Subsequent Event [Member] August Twenty Three Warrant [Member] August Twenty Three Warrant One [Member] August Twenty Three Warrant Two [Member] August Twenty Three Warrant Three [Member] July Eighteen Notes [Member] July Twenty Seven Notes [Member] September Five Warrants [Member] September Five Warrants One [Member] September Five Warrants Two [Member] September Five Warrants Three [Member] June Twenty Seven Warrants [Member] July Thirteen Notes [Member] Lease Contractual Term [Axis] Less Than One Year [Member] Between 1 - 2 Years [Member] More Than 2 Years [Member] July 30 Notes [Member] Legal Entity of Counterparty, Type [Axis] Israeli Innovation Authority [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Legal Entity [Axis] Intellectual Property Purchase Agreement [Member] Class of Stock [Axis] Trueup Shares [Member] Series A Common Warrant [Member] Series B Common Warrant [Member] Series Common Warrant [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Entity Listing, Par Value Per Share Statement of Financial Position [Abstract] ASSETS Current assets Cash and cash equivalents Other current assets Total current assets Operating lease right-of-use asset, net (Note 3C) Property and equipment, net Restricted cash TOTAL ASSETS LIABILITIES AND STOCKHOLDERSâ€™ (DEFICIT) EQUITY Current liabilities Accounts payable Operating lease liability, current (Note 3C) Promissory notes (Note 3G and Note 3H) Convertible promissory notes (Note 3F) Derivative financial liabilities (Note 3G and Note 3H) Other current liabilities Total current liabilities Non-current liabilities Loans from stockholders Operating lease liability, non-current (Note 3C) Total liabilities Commitments and contingent liabilities (Note 4) Stockholdersâ€™ equity Common Stock of \$ 0.001 par value (â€œCommon Stockâ€):100,000,000 shares authorized as of September 30, 2024 and December 31, 2023; 5,772,190 and 4,178,274 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively Additional paid-in capital Receipts on account of shares Accumulated other comprehensive income Accumulated deficit Total stockholdersâ€™ (deficit) equity TOTAL LIABILITIES AND STOCKHOLDERSâ€™ (DEFICIT) EQUITY Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Research and development expenses Marketing expenses General and administrative expenses Total operating expenses Operating loss Other income Finance (income) expenses, net (Note 5) Net Loss Other comprehensive (income) loss: Foreign currency translation adjustment Comprehensive loss for the period Basic net loss per common stock Diluted net loss per common stock Weighted average number of common stock outstanding used in computing basic net loss per share Weighted average number of common stock outstanding used in computing diluted net loss per share Statement [Table] Statement [Line Items] Balance Balance, shares Loss for the period Stock-based compensation Other comprehensive income Deemed dividend resulted from trigger of down round protection feature of certain warrants granted Issuance of Common Stock upon private placement transaction (Note 3D) Issuance of Common Stock upon private placement transaction (Note 3D), shares Issuance of restricted shares as compensation towards directors Issuance of shares as compensation to the board of directors, shares Issuance of restricted shares as compensation towards directors Issuance of restricted shares as compensation towards directors, shares Restricted shares to be issued as compensation towards directors Exercise of prefunded warrants into shares (Note 3A) Exercise of prefunded warrants into shares (Note 3A), shares Exchange of warrants into shares (Note 3B) Exchange of warrants into shares (Note 3B), shares Issuance of detachable warrants through private placement transactions (Note 3F and Note 3H) Issuance of shares and warrants as settlement of financial liabilities (Note 3I and Note 3J) Issuance of Common Stock upon private placement transaction (Note 3D), shares Issuance of restricted shares as payment for a previous achievement of milestone pursuant to purchase agreement (Note 4B) Issuance of restricted shares as payment for a previous achievement of milestone pursuant to purchase agreement (Note 4B), shares Issuance of detachable warrants through private placement transactions (Note 3F and Note 3H) Settlement of liabilities with equity, shares Issuance of shares and warrants as settlement of financial liabilities (Note 3I and Note 3J) Balance Balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Adjustments to reconcile net loss to net cash used in operating activities: Depreciation Stock-based compensation Issuance of restricted shares as compensation towards directors Linkage difference on principal of loans from stockholders Revaluation expenses incurred from settlement of financial liabilities (Note 3I and Note 3J) Revaluation expenses related to derivative financial liabilities (Note 3H) Discount amortization and interest expenses related to promissory notes (Note 3F, Note 3G and Note 3H) Changes in assets and liabilities: Other current assets Accounts payable Other current liabilities Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of property and equipment Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds received from private placement transaction (Note 3D) Issuance of promissory notes and detachable warrants through private placement transaction (Note 3F) Issuance of convertible promissory notes and bifurcated conversion feature through private placement transaction (Note 3G) Issuance of convertible promissory note, bifurcated conversion and redemption features and detachable warrants through private placement transaction (Note 3H) Net proceeds received from underwritten U.S. public offering Net cash provided by financing activities Effect of exchange rate changes on cash and cash equivalents, and restricted cash Change in cash and cash equivalents, and restricted cash Cash and cash equivalents, and restricted cash at beginning of the period Cash and cash equivalents, and restricted cash, end of period Supplemental disclosure of cash flow activities: (a) Net cash (received) paid during the year for: Interest (b) Non-cash investment and financing activities: Deemed dividend upon trigger of down round protection Recognition of right for use asset against a lease liability (Note 3C) Issuance of shares and warrants

as settlement of financial liabilities (Note 3I and Note 3J) Organization, Consolidation and Presentation of Financial Statements [Abstract] GENERAL Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Significant Transactions SIGNIFICANT TRANSACTIONS Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENT LIABILITIES Investments, All Other Investments [Abstract] FINANCE (INCOME) EXPENSES, NET Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of Presentation Use of Estimates in the Preparation of Financial Statements Principles of Consolidation Cash and Cash Equivalents Modification of equity-classified contracts Convertible Promissory Notes Allocation of proceeds and related issuance costs Warrants Leases Basic and diluted loss per share SCHEDULE OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE SCHEDULE OF OPERATING LEASE SCHEDULE OF MATURITY ANALYSIS OF LEASE LIABILITY SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERMS AND DISCOUNT RATE SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JULY 30 NOTES SCHEDULE OF RECONCILIATION OF FAIR VALUE OF EMBEDDED CONVERSION FEATURE SCHEDULE OF FINANCE EXPENSES Subsidiary or Equity Method Investee, Sale of Stock, [Table] Subsidiary, Sale of Stock [Line Items] Retained Earnings (Accumulated Deficit) Net proceeds from public offering Proceeds from Debt, Net of Issuance Costs Unsecured promissory notes Secured promissory notes Debt Securities Net loss Deemed dividend related to trigger of down round protection feature Net loss attributable to common stockholders Weighted average number of Common Stock outstanding used in computing basic net loss per share Weighted average number of Common Stock outstanding used in computing diluted net loss per share Diluted net loss per common stock Schedule Of Operating Lease Operating right-of-use asset Current operating lease liability Non-Current operating lease liability Lessee, Lease, Description [Table] Lessee, Lease, Description [Line Items] Total operating lease payments Less: imputed interest Present value of lease liabilities Schedule Of Weighted Average Remaining Lease Terms And Discount Rate Lease term (years) Weighted average discount rate Open balance Total proceeds received Total proceeds allocated to June 27 Warrants at initial recognition Discount amortization and interest expenses related to June 27 Notes (Note 5 below) Partial conversion June 27 Notes and accrued Interest (Note 3I and Note 3J below) Ending balance Open balance Total proceeds allocated to July 18 Notes at initial recognition Interest expenses related to July 18 Notes (Note 5 below) Partial conversion July 18 Notes and accrued Interest (Note 3J below) Ending balance Total proceeds received Total proceeds allocated to July 30 Warrants at initial recognition Total proceeds allocated to embedded redemption feature at initial recognition Amortization of discount and interest expenses related to July 30 Note (Note 5 below) Open balance Proceeds allocated to embedded redemption feature at initial recognition Revaluation expenses related to embedded redemption feature (Note 5 below) Ending balance Short-Term Debt [Table] Short-Term Debt [Line Items] Pre-funded warrants Shares of Common Stock Lock-up period conditions Share price Monthly rental fee Lessee term of contract Security deposit Lease liability Number of shares issued Common stock share price Aggregate gross proceeds offering Reverse stock split Debt instrument face amount Class of warrant or right number of securities called by warrants or rights Notes payable description Exercise price Warrants and rights outstanding term Proceeds from notes Fair value of warrants Debt discount rate Volatility Risk- free interest rate Debt instrument interest rate Gross proceeds from notes conversion Conversion price Conversion price Debt instrument description Sale of stock issued price per share Sale of stock description of transaction Debt description of notice of default Debt default long term debt amount Debt Instrument, Term Embedded conversion feature percentage Fair value of embedded derivative liability Interest expense Stock issued during period shares issued for services Warrants exercisable Equity fair value disclosure Loss Contingencies [Table] Loss Contingencies [Line Items] Contingent consideration liability Royalty percentage maximum Number of common shares issued Commission as a percentage of aggregate sales price Restricted shares Research and development expenses Stock based compensation Discount rate Discount amortization and interest expenses related to June 27 Notes Interest expenses related to July 18 Notes Discount amortization and interest expenses related to July 30 Note Revaluation expenses related to derivative financial liabilities Revaluation expenses incurred from settlement of financial liabilities Interest on bank deposits Exchange rate differentials, bank commissions and miscellaneous Finance (income) expenses, net Subsequent Event [Table] Subsequent Event [Line Items] Gross proceeds from public offering Stock issuance Warrant, exercise price Incremental and direct issuance costs Debt conversion converted instrument amount Conversion price, per share Receipts on account of shares. Finance income net. Receipts on Account of Shares [Member] Adjustments to additional paid in capital deemed dividend resulted from trigger of down round protection feature of certain warrants granted Stock to be issued during period value restricted stock award gross. Issuance of restricted shares as payment for achievement of milestone pursuant to purchase agreement . Exercise of prefunded warrants into shares. Stock issued during period value issuance of warrant Stock issued during period value settlement of liabilities with equity. Stock issued during period shares settlement of liabilities with equity. Exercise of prefunded warrants into shares ,shares. Issuance of restricted shares as payment for achievement of milestone pursuant to purchase agreement ,shares Issuance of restricted shares as compensation to the board of directors. Linkage difference on principal of loans from stockholders . Proceeds received from underwritten public offering. Deemed dividend upon trigger of down round protection. Deemed dividend related to trigger of down round protection feature. Prefunded Warrants [Member] Earnings per share diluted including warrants and performance milestones. Exchange Agreement [Member] Lock up period description. Lessee operating lease liability imputed interest Schedule Of Weighted Average Remaining Lease Terms And Discount Rate [Table Text Block] Unsecured Promissory Notes [Member] Convertible Promissory Notes [Member] Warrants Agreement [Member] First Warrant [Member] Second Warrant [Member] Third Warrant [Member] Israeli Innovation Authority [Member] Royalty percentage. Intellectual Property Purchase Agreement [Member] Aggregate sales price of units percentage. Trueup Shares [Member] Marketability discount rate Modification Of Equity Classified Contracts [Policy Text Block] Significant Transactions [Text Block] Performance Milestone [Member] Less Than One Year [Member] Between 1 - 2 Years [Member] More Than 2 Years [Member] Promissory notes current. Stock issued during period value issuance of detachable warrants through private placement transactions. Stock issued during period value issuance of shares and warrants as settlement of financial liabilities. Stock issued during period shares issuance of shares and warrants as settlement of financial liabilities. Revaluation expenses incurred from settlement of financial liabilities. Revaluation expenses related to derivative financial liabilities. Proceeds from convertible debt private placement transaction. Convertible Promissory Notes [Policy Text Block] Allocation Of Proceeds And Related Issuance Costs [Policy Text Block] Schedule Of Reconciliation Of Carrying Amount Of Notes [Table Text Block] June Twenty Seven Warrants [Member] Proceeds from allocated warrants at initial recognition. Discount amortization and interest expenses. Partial conversion notes and accrued interest. July Eighteen Notes [Member] Partial conversion and accrued interest. Embedded conversion feature percentage. Issuance of shares and warrants as settlement of financial liabilities. July Thirteen Notes [Member] Schedule Of Reconciliation Of Fair Value Of Embedded Conversion Feature [Table Text Block] Revaluation expenses related to embedded redemption feature. August Twenty Three Warrant [Member] August Twenty Three Warrant One [Member] August Twenty Three Warrant Two [Member] August Twenty Three Warrant Three [Member] June Twenty Seven Notes [Member] September Five Two Thousand Twenty Four Warrant One [Member] September Five Warrants One [Member] September Five Warrants [Member] September Five Warrants Two [Member] September Five Warrants Three [Member] Discount amortization and interest expenses one. Discount amortization and interest expenses two. Series A Warrant Shares [Member] Series B Warrant Shares [Member] Series A Common Warrant [Member] Series B Common Warrant [Member] July Thirty Notes [Member] Assets, Current Assets Liabilities, Current Liabilities Equity, Attributable to Parent Liabilities and Equity Operating Expenses Operating Income (Loss) Other Nonoperating Income (Expense) FinanceIncomeNet Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Comprehensive Income (Loss), Net of Tax, Attributable to Parent Shares, Outstanding Shares Issued, Value, Share-Based Payment Arrangement, before Forfeiture StockIssuedDuringPeriodSharesIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities StockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity StockIssuedDuringPeriodValueIssuanceOfWarrant IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors Increase (Decrease) in Other Current Assets Increase (Decrease) in Accounts Payable Increase (Decrease) in Other Current Liabilities Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Interest Paid, Excluding Capitalized Interest, Operating Activities IssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature Net Income (Loss) Available to Common Stockholders, Basic EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones LesseeOperatingLeaseLiabilityImputedInterest Warrants and Rights Outstanding Convertible Debt Stock Issued During Period, Value, Conversion of Units Other Research and Development Expense EX-101.PRE 10 gctk-20240930_pre.xml XBRL PRESENTATION FILE XML 12 RI.htm IDEA: XBRL DOCUMENT Y3.v24.3 Cover - \$ / shares 9 Months Ended Sep. 30, 2024 Nov. 03, 2024 Cover [Abstract] A Document Type 10-Q 4 Amendment Flag false A Document Quarterly Report true A Document Transition Report false A Document Period End Date Sep. 30, 2024 A Document Fiscal Period Focus Q3 A Document Fiscal Year Focus 2024 A Current Fiscal Year End Date -12-31 A Entity File Number 001-41141 A Entity Registrant Name GLUCOTRACK, INC. A Entity Central Index Key 0001506983 A Entity Tax Identification Number 98-0668934 A Entity Incorporation, State or Country Code DE A Entity Address, Address Line One 301 Route 17 North A Entity Address, Address Line Two Suite 800 A Entity Address, City or Town Rutherford A Entity Address, State or Province NJ A Entity Address, Postal Zip Code 07070 A City Area Code (201) A Local Phone Number 842-7715 A Title of 12(b) Security Common Stock A Trading Symbol GCTK A Security Exchange Name NASDAQ A Entity Current Reporting Status Yes A Entity Interactive Data Current Yes A Entity Filer Category Non-accelerated Filer A Entity Small Business true A Entity Emerging Growth Company false A Entity Shell Company false A Entity Common Stock, Shares Outstanding A 5,772,026 Entity Listing, Par Value Per Share \$ 0.001 X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:yearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrli.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrli.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine2 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrli.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrli.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrli.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrli.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe par value per share of security quoted in same currency as Trading currency. Example: '0.01'. + ReferencesNo definition available. + Details Name: dei_EntityListingParValuePerShare Namespace Prefix: dei_ Data Type: dt-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrli.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrli.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -

Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1:

changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1:

holders and owners, may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3> + Details Name: us-gaap CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD (\$) \$ in Thousands 3 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2023 Income Statement [Abstract] A A A Research and development expenses \$ 2,063 \$ 1,693 \$ 7,800 \$ 2,962 Marketing expenses 125 295 General and administrative expenses 1,063 531 2,598 1,725 Total operating expenses 3,251 2,224 10,693 4,687 Operating loss 3,251 2,224 10,693 4,687 Other income (12) (12) Finance (income) expenses, net (Note 5) 1,848 (1) 1,822 (2) Net Loss 5,087 2,223 12,503 4,685 Other comprehensive (income) loss: A A A Foreign currency translation adjustment 17 (6) 11 (17) Comprehensive loss for the period \$ 5,104 \$ 2,217 \$ 12,514 \$ 4,668 Basic net loss per common stock \$ (0.91) \$ (0.49) \$ (2.39) \$ (1.38) Diluted net loss per common stock \$ (0.91) \$ (0.49) \$ (2.39) \$ (1.38) Weighted average number of common stock outstanding used in computing basic net loss per share 5,594,880 4,593,733 5,355,806 4,006,527 Weighted average number of common stock outstanding used in computing diluted net loss per share 5,594,880 4,593,733 5,355,806 4,006,527 X - DefinitionFinance income net. + ReferencesNo definition available. + Details Name: GCTK FinanceIncomeNet Namespace Prefix: GCTK_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef> -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-5> + Details Name: us-gaap ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef> -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI

10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(ii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term investment nature. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 + Details Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited) - USD (\$) Common Stock [Member] Additional Paid-in Capital [Member] Receipts on Account of Shares [Member] AOCI Attributable to Parent [Member] Retained Earnings [Member] Total Balance at Dec. 31, 2022 \$ 3,000 \$ 103,107,000 \$ 4,000 \$ 17,000 \$ (101,901,000) \$ 1,230,000 Balance, shares at Dec. 31, 2022 3,099,982 Á Á Á Á Loss for the period (4,685,000) (4,685,000) Stock-based compensation 17,000 17,000 Other comprehensive income 260,000 Á 260,000 Deemed dividend resulted from trigger of down round protection feature of certain warrants granted 855,000 (855,000) Issuance of Common Stock upon private placement transaction (Note 3D) \$ 1,000 8,729,000 8,730,000 Issuance of Common Stock upon private placement transaction (Note 3D), shares 1,075,294 Á Á Á Á Issuance of restricted shares as compensation towards directors [1] 9,000 (4,000) 5,000 Issuance of shares as compensation to the board of directors, shares 2,998 Á Á Á Á Balance at Sep. 30, 2023 4,000 112,960,000 34,000 (107,441,000) 5,557,000 Balance, shares at Sep. 30, 2023 4,178,274 Á Á Á Á Balance at Jun. 30, 2023 4,000 112,929,000 28,000 (105,218,000) 7,743,000 Balance, shares at Jun. 30, 2023 4,178,274 Á Á Á Á Loss for the period (2,223,000) (2,223,000) Stock-based compensation 6,000 6,000 Other comprehensive income 31,000 31,000 Balance at Sep. 30, 2023 4,000 112,960,000 34,000 (107,441,000) 5,557,000 Balance, shares at Sep. 30, 2023 4,178,274 Á Á Á Á Balance at Dec. 31, 2023 4,000 112,982,000 48,000 16,000 (109,853,000) 3,197,000 Balance, shares at Dec. 31, 2023 4,178,274 Á Á Á Á Loss for the period (12,503,000) (12,503,000) Stock-based compensation (11,000) (11,000) Other comprehensive income 239,000 239,000 Issuance of Common Stock upon private placement transaction (Note 3D) Á 500,000 500,000 Issuance of Common Stock upon private placement transaction (Note 3D), shares 79,366 Á Á Á Á Issuance of restricted shares as compensation towards directors Á 126,000 (48,000) 78,000 Issuance of restricted shares as compensation towards directors, shares 86,861 Á Á Á Á Restricted shares to be issued as compensation towards directors 100,000 100,000 Exercise of prefunded warrants into shares (Note 3A) Á Exercise of prefunded warrants into shares (Note 3A), shares 395,294 Á Á Á Á Exchange of warrants into shares (Note 3B) \$ 1,000 (1,000) Exchange of warrants into shares (Note 3B), shares 718,641 Á Á Á Á Issuance of detachable warrants through private placement transactions (Note 3F and Note 3H) 2,635,000 2,635,000 Issuance of shares and warrants as settlement of financial liabilities (Note 3I and Note 3J) \$ 1,000 1,742,000 1,743,000 Issuance of Common Stock upon private placement transaction (Note 3D), shares 293,590 Á Á Á Á Issuance of restricted shares as payment for a previous achievement of milestone pursuant to purchase agreement (Note 4B) Issuance of restricted shares as payment for a previous achievement of milestone pursuant to purchase agreement (Note 4B), shares 20,000 Á Á Á Á Balance at Sep. 30, 2024 6,000 118,223,000 100,000 5,000 (122,356,000) (4,022,000) Balance, shares at Sep. 30, 2024 5,772,026 Á Á Á Á Balance at Jun. 30, 2024 5,000 113,903,000 50,000 22,000 (117,269,000) (3,289,000) Balance, shares at Jun. 30, 2024 5,478,436 Á Á Á Á Loss for the period (5,087,000) (5,087,000) Stock-based compensation 11,000 11,000 Other comprehensive income (17,000) (17,000) Restricted shares to be issued as compensation towards directors 50,000 50,000 Issuance of detachable warrants through private placement transactions (Note 3F and Note 3H) 2,567,000 2,567,000 Settlement of liabilities with equity, shares Á Á Á Á Issuance of shares and warrants as settlement of financial liabilities (Note 3I and Note 3J) 1,000 1,742,000 1,743,000 Balance at Sep. 30, 2024 6,000 118,223,000 100,000 5,000 (122,356,000) (4,022,000) Balance, shares at Sep. 30, 2024 5,772,026 Á Á Á [1] Represents amount lower than \$1. X - DefinitionAdjustments to additional paid in capital deemed dividend resulted from trigger of down round protection feature of certain warrants granted + ReferencesNo definition available. + Details Name: GCTK_AdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted Namespace Prefix: GCTK_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionExercise of prefunded warrants into shares ,shares. + ReferencesNo definition available. + Details Name: GCTK_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrantsIntoShares Namespace Prefix: GCTK_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIssuance of restricted shares as payment for achievement of milestone pursuant to purchase agreement ,shares + ReferencesNo definition available. + Details Name: GCTK_StockIssuedDuringPeriodSharesIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b Namespace Prefix: GCTK_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionStock issued during period shares issuance of shares and warrants as settlement of financial liabilities. + ReferencesNo definition available. + Details Name: GCTK_StockIssuedDuringPeriodSharesIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities Namespace Prefix: GCTK_Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionStock issued during period shares settlement of liabilities with equity. + ReferencesNo definition available. + Details Name: GCTK_StockIssuedDuringPeriodSharesSettlementOfLiabilitiesWithEquity Namespace Prefix: GCTK_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionExercise of prefunded warrants into shares. + ReferencesNo definition available. + Details Name: GCTK_StockIssuedDuringPeriodValueExerciseOfPrefundedWarrantsIntoShares Namespace Prefix: GCTK_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionStock issued during period value issuance of detachable warrants through private placement transactions. + ReferencesNo definition available. + Details Name: GCTK_StockIssuedDuringPeriodValueIssuanceOfDetachableWarrantsThroughPrivatePlacementTransactions Namespace Prefix: GCTK_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIssuance of restricted shares as payment for achievement of milestone pursuant to purchase agreement . + ReferencesNo definition available. + Details Name: GCTK_StockIssuedDuringPeriodValueIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b Namespace Prefix: GCTK_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionStock issued during period value issuance of shares and warrants as settlement of financial liabilities. + ReferencesNo definition available. + Details Name: GCTK_StockIssuedDuringPeriodValueIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities Namespace Prefix: GCTK_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionStock issued during period value issuance of warrant + ReferencesNo definition available. + Details Name: GCTK_StockIssuedDuringPeriodValueIssuanceOfWarrant Namespace Prefix: GCTK_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionStock issued during period value settlement of liabilities with equity. + ReferencesNo definition available. + Details Name: GCTK_StockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity Namespace Prefix: GCTK_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionStock to be issued during period value restricted stock award gross. +

ReferencesNot credit available. + Details Name: GCTK StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross Namespace Prefix: GCTK_ Data Type: xbrli:monetaryItemType
Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1:
<http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI>
<https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2:> <http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3:> [http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4:>
[http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI)
<https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5:> [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(20\)\) -Publisher FASB -URI](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6:> [http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7:> [http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8:> [http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9:> <http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10:>
<http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11:> [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(2\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12:> [http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13:>
<http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14:> [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15:> [http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16:>
<http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17:> <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18:> <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19:>
[http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(18\)\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20:> [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(9\)\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21:>
[http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(1\)\(d\)\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22:> [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23:>
[http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24:> [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25:>
[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26:> [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27:>
[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28:> [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(ii\)\(A\)\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(ii)(A)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29:>
[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30:> [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31:>
[http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32:> [http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(a\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33:> <http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34:>
<http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35:> [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(a\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36:> [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37:>
[http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(22\)\) -Publisher FASB -URI](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI) [https://asc.fasb.org/1943274/2147478524/942-220-S99-1+ Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of other comprehensive income \(loss\). + ReferencesReference 1:](https://asc.fasb.org/1943274/2147478524/942-220-S99-1+ Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of other comprehensive income (loss). + ReferencesReference 1:) <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2:>
<http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 3:> <http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4:> <http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5:> [http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(19\)\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 6:> <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 7:> <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 8:> <http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 9:>
[http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(21\)\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10:> [http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-04\(23\)\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 11:>
[http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(b\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 12:> <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147482739/220-10-55-15Reference 13:> [http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(b\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI) https://asc.fasb.org/1943274/2147482790/220-10-45-1A+ Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued which are neither cancelled nor held in the treasury. + ReferencesNo definition available. + Details Name: us-gaap_SharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued during the period as a result of the conversion of convertible securities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI> <https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2:> [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3:> [http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph \(c\) -Publisher FASB -URI](http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI) <https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 5:> [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI)

1Reference 4: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11>Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(4\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 8: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1) + Details Name: us-gaap StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1) + Details Name: us-gaap StockIssuedDuringPeriodValueRestrictedStockAwardNetOffForfeitures Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1)Reference 4: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph \(d\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2) + Details Name: us-gaap StockIssuedDuringPeriodValueShareBasedCompensation Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). + ReferencesNo definition available. + Details Name: us-gaap StockIssuedDuringPeriodValueShareBasedCompensationGross Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(30\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(31\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 5: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(19\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.6-05\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2)Reference 8: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(4\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(6\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(7\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 11: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 12: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 13: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 14: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SAB Topic 4.E\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2) + Details Name: us-gaap StockholdersEquity Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Cash Flows (Unaudited) - USD (\$) in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 CASH FLOWS FROM OPERATING ACTIVITIES: A Loss for the period \$ (12,503) \$ (4,685) Adjustments to reconcile net loss to net cash used in operating activities: A Depreciation 22 21 Stock-based compensation 239 260 Issuance of restricted shares as compensation towards directors 178 5 Linkage difference on principal of loans from stockholders 1 4 Revaluation expenses incurred from settlement of financial liabilities (Note 31 and Note 3J) 1,505 Revaluation expenses related to derivative financial liabilities (Note 3H) 2 Discount amortization and interest expenses related to promissory notes (Note 3F, Note 3G and Note 3H) 330 Changes in assets and liabilities: A Other current assets 80 (216) Accounts payable 1,129 598 Other current liabilities 26 (134) Net cash used in operating activities (8,991) (4,147) CASH FLOWS FROM INVESTING ACTIVITIES: A Purchase of property and equipment (104) Net cash used in investing activities (104) CASH FLOWS FROM FINANCING ACTIVITIES: A Proceeds received from private placement transaction (Note 3D) 500 Issuance of promissory notes and detachable warrants through private placement transaction (Note 3F) 100 Issuance of convertible promissory notes and bifurcated conversion feature through private placement transaction (Note 3G) 360 Issuance of convertible promissory note, bifurcated conversion and redemption features and detachable warrants through private placement transaction (Note 3H) 4,000 Net proceeds received from underwritten U.S. public offering 8,730 Net cash provided by financing activities 4,960 8,730 Effect of exchange rate changes on cash and cash equivalents, and restricted cash (11) (17) Change in cash and cash equivalents, and restricted cash (4,146) 4,566 Cash and cash equivalents, and restricted cash at beginning of the period 4,502 2,331 Cash and cash equivalents, and restricted cash, end of period 356 6,897 (a) Net cash (received) paid during the year for: A Interest (37) (b) Non-cash investment and financing activities: A Deemed dividend upon trigger of down round protection 855 Recognition of right for use asset against a lease liability (Note 3C) 79 Issuance of shares and warrants as settlement of financial liabilities (Note 3I and Note 3J) \$ 238 X - DefinitionDeemed dividend upon trigger of down round protection. + ReferencesNo definition available. + Details Name: GCTK DeemedDividendUponTriggerOfDownRoundProtection Namespace Prefix: GCTK Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIssuance of restricted shares as compensation to the board of directors. + ReferencesNo definition available. + Details Name: GCTK IssuanceOfRestrictedSharesAsCompensationToBoardOfDirectors Namespace Prefix: GCTK Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIssuance of shares and warrants as settlement of financial liabilities. + ReferencesNo definition available. + Details Name: GCTK IssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities Namespace Prefix: GCTK Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLinkage difference on principal of loans from stockholders. + ReferencesNo definition available. + Details Name: GCTK LinkageDifferenceOnPrincipalOfLoansFromStockholders Namespace Prefix: GCTK Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProceeds from convertible debt private placement transaction. + ReferencesNo definition available. + Details Name: GCTK ProceedsFromConvertibleDebtPrivatePlacementTransaction Namespace Prefix: GCTK Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProceeds received from underwritten public offering. + ReferencesNo definition available. + Details Name: GCTK ProceedsReceivedFromUnderwrittenPublicOffering Namespace Prefix: GCTK Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRevaluation expenses incurred from settlement of financial liabilities. + ReferencesNo definition available. + Details Name: GCTK RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities Namespace Prefix: GCTK Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRevaluation expenses related to derivative financial liabilities. + ReferencesNo definition available. + Details Name: GCTK RevaluationExpensesRelatedToDerivativeFinancialLiabilities Namespace Prefix: GCTK Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of amortization expense attributable to debt discount (premium) and debt issuance costs. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E>Reference 2: <http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F](http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F)Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 5: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3> + Details Name: us-gaap AmortizationOffinancingCostsAndDiscounts Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4> + Details Name: us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1> + Details Name: us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1) + Details Name: us-gaap Depreciation Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1> + Details Name: us-gaap EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in current assets classified as other. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap IncreaseDecreaseInOtherCurrentAssets Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in current liabilities classified as other. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap IncreaseDecreaseInOtherCurrentLiabilities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap InterestPaidAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to

settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17](http://www.xbrl.org/2003/role/disclosureRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph \(e\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25](http://www.xbrl.org/2003/role/disclosureRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap InterestPaidNet Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: <a href=)Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25> + Details Name: us-gaap NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph \(g\)\(3\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.5-03\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(b\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 13: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 16: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 17: <http://www.xbrl.org/2003/role/exampleRef-Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-1>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7>Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-04\(18\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-07\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(1\)\(d\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 23: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 28: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 29: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 30: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 31: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 32: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 33: <http://www.xbrl.org/2003/role/disclosureRef-Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 34: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 35: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A)Reference 36: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B)Reference 37: [http://www.xbrl.org/2003/role/exampleRef-Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap NetIncomeLoss Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap NoncashInvestingAndFinancingItemsAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: <a href=)Reference 2:

gaap OrganizationConsolidationAndPresentationOffinancialStatementsAbstract X-Name Prefix: us-gaap Data Type: xbrl:stringItemType Balance Type: na Period Type: duration X-

DefinitionThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. + ReferencesReference 1:

<http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI>

[| | 2024 | 2023 | US dollars \(except share data\) | US dollars \(except share data\) |
| --- | --- | --- | --- | --- |
| Three-month period ended September 30, | Nine-month period ended September 30, | \(Unaudited\) | \(Unaudited\) | |
| 2024 | 2023 | 2024 | 2023 | |
| Net loss | \\$5,087 | \\$2,223 | \\$12,503 | \\$4,685 |
| Deemed dividend related to trigger of down round protection feature | - | - | - | - |
| Net loss attributable to common stockholders | \\$5,087 | \\$2,223 | \\$12,503 | \\$4,685 |
| Shares of Common Stock used in computing basic and diluted net loss per common stock | 5,564,880 | 4,593,733 | 5,340,532 | 3,758,590 |
| Shares of Common Stock to be issued upon exercise of pre-funded warrants | 241,266 | 15,275 | 6,691 | |
| Weighted average number of Common Stock outstanding used in computing basic and diluted net loss per share | 5,594,880 | 4,593,733 | 5,355,866 | 4,006,527 |
| Basic and diluted net loss per common stock | \(\\$0.91\) | \(\\$0.49\) | \(\\$2.39\) | \(\\$1.38\) |

GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS \(UNAUDITED\)\(CONT.\) \(in thousands of US Dollars\) A X - ReferencesNo definition available. + Details Name: us-gaap AccountingPoliciesAbstract Namespace Prefix: us-gaap Data Type: xbrl:stringItemType Balance Type: na Period Type: duration X- DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1:](https://asc.fasb.org/1943274/2147480424/946-10-50-1-Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2-Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap OrganizationConsolidationAndPresentationOffinancialStatementsDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.3 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] A SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES A NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES A A.</p><p>Basis of Presentation A The accompanying unaudited condensed interim consolidated financial statements and related notes should be read in conjunction with the Company's consolidated financial statements and related notes included in the Company's annual report on Form 10-K for the fiscal year ended December 31, 2023, as was filed with the Securities and Exchange Commission (SEC) on March 28, 2024. The unaudited condensed interim consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC related to interim financial statements. As permitted under those rules, certain information and footnote disclosures normally required or included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The financial information contained herein is unaudited; however, management believes all adjustments have been made that are considered necessary to present fairly the results of the Company's financial position and operating results for the interim periods. All such adjustments are of a normal recurring nature. A</p><p>A The results for the period of three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024 or for any other interim period or for any future period. B. Use of Estimates in the Preparation of Financial Statements A The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these interim financial statements, the most significant estimates and assumptions include identification and measurement of financial instruments. A C. Principles of Consolidation A The condensed interim consolidated financial statements include the accounts of the Company and its subsidiary. Significant intercompany balances and transactions have been eliminated in consolidation. A D. Cash and Cash Equivalents A Cash equivalents are short-term highly liquid investments which include short-term bank deposits (up to three months from date of deposit), that are not restricted as to withdrawals or use that are readily convertible to cash with maturities of three months or less as of the date acquired. A E. Modification of equity-classified contracts A The modification or exchange of equity-classified contracts, such as warrants that were classified as equity before the modification or exchange and remained eligible for equity classification after the modification, is accounted for in a similar manner to a modification of stock-based compensation. Accordingly, the incremental fair value from the modification or exchange (the change in the fair value of the instrument before and after the modification or exchange) is recognized as a reduction of retained earnings of increase of accumulated deficit as a deemed dividend. Modifications or exchanges that result in a decrease in the fair value of an equity-classified share-based payment awards are not recognized. In addition, the amount of the deemed dividend is also recognized as an adjustment to earnings available to common shareholders for purposes of calculating earnings per share. A GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (in thousands of US Dollars) A NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.) A F. Convertible Promissory Notes A Upon initial recognition of convertible promissory notes and similar instruments, the Company considers the provisions of ASC 815-40, Derivatives and Hedging - Contracts in Entity's Own Equity (ASC 815-40A) in order to determine whether the conversion features embedded within the convertible instrument should be separated from the host instrument. A When it is determined that an embedded derivative required to be bifurcated (such as embedded conversion feature that does not qualify for equity classification), the Company recognized the embedded derivative bifurcated as a separate derivative liability upon initial recognition and on subsequent periods at fair value. The remaining consideration amount received or allocated to the entire convertible instrument is allocated to the host debt instrument. The difference between the face value of the host and such an allocated amount represents a discount which is amortized as finance expense to profit or loss using an effective interest method over the term of the note until its stated maturity. A When it is determined that the embedded conversion feature qualifies for equity classification (such when the embedded conversion option, if it were freestanding, is not qualified as a derivative in accordance with the provisions of ASC 815-10, Derivatives and Hedging since its terms did not require or permit net settlement or when the embedded conversion option is indexed to the entity's own stock), the conversion option is not bifurcated. When bifurcation is not required, the Company considers whether the debt instrument involves a significant premium (i.e. when the proceeds received or allocated upon issuance exceed the principal amount that will be paid at maturity). When it is determined that a substantial premium exists, the entire premium is allocated to paid-in capital and when it is determined, otherwise no additional accounting is required and the convertible promissory note is accounted for at amortized cost using effective interest method over the term of the note until its stated maturity. A G. Allocation of proceeds and related issuance costs A A When multiple instruments are issued in a single transaction (package issuance), the total net proceeds from the transaction are allocated among the individual freestanding instruments identified. The allocation occurs after identifying all freestanding instruments and the subsequent measurement basis for those instruments. A Financial instruments that are required to be subsequently measured at fair value (such as derivative liabilities) are measured at fair value and the remaining consideration is allocated to other financial instruments that are not required to be subsequently measured at fair value (such as liabilities measured at amortized cost, common shares and warrants eligible for equity classification), based on the relative fair value basis for such instruments. A Issuance costs allocated to financial instruments that are required to be subsequently measured at fair value immediately expensed. Issuance costs allocated to shares and warrants classified as equity components and are recorded as a reduction of additional paid-in capital. Issuance costs allocated to financial liabilities measured at amortized cost are recorded as a discount and accreted over the contractual term of the financial instrument using the effective interest method. A GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (in thousands of US Dollars) A NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.) A H. Warrants A Certain warrants that were issued to several holders are classified as a component of permanent equity since they are freestanding financial instruments that are legally detachable and separately exercisable, do not embody an obligation for the Company to repurchase its own shares, and permit the holders to receive a fixed number of Ordinary Shares upon exercise for a fixed exercise price and thus, are considered as indexed to the Company's own shares. As such warrants were issued together with financial instruments that are not subsequently measured at fair value and the warrants were measured based on allocation of the proceeds received by the Company in accordance with the relative fair value basis. When applicable, direct issuance expenses that were allocated to certain warrants were deducted from additional paid-in capital. A I. Leases A The Company applies ASC Topic 842, Leases (ASC 842A) under which the Company determines if an arrangement is a lease at inception. A Leases are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: (i) the lease transfers ownership of the asset by the end of the lease term, (ii) the lease contains an option to purchase the asset that is reasonably certain to be exercised, (iii) the lease term is for a major part of the remaining useful life of the asset, (iv) the present value of the lease payments equals or exceeds substantially all of the fair value of the asset, or (v) the underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of lease term. A lease is classified as an operating lease if it does not meet any one of these criteria. Since all the Company's lease contracts for premises do not meet any of the criteria above, the Company concluded that all its lease contracts should be classified as operating leases. A Right of Use (ROU) assets and liabilities are recognized on the commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company's leases do not provide an implicit rate, the Company uses its Incremental Borrowing Rate (IBR) based on the information available on the commencement date in determining the present value of lease payments. The Company's IBR is estimated to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic environments where the leased asset is located. The ROU asset also includes any lease payments made prior to commencement and is recorded net of any lease incentives received. Moreover, the ROU asset may also include initial direct costs, which are incremental costs of a lease that would not have been incurred if the lease had not been obtained. The Company uses the long-lived assets impairment guidance in ASC 360-10, Property, Plant, and Equipment - Overall, to determine whether a ROU asset is impaired, and if so, the amount of the impairment loss to recognize. Certain leases include options to extend or terminate the lease. An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain that the Company will exercise that option. An option to terminate is considered unless it is reasonably certain that the Company will not exercise the option. A GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (in thousands of US Dollars) A NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.) A J. Basic and diluted loss per share A Basic loss per share is computed by dividing the loss for the period applicable (after considering the effect of deemed dividend related to trigger of down round protection feature) for Common Stockholders by the weighted average number of shares of Common Stock outstanding and shares of Common Stock to be issued upon achievement of certain performance milestones during the period and upon exercise of pre-funded warrants. In computing, diluted loss per share, basic earnings per share are adjusted to reflect the potential dilution that could occur upon the exercise of options or warrants issued or granted using the treasury stock method and using the if-converted method with respect to certain convertible promissory notes and bifurcated redemption feature accounted for as derivative financial liability, if the effect of each of such financial instruments is dilutive. In computing diluted loss per share, the average stock price for the period is used in determining the number of Common Stock assumed to be purchased from the proceeds to be received from the exercise of stock options or stock warrants. A Shares to be issued upon exercise of all options and warrants, convertible promissory notes and bifurcated redemption feature, have been excluded from the calculation of the diluted net loss per share for all the reported periods for which net loss was reported because the effect of the common shares issuable as result of the exercise or conversion of these instruments was anti-dilutive. A The net loss and the weighted average number of shares of Common Stock used in computing basic and diluted net loss per Common Stock for the period of three and nine months ended September 30, 2024 and 2023, is as follows: A SCHEDULE OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE</p><table border=)

À 13Ã À À À À À Total operating lease paymentsÀ \$73Ã À À À À Less: imputed interestÀ \$8Ã À À À À Present value of lease liabilitiesÀ \$65Ã À À Additional information on lease À

The following is a summary of the weighted average remaining lease terms and discount rate for the lease: À À SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERMS AND DISCOUNT RATE À À September 30, 2024À Lease term (years)À 4.2Ã 2.4Ã Weighted average discount rateÀ 9.03% À D. Private Placement Agreement À À On April 22, 2024, the Company entered into a private placement agreement under which the Company issued 79,366 shares of its common stock at a price of \$6.30 per share for aggregate gross proceeds of \$500 (the â€œOfferingâ€). The Offering included participation of certain members of the Companyâ€™s executive management, Board of Directors and existing shareholders. À E. Adoption of 2024 Equity Incentive Plan and Reverse Share Split À À On April 26, 2024, the Company held its Annual Meeting of Shareholders (the â€œAnnual Meetingâ€) under which the Companyâ€™s stockholders approved, inter alia, the following proposals: (i) adoption of the Companyâ€™s 2024 Equity Incentive Plan and (ii) an amendment to Article IV of the Companyâ€™s Certificate of Incorporation, to effect a reverse stock split of the Companyâ€™s Common Stock at a ratio of between one-for-five and one-for-thirty, with such ratio to be determined at the sole discretion of the Board of Directors. Following the Annual Meeting, on April 30, 2024, the Companyâ€™s Board of Directors approved a one-for-five reverse stock split of the Companyâ€™s issued and outstanding shares of common stock (the â€œReverse Stock Splitâ€). On May 17, 2024, the Company filed a Certificate of Amendment to the Companyâ€™s Certificate of Incorporation with the Secretary of State of the State of Delaware which effected the Reverse Stock Split. À For accounting purposes, all shares, options and warrants to purchase shares of common stock and loss per share amounts have been adjusted to give retroactive effect to the Reverse Share Split for all periods presented in these interim consolidated financial statements. Any fractional shares resulting from the Reverse Share Split were rounded up to the nearest whole share. À À GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.) (in thousands of US Dollars) À NOTE 3 - SIGNIFICANT TRANSACTIONS (CONT.) À F. Note and Warrant Purchase Agreements À À On June 27, 2024, the Company entered into note and warrant purchase agreements (the â€œPurchase Agreementâ€) with certain investors (the â€œJune 27 Investorsâ€), providing for the private placement of unsecured promissory notes in the aggregate principal amount of \$100 (the â€œJune 27 Notesâ€ and each a â€œJune 27 Noteâ€) and warrants to purchase up to an aggregate of 300,000 shares of the Companyâ€™s Common Stock (the â€œJune 27 Warrantsâ€). À The June 27 Notes bear simple interest at a rate of 3% per annum and are due and payable in cash on the earlier of: (a) 12 months from the date of the June 27 Note; or (b) the date the Company raises third-party equity capital in an amount equal to or in excess of \$1,000 (the â€œMaturity Dateâ€). The Company may prepay the June 27 Notes at any time prior to the Maturity Date without penalty. If an event of default occurs, the then-outstanding principal amount of the June 27 Notes plus any unpaid accrued interest will accelerate and become immediately payable in cash. À Each of June 27 Warrants has an exercise price of \$4.95 per share. The June 27 Warrants are immediately exercisable and have a 5-year term. À Upon initial recognition, the management allocated the gross cash proceeds received based on the relative fair value of the June 27 Notes and the detachable June 27 Warrants in total amount of \$15 and \$85, respectively. The fair value of the June 27 Note was determined based on a rating model using a debt discount rate of 28.65% which represented the Companyâ€™s applicable rate of risk. The fair value of the June 27 Warrants was determined by using Black-Scholes pricing model taking into account, inter alia, expected stock price volatility of 245% and risk-free interest rate of 4.52%. The amount allocated to June 27 Warrants was classified as a component of permanent equity (as their terms permit the holders to receive a fixed number of shares of common stock upon exercise for a fixed exercise price). À The June 27 Notes are accounted for as a financial liability measured at amortized cost. In subsequent periods, the Company recognized a discount and interest expense over the economic life of the June 27 Notes based on the effective interest rate method. À The following tabular presentation reflects the reconciliation of the carrying amount of the June 27 Notes during the period of nine months ended September 30, 2024: À À SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JUNE 27 NOTES À À Nine-month period ended September 30, 2024À À (Unaudited)À Open balanceÀ \$-À Total proceeds receivedÀ À 100Ã Total proceeds allocated to June 27 Warrants at initial recognitionÀ À (85) Discount amortization and interest expenses related to June 27 Notes (Note 5 below)À À 16Ã Partial conversion June 27 Notes and accrued Interest (Note 3) and Note 3) below)À À (26) Ending balanceÀ 5Ã À During the period commencing the issuance date through September 30, 2024, none of the June 27 Warrants have been exercised.À À À GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.) (in thousands of US Dollars) À NOTE 3 - SIGNIFICANT TRANSACTIONS (CONT.) À G. Convertible Promissory Notes À À On July 18, 2024, the Company entered into a series of convertible promissory notes with three directors, and one member of the Companyâ€™s executive management (the â€œJuly 18 Investorsâ€), providing for the private placement of unsecured convertible promissory notes in the aggregate principal amount of \$360 (the â€œJuly 18 Notesâ€ and each a â€œJuly 18 Noteâ€). À The July 18 Notes bear simple interest at a rate of 8% per annum. Interest on the outstanding principal will accrue and, unless converted earlier as set forth below, be due and payable on (i) the 12-month anniversary of the date hereof, or (ii) the closing date of a Qualified Financing, as defined herein (the â€œMaturity Dateâ€). À Except regarding the conversion of the July 18 Notes as discussed below, the Company may not prepay the July 18 Notes without the written consent of the July 18 Investors. If not sooner repaid, all outstanding principal and accrued but unpaid interest on the July 18 Notes (the â€œJuly 18 Note Balanceâ€), as of the close of business on the day immediately preceding the date of the closing of the next issuance and sale of capital stock of the Company, in a single transaction or series of related transactions, to investors resulting in gross proceeds to the Company of at least \$500 (excluding indebtedness converted in such financing) (a â€œQualified Financingâ€), will automatically be converted into that number of shares of equity securities of the Company sold in the Qualified Financing equal to the number of shares calculated by dividing (X) the July 18 Note Balance by (Y) an amount equal to the price per share or other unit of equity securities issued in such Qualified Financing, and otherwise on the same terms as the security issued in the Qualified Financing, provided that the conversion price per share shall not be lower than \$1.56. À Upon the occurrence of an Event of Default (as defined below), each July 18 Investors may, by written notice to the Company, declare the July 18 Note to be due immediately and payable with respect to the July 18 Note Balance. An â€œEvent of Defaultâ€ means (i) failure by the Company to pay the July 18 Note Balance on the Maturity Date, (ii) voluntary bankruptcy, or (iii) involuntary bankruptcy. Upon the occurrence of an Event of Default specified in clause (iii) above, the July 18 Note Balance shall automatically and immediately become due and payable, in all cases without any action on the part of any July 18 Investors. À Upon initial date, the management measured the fair value of the embedded conversion feature which is accounted for as embedded derivative liability. The difference between the total gross cash proceeds received and the fair value of the embedded conversion feature is allocated to July 18 Notes that are measured at amortized cost under which in subsequent periods the Company recognizes a discount expense over the economic life of the July 18 Notes based on the effective interest rate method. However, the fair value of the embedded derivative liability related to the conversion feature was determined by the management at an insignificant amount since upon closing of a Qualified Financing the conversion will be done based on market conditions (i.e. conversion price will be equal to the fair value of the share upon conversion) and thus all proceeds received of \$360 were allocated to the July 18 Notes. À The following tabular presentation reflects the reconciliation of the carrying amount of the July 18 Notes during the period of nine months ended September 30, 2024: À À SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JUNE 27 NOTES À À Nine-month period ended September 30, 2024À À (Unaudited)À À À À Open balanceÀ \$-À Total proceeds allocated to July 18 Notes at initial recognitionÀ À 360Ã Interest expenses related to July 18 Notes (Note 5 below)À À 5Ã Partial conversion July 18 Notes and accrued Interest (Note 3) below)À À (101) Ending balanceÀ 264Ã À À GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.) (in thousands of US Dollars) À NOTE 3 - SIGNIFICANT TRANSACTIONS (CONT.) À H. Convertible Promissory Note and Warrant Agreements À À On July 30, 2024, the Company entered into a convertible promissory note and three warrant agreements (the â€œJuly 30 Warrantsâ€) with an existing investor (the â€œJuly 30 Holderâ€), providing for the private placement of a secured convertible promissory note in the aggregate principal amount of \$4,000 (the â€œJuly 30 Noteâ€). The July 30 Note is not convertible until and unless approved at a meeting of the Companyâ€™s stockholders (the â€œStockholder Approvalâ€). À The July 30 Note bears simple interest at a rate of 8% per annum and is due and payable in cash on earlier of: (i) 12 months anniversary of July 30 Note, or (ii) closing date of a Sale Transaction (defined below) (the â€œMaturity Dateâ€). The July 30 Note is secured by a first-priority security interest on all Companyâ€™s assets. À Except regarding the conversion of the July 30 Note or a Sale Transaction as discussed below, the Company may not prepay the July 30 Note without the written consent of the July 30 Holder. If Stockholder Approval is obtained, the July 30 Note (i) is convertible at the discretion of the July 30 Holder at a price equal to the closing price of the Common Stock on the date of conversion and, (ii) if the Closing Price of the Common stock exceeds \$5.00 per share for a period of 5 consecutive trading days, will automatically convert at a price equal to the 5 daily Volume Weighted Average Price (â€œVWAPâ€) of the Common Stock (subject to adjustment for any stock split, stock dividend, reverse stock split, combination or similar transaction). À Upon Sale Transaction on or prior to the Maturity Date, the Company will repay the July 30 Holder, at the July 30 Holderâ€™s election, as follows: (i) cash equal to 200% of the Note balance, or (ii) transaction consideration in the amount to be received by the Holder in such Sale Transaction if the July 30 Note was converted pursuant to an optional conversion. â€œSale Transactionâ€ means a merger or consolidation of the Company with or into any other entity, or a sale of all or substantially all of the Companyâ€™s assets, or any other transaction or series of related transactions in which the Companyâ€™s stockholders immediately prior to such transaction(s) receive cash, securities or other property in exchange for their shares and, immediately after such transaction(s), own less than 50% of the equity securities of the surviving corporation or its parent. À Upon the occurrence of an Event of Default (defined below), the July 30 Holder may, by written notice to the Company, declare the Note to be due immediately and payable with respect to the July 30 Note balance. An â€œEvent of Defaultâ€ means (i) failure by the Company to pay the July 30 Note balance on the Maturity Date, (ii) the Company becomes subject to a judgement of more than \$50,000, (iii) voluntary bankruptcy, or (iv) involuntary bankruptcy. Upon the occurrence of an Event of Default specified in clause (iii) above, the July 30 Note balance shall automatically and immediately become due and payable, in all cases without any action on the part of the July 30 Holder. À Each July 30 Warrant becomes exercisable 12 months after its issuance and has term of 10 years. The July 30 Warrants are exercisable for cash only and have no price-based antidilution. The first July 30 Warrant is for 2,133,334 shares at \$1.875 per share. The second July 30 Warrant is for 1,523,810 shares at \$2.625 per share. The third July 30 Warrant is for 1,185,186 shares at \$3.375 per share. À At the initial date, the Company has issued two instruments that include (i) a financial instrument that is considered as â€œhostâ€ which comprised of July 30 Note and two embedded derivative financial instruments (i.e. an embedded conversion feature and an embedded redemption feature to receive cash equals to 200% of July 30 Note balance upon Sale Transaction) and (ii) three series of detachable warrants. At the initial date, the Company is required to estimate the fair value of both two instruments and allocate the total gross proceeds received between them based on that relative fair value identified. The fair value of the embedded derivative financial instruments (i.e. the conversion right and the redemption right) should be bifurcated from the host instrument and remeasured on recurring basis at each reporting period under marked to market approach, the July 30 Note is accounted for under carrying amount whereby discount and interest expenses are recorded over the economic life of the July 30 Note based on the effective interest rate method and the July 30 Warrants are classified into equity without any further subsequent measurement. À À GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.) (in thousands of US Dollars) À NOTE 3 - SIGNIFICANT TRANSACTIONS (CONT.) À H. Convertible Promissory Note and Warrant Agreements (Cont.) À À Upon initial recognition, the management by using the assistance of an external appraiser allocated the gross cash proceeds received based on the relative fair value of the July 30 Note and the detachable July 30 Warrants in total amount of \$1,450 and \$2,550, respectively. The fair value of the convertible note was determined by using hybrid method that includes conversion scenario and liquidation scenario taking into account, inter alia, a debt discount rate of 28.65%. The fair value of the July 30 Warrants was determined by using Black-Scholes pricing model taking into account, inter alia, expected stock price volatility of 122.8% and risk-free interest rate of 4.78%. The amount allocated to July 30 Warrants was classified as a component of permanent equity (as their terms permit the holders to receive a fixed number of shares of common stock upon exercise for a fixed exercise price). À Furthermore, it was determined that the embedded conversion feature and embedded redemption feature are required to be bifurcated from the host loan instrument. The fair value of the bifurcated derivatives was determined by the management using the assistance of an external appraiser in a total amount of \$35 upon initial recognition and in subsequent periods as derivative liability at fair value through profit and loss. The remaining amount of \$1,415 was allocated to the host loan instrument which in subsequent periods is accounted for using the effective interest method over the term of the loan, until its stated maturity. À The following tabular presentation reflects the reconciliation of the carrying amount of the July 30 Note during the period of nine months ended September 30, 2024: À SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JULY 30 NOTES À À Nine-month period ended September 30, 2024À À (Unaudited)À À À À Open balanceÀ \$-À Total proceeds receivedÀ À 4,000Ã Total proceeds allocated to July 30 Warrants at initial recognitionÀ À (2,550) Total proceeds allocated to embedded redemption feature at initial recognitionÀ À (35) Amortization of discount and interest expenses related to July 30 Note (Note 5 below)À À 309Ã Ending balanceÀ 1,724Ã À The following tabular presentation reflects the reconciliation of the fair value of the embedded conversion feature and embedded redemption feature during the period of nine months ended September 30, 2024: À SCHEDULE OF RECONCILIATION OF FAIR VALUE OF EMBEDDED CONVERSION FEATURE À À Nine-month period ended September 30, 2024À À (Unaudited)À À À À Open balanceÀ \$-À À À À À À À À À -À Proceeds allocated to embedded redemption feature at initial recognitionÀ À 35Ã Revaluation expenses related to embedded redemption feature (Note 5 below)À À 2Ã Ending balanceÀ 37Ã À On September 24, 2024, the Company held a special meeting of its stockholders under which shares of common stock issuable by the Company upon conversion of the July 30 Note and exercise of the July 30 Warrants has been approved. However, through September 30, 2024, July 30 Holder has not elected to trigger the conversion of July 30 Note or the exercise of the July 30 Warrants into shares of common stock. À GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.) (in thousands of US Dollars) À NOTE 3 - SIGNIFICANT TRANSACTIONS (CONT.) À I. August 23 Conversion À À On August 23, 2024 (the â€œCommitment Dateâ€), the Company and two of June 27 Investors entered into conversion agreement, under which the Company agreed to convert the principal nominal amount plus any accrued but unpaid interest pursuant to each of June 27 Notes, totalling approximately \$20 each (the â€œDebtâ€), held by the Investors to Common Stock at a conversion price of \$1.02 per share. On October 15, 2024, the Company issued 19,682 shares of common stock for each of the two of the June 27 Investors in respect of each respective Debt converted. À In satisfaction of the Debt, the Company also issued to each of the two June 27 Investors three warrants (each an â€œAugust 23 Warrantâ€). Each August 23 Warrant becomes exercisable on August 16, 2025 and has term of 10 years. The August 23 Warrants are exercisable for cash only and have no price-based antidilution. The first August 23 Warrant is for 10,707 shares of Common Stock and is exercisable at \$1.875 per share. The second August 23 Warrant is for 7,648 shares of Common Stock, exercisable at \$2.625 per share. The third August 23 Warrant is for 5,948 shares of Common Stock, exercisable at \$3.375 per share. À The above transaction was accounted for as settlements of financial liabilities under which the instruments issued or to be issued to the June 27 Investors (i.e. shares of common stock and August 23 Warrants) are eligible for equity classification and thus both have been recorded as part of the permanent equity based on the total fair value of \$238 at the Commitment Date. The difference between the fair value of these equity instruments and the carrying amount of each of the respective Debt at the Commitment Date amounted to \$11 was charged immediately to the finance expenses (see also Note 5 below). À During the period commencing the issuance date through September 30, 2024, none of the August 23 Warrants have been exercised. À J. Sep 5 Conversion À À On September 5, 2024 (the â€œCommitment Dateâ€), the Company and one of June 27 Investors and July 18 Investors entered into a conversion agreement, under which the Company agreed to convert outstanding board fees amounted \$113 and the principal nominal amount plus any accrued but unpaid interest pursuant to June 27 Note and July 18 Note, totalling \$146 (referring together as a â€œDebtâ€), held by the Investor to Common Stock at a conversion price of \$1.02 per share. On October 15, 2024, the Company issued 254,226 shares of common stock for the June 27 Investor in respect of the Debt converted. À In satisfaction of the Debt, the Company also issued to June 27 Investor and July 18 Investor three warrants (each an â€œSeptember 5 Warrantâ€). Each September 5 Warrant becomes exercisable on August 16, 2025 and has term of 10 years. The September 5 Warrants are exercisable for cash only and have no price-based antidilution. The first September 5 Warrant is for 138,299 shares of Common Stock and is exercisable at \$1.875 per share. The second September 5 Warrant is for 98,785 shares of Common Stock, exercisable at \$2.625 per share. The third September 5 Warrant is for 76,833 shares of Common Stock, exercisable at \$3.375 per share. À The above transaction was accounted for as settlements of financial liabilities under which the instruments issued or to be issued to the July 18 Investor (i.e. shares of common stock and September 5 Warrants) are eligible for equity classification and thus both have been recorded as part of permanent equity based on the total fair value of \$1,505 at the Commitment Date. The difference between the fair value of these equity instruments and the carrying amount of the Debt at the Commitment Date amounted to \$227 was charged immediately to the finance expenses (see also Note 5 below). À During the period commencing the issuance date through September 30, 2024, none of the September 5 Warrants have been exercised. À GLUCOTRACK INC. NOTES TO CONDENSED

CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.) (in thousands of US Dollars) X - ReferencesNo definition available. + Details Name: GCTK DisclosureSignificantTransactionsAbstract Namespace Prefix: GCTK Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionSignificant Transactions [Text Block] + ReferencesNo definition available. + Details Name: GCTK SignificantTransactionsTextBlock Namespace Prefix: GCTK Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.3 COMMITMENTS AND CONTINGENT LIABILITIES 9 Months Ended Sep. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â COMMITMENTS AND CONTINGENT LIABILITIES Â NOTE 4 - COMMITMENTS AND CONTINGENT LIABILITIES Â A. In 2004, the Israeli Innovation Authority (IIA) provided Integrity Israel with a grant of approximately \$93 (NIS 420,000), for develop a non-invasive blood glucose monitor (the â€œDevelopment Planâ€). Integrity Israel is required to pay royalties to IIA at a rate ranging between 3-5% of the proceeds from sale of the Companyâ€™s products arising from the Development Plan up to an amount equal to \$93, plus interest at LIBOR from the grant date. As to replacement of the LIBOR benchmark rate, even though the IIA has not declared the alternative benchmark rate to replace the LIBOR, the Company does not believe it will have a significant impact. As of September 30, 2024, the remaining contingent liability with respect to royalty payment on future sales equals approximately \$73, excluding interest. Such contingent obligation has no expiration date. Â B. On October 7, 2022 (â€œthe Closing Dateâ€), the Company entered into Intellectual Property Purchase Agreement (the â€œAgreementâ€) with Paul Goode, which is the Companyâ€™s Chief Executive Officer (the â€œSellerâ€), under which it was agreed that on and subject to the terms and conditions of the Agreement, at the Closing Date, Seller sold and assigned to the Company, all of Sellerâ€™s right, title and interest in and to the following assets, properties and rights (collectively, the â€œPurchased Assetsâ€): (i) all rights, title, interests in all current and future intellectual property, including, but not limited to patents, trademarks, trade secrets, industry know-how and other IP rights relating to an implantable continuous glucose sensor (collectively, the â€œConveyed Intellectual Propertyâ€); and (ii) all the goodwill relating to the Purchased Assets. Â C. In consideration for the sale of the Purchased Assets to the Company, at the Closing Date, the Company paid to Seller cash in the amount of one dollar and obligated to issue up to 200,000 shares of Common Stock to be issued based upon specified performance milestones as set forth in the Agreement (the â€œPurchase Priceâ€). In addition, if upon the final issuance, the aggregate 200,000 shares represent less than 1.5% of the then outstanding Common Stock of the Company, the final issuance will include such number of additional shares so that the total aggregate issuance equals 1.5% of the outstanding shares (the â€œTrue-Up Sharesâ€). All shares of Common Stock of the Company that will be issued under the agreement shall be (i) restricted over a limited period as defined in the Agreement and (ii) subject to the lockup provisions. Â D. When the Company acquires net assets that do not constitute a business, as defined under ASU 2017-01 Business Combinations (Topic 805) Clarifying the Definition of a Business (such when there is no substantive process in the acquired entity) the transaction is accounted for as asset acquisition and no goodwill is recognized. The acquired In-Process Research and Development intangible asset (â€œIPR&Dâ€) to be used in research and development projects which have been determined not to have alternative future use at the acquisition date, is expensed immediately. Â E. At the Closing Date, it was determined that the asset acquisition represents the purchase of IPR&D with no alternative future use. However, the achievement of each of the performance milestones is considered as a contingent event outside the Companyâ€™s control and thus the contingent consideration which is equal to the fair value of the Purchase Price as measured at the Closing Date will be recognized when it becomes probable that each target will be achieved within the reasonable period. Such additional contingent consideration will be recognized in subsequent periods if and when the contingency (the achievement of targets) is resolved. Â F. In June 2023, the Company achieved the first performance milestone out of the five performance milestones outlined in the Agreement executed between the Company and the Seller as of the Closing Date. As a result, upon the date of the fulfillment of the first performance milestone the Company was committed to issue 20,000 restricted shares to the Seller. Accordingly, the Company recorded an amount of \$131 as research and development expenses with a similar amount as an increase to additional paid-in capital. The first performance milestone shares were issued on February 6, 2024. Â G. In May 2024, the Company achieved the second performance milestone out of the five performance milestones outlined in the Agreement executed between the Company and the Seller as of the Closing Date. As result, the Company is committed to issue 30,000 restricted shares to the Seller. Accordingly, the Company recorded stock-based compensation expenses amounted to \$192 which represents the quoted price of its Common Stock at the Closing Date, after taking into consideration a discount for lack of marketability in a rate of 30 % over the applicable restriction period. As of September 30, 2024, the second performance milestone shares were not yet issued. Â H. As of September 30, 2024, the achievement of all other remaining performance milestones was not considered probable and thus no stock-based compensation expenses were recorded with respect to thereof. Â I. GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)(CONT.) (in thousands of US Dollars) X - ReferencesNo definition available. + Details Name: us-gaap CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.3 FINANCE (INCOME) EXPENSES, NET 9 Months Ended Sep. 30, 2024 Investments, All Other Investments [Abstract] Â FINANCE (INCOME) EXPENSES, NET NOTE 5 - FINANCE (INCOME) EXPENSES, NET Â SCHEDULE OF FINANCE EXPENSES Â A Â A Â A Â A Â A Â A Â A Â A Â A Three-month period ended September 30, Â A Nine-month period ended September 30, Â A Â A 2024 Â A 2023 Â A 2024 Â A 2023 Â A Unaudited Â A Unaudited Â A Â A Â A Â A Â A Â A Â A Discount amortization and interest expenses related to June 27 Notes Â A 16 Â A Â A Â A 16 Â A Â A Interest expenses related to July 18 Notes Â A 5 Â A Â A Â A 5 Â A Â A Discount amortization and interest expenses related to July 30 Note Â A 309 Â A Â A 309 Â A Â A Revaluation expenses related to derivative financial liabilities Â A 2 Â A Â A Â A 2 Â A Â A Revaluation expenses incurred from settlement of financial liabilities Â A 1,505 Â A Â A Â A 1,505 Â A Â A Interest on bank deposits Â A (7) Â A (1) Â A (38) Â A (2) Exchange rate differentials, bank commissions and miscellaneous Â A 18 Â A Â A Â A 23 Â A Â A Finance (income) expenses, net Â \$1,848 Â A \$(1) Â \$1,822 Â A \$(2) Â X - DefinitionThe entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures. + ReferencesNo definition available. + Details Name: us-gaap FinancialInstrumentsDisclosureTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap InvestmentsAllOtherInvestmentsAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.3 SUBSEQUENT EVENTS 9 Months Ended Sep. 30, 2024 Subsequent Events [Abstract] Â SUBSEQUENT EVENTS NOTE 6 - SUBSEQUENT EVENTS Â Management evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the condensed interim consolidated financial statements were available to be issued. Based upon this review, the Company did not identify any other significant subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed below. Â Completion of underwritten U.S. public offering Â On November 12, 2024, the Company completed a public offering (the â€œOfferingâ€) under which the Company received gross proceeds of \$10,000 in exchange for issuance of an aggregate of (i) 2,437,340 shares (the â€œSharesâ€) of its Common Stock, (ii) 4,756,900 pre-funded warrants (the â€œPre-Funded Warrantsâ€) to purchase up to an aggregate of 4,756,900 shares of Common Stock (the â€œPre-Funded Warrant Sharesâ€) in lieu of Shares, (iii) Series A Warrants (the â€œSeries A Warrantsâ€) to purchase up to 7,194,240 shares of Common Stock (the â€œSeries A Warrant Sharesâ€) and (iv) Series B Warrants (the â€œSeries B Warrantsâ€) and, together with the Series A Warrants, the â€œCommon Warrantsâ€) to purchase up to 7,194,240 shares of Common Stock (â€œthe â€œSeries B Warrant Sharesâ€ together with the Series A Warrant Shares, the â€œWarrant Sharesâ€). Each Share or Pre-Funded Warrant, as applicable, was sold together with one Series A Warrant to purchase one share of Common Stock and one Series B Warrant to purchase one Common Share. The public offering price for each Share and accompanying Common Warrants was \$1.39, and the public offering price for each Pre-Funded Warrant and accompanying Common Warrants was \$1.389 (the â€œOffering Priceâ€). Â The Pre-Funded Warrants have an exercise price of \$0.001 per share, are exercisable immediately and expire when exercised in full. Each Series A Common Warrant will have an exercise price per share of \$1.81 and will be exercisable beginning on the date on which Stockholder Approval (as defined below) is received and deemed effective (the â€œInitial Exercise Dateâ€ or the â€œStockholder Approval Dateâ€). The Series A Warrants will expire on the five-year anniversary of the Initial Exercise Date. The Series B Warrants will have an exercise price per share of \$1.81 and will be exercisable beginning on the Initial Exercise Date. The Series B Warrants will expire on the two and one-half year anniversary of the Initial Exercise Date. The issuance of Common Warrant Shares upon exercise of the Common Warrants is subject to stockholder approval under applicable rules and regulations of The Nasdaq Stock Market LLC (â€œNasdaqâ€) (â€œStockholder Approvalâ€) and the date on which Stockholder Approval is received and deemed effective, the â€œStockholder Approval Dateâ€). Â The exercise price of Series A Warrants and Series B Warrants is subject to certain adjustments. If at the time of exercise there is no effective registration statement registering, or the prospectus contained therein is not available for the issuance of the Series A Warrants Shares and Series B Warrant Shares to the holders, then the Series A Warrants and Series B Warrants may also be exercised, in whole or in part, at such time by means of a â€œcashless exerciseâ€. In addition, the holders are entitled to an option to require the Company to purchase the Series A Warrants and Series B Warrants for cash in an amount equal to their Black-Scholes Option Pricing Model value, in the event that certain fundamental transactions (which some of them are not considered solely within the control of the Company) as defined in the Series B Warrants agreement, occur. Additionally, holders of Series B Warrants may also effect an â€œalternative cashless exerciseâ€ at any time while the Series B Warrants are outstanding following the Initial Exercise Date. Under the alternate cashless exercise option, the holder of the Series B Warrant has the right to receive an aggregate number of shares equal to the product of (i) the aggregate number of shares of Common Stock that would be issuable upon a cashless exercise of the Series B Warrant and (ii) 3.0. Â Total incremental and direct issuance costs are estimated at the total amount of \$1,127. Â The closing of the public offering occurred on November 14, 2024 (the â€œClosing Dateâ€). Â In a private placement offering completed concurrently with the completion of the public offering, the July 30 Investor voluntarily converted approximately \$4,089 of Debt, which represents the outstanding minimal amount of principal and accrued interest under the July 30 Note as of November 12, 2024, on substantially the same terms as the public offering, resulting in the issuance of 2,640,717 shares of Common Stock (plus 2,640,717 accompanying Series A Warrants and 2,640,717 accompanying Series B Common Warrants), based on a conversion price of \$1.55 per share. X - ReferencesNo definition available. + Details Name: us-gaap SubsequentEventsAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/855/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details Name: us-gaap SubsequentEventsTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.3 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) 9 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Basis of Presentation Â A. Basis of Presentation Â A The accompanying unaudited condensed interim consolidated financial statements and related notes should be read in conjunction with the Companyâ€™s consolidated financial statements and related notes included in the Companyâ€™s annual report on Form 10-K for the fiscal year ended December 31, 2023, as was filed with the Securities and Exchange Commission (â€œSECâ€) on March 28, 2024. The unaudited condensed interim consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC related to interim financial statements. As permitted under those rules, certain information and footnote disclosures normally required or included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The financial information contained herein is unaudited; however, management believes all adjustments have been made that are considered necessary to present fairly the results of the Companyâ€™s financial position and operating results for the interim periods. All such adjustments are of a normal recurring nature. Â B The results for the period of three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024 or for any other interim period or for any future period. Use of Estimates in the Preparation of Financial Statements Â B. Use of Estimates in the Preparation of Financial Statements Â A The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these interim financial statements, the most significant estimates and assumptions include identification and measurement of financial instruments. Principles of Consolidation Â C. Principles of Consolidation Â A The condensed interim consolidated financial statements include the accounts of the Company and its subsidiary. Significant intercompany balances and transactions have been eliminated in consolidation. Cash and Cash Equivalents Â D. Cash and Cash Equivalents Â A Cash equivalents are short-term highly liquid investments which include short-term bank deposits (up to three months from date of deposit), that are not restricted as to withdrawals or use that are readily convertible to cash with maturities of three months or less as of the date acquired. Modification of equity-classified contracts Â E. Modification of equity-classified contracts Â A The modification or exchange of equity-classified contracts, such as warrants that were classified as equity before the modification or exchange and remained eligible for equity classification after the modification, is accounted for in a similar manner to a modification of stock-based compensation. Accordingly, the incremental fair value from the modification or exchange (the change in the fair value of the instrument before and after the modification or exchange) is recognized as a reduction of retained earnings of increase of accumulated deficit as a deemed dividend. Modifications or exchanges that result in a decrease in the fair value of an equity-classified share-based payment awards are not recognized. In addition, the amount of the deemed dividend is also recognized as an adjustment to earnings available to common shareholders for purposes of calculating earnings per share. Â F. GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (in thousands of US Dollars) Â NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.) Convertible Promissory Notes Â F. Convertible Promissory Notes Â A Upon initial recognition of convertible promissory notes and similar instruments, the Company considers the provisions of ASC 815-40, â€œDerivatives and Hedging - Contracts in Entityâ€™s Own Equityâ€ (â€œASC 815-40â€) in order to determine whether the conversion features embedded within the convertible instrument should be separated from the host instrument. Â When it is determined that an embedded derivative required to be bifurcated (such as embedded conversion feature that does not qualify for equity classification), the Company recognized the embedded derivative bifurcated as a separate derivative liability upon initial recognition and on subsequent periods at fair value. The remaining consideration amount received or allocated to the entire convertible instrument is allocated to the host debt instrument. The difference between the face value of the host and such an allocated amount represents a discount which is amortized as finance expense to profit or loss using an effective interest method over the term of the note until its stated maturity. Â When it is determined that the embedded conversion feature qualifies for equity classification (such when the embedded conversion option, if it were freestanding, is not qualified as a derivative in accordance with the provisions of ASC 815-10, â€œDerivatives and Hedgingâ€ since its terms did not require or permit net settlement or when the embedded conversion option is indexed to the entityâ€™s own stock), the conversion option is not bifurcated. When bifurcation is not required, the Company considers whether the debt instrument involves a significant premium (i.e. when the proceeds received or allocated upon issuance exceed the principal amount that will be paid at maturity). When it is determined

A substantial premium exists, the entire amount is allocated to paid-in capital and when it is determined, otherwise no additional accounting is required and the convertible promissory note is accounted for at amortized cost using effective interest method over the term of the note until its stated maturity. Allocation of proceeds and related issuance costs A G. Allocation of proceeds and related issuance costs A A When multiple instruments are issued in a single transaction (package issuance), the total net proceeds from the transaction are allocated among the individual freestanding instruments identified. The allocation occurs after identifying all freestanding instruments and the subsequent measurement basis for those instruments. A Financial instruments that are required to be subsequently measured at fair value (such as derivative liabilities) are measured at fair value and the remaining consideration is allocated to other financial instruments that are not required to be subsequently measured at fair value (such as liabilities measured at amortized cost, common shares and warrants eligible for equity classification), based on the relative fair value basis for such instruments. A Issuance costs allocated to financial instruments that are required to be subsequently measured at fair value immediately expensed. Issuance costs allocated to shares and warrants classified as equity components and are recorded as a reduction of additional paid-in capital. Issuance costs allocated to financial liabilities measured at amortized cost are recorded as a discount and accreted over the contractual term of the financial instrument using the effective interest method. A GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (in thousands of US Dollars) NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.) Warrants A H. Warrants A Certain warrants that were issued to several holders are classified as a component of permanent equity since they are freestanding financial instruments that are legally detachable and separately exercisable, do not embody an obligation for the Company to repurchase its own shares, and permit the holders to receive a fixed number of Ordinary Shares upon exercise for a fixed exercise price and thus, are considered as indexed to the Company's own shares. As such warrants were issued together with financial instruments that are not subsequently measured at fair value and the warrants were measured based on allocation of the proceeds received by the Company in accordance with the relative fair value basis. When applicable, direct issuance expenses that were allocated to certain warrants were deducted from additional paid-in capital. Leases A I. Leases A The Company applies ASC Topic 842, "Leases" under which the Company determines if an arrangement is a lease at inception. A Leases are classified as either finance leases or operating leases. A lease is classified as a finance lease if any one of the following criteria are met: (i) the lease transfers ownership of the asset by the end of the lease term, (ii) the lease contains an option to purchase the asset that is reasonably certain to be exercised, (iii) the lease term is for a major part of the remaining useful life of the asset, (iv) the present value of the lease payments equals or exceeds substantially all of the fair value of the asset, or (v) the underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of lease term. A lease is classified as an operating lease if it does not meet any one of these criteria. Since all the Company's lease contracts for premises do not meet any of the criteria above, the Company concluded that all its lease contracts should be classified as operating leases. A Right of Use Assets assets and liabilities are recognized on the commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company's leases do not provide an implicit rate, the Company uses its Incremental Borrowing Rate based on the information available on the commencement date in determining the present value of lease payments. The Company's IBR is estimated to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic environments where the leased asset is located. The ROU asset also includes any lease payments made prior to commencement and is recorded net of any lease incentives received. Moreover, the ROU asset may also include initial direct costs, which are incremental costs of a lease that would not have been incurred if the lease had not been obtained. The Company uses the long-lived assets impairment guidance in ASC 360-10, Property, Plant, and Equipment - Overallle, to determine whether a ROU asset is impaired, and if so, the amount of the impairment loss to recognize. Certain leases include options to extend or terminate the lease. An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain that the Company will exercise that option. An option to terminate is considered unless it is reasonably certain that the Company will not exercise the option. A GLUCOTRACK INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) (in thousands of US Dollars) NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.) Basic and diluted loss per share A J. Basic and diluted loss per share A Basic loss per share is computed by dividing the loss for the period applicable (after considering the effect of deemed dividend related to trigger of down round protection feature) for Common Stockholders by the weighted average number of shares of Common Stock outstanding and shares of Common Stock to be issued upon achievement of certain performance milestones during the period and upon exercise of pre-funded warrants. In computing, diluted loss per share, basic earnings per share are adjusted to reflect the potential dilution that could occur upon the exercise of options or warrants issued or granted using the treasury stock method and using the if-converted method with respect to certain convertible promissory notes and bifurcated redemption feature accounted for as derivative financial liability, if the effect of each of such financial instruments is dilutive. In computing diluted loss per share, the average stock price for the period is used in determining the number of Common Stock assumed to be purchased from the proceeds to be received from the exercise of stock options or stock warrants. A Shares to be issued upon exercise of all options and warrants, convertible promissory notes and bifurcated redemption feature, have been excluded from the calculation of the diluted net loss per share for all the reported periods for which net loss was reported because the effect of the common shares issuable as result of the exercise or conversion of these instruments was anti-dilutive. A The net loss and the weighted average number of shares of Common Stock used in computing basic and diluted net loss per Common Stock for the period of three and nine months ended September 30, 2024 and 2023, is as follows:

	SCHEDULE OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE	2024A	2023A	2024A	2023A	US dollars (except share data)	US dollars (except share data)	Three-month period ended September 30,	Nine-month period ended September 30,																																																																				
(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	\$	\$	2024A	2023A	\$	\$																																																																				
Net loss attributable to common stockholders \$	5,087A	\$	2,223A	\$	12,503A	\$	4,685A	Deemed dividend related to trigger of down round protection feature	-A	-A	-A	-A	855A	Net loss attributable to common stockholders \$	5,087A	\$	2,223A	\$	12,503A	\$	4,685A	Denominator	A	A	A	A	A	A	A	A	A	Shares of Common Stock used in computing basic and diluted net loss per common stock	A	5,564,880A	A	4,593,733A	A	5,340,532A	A	3,758,590A	Shares of Common Stock to be issued upon exercise of pre-funded warrants	A	-A	-A	-A	-A	241,246A	Shares of Common Stock to be issued upon achievement of performance milestones	A	30,000A	-A	-A	-A	15,275A	A	6,691A	Weighted average number of Common Stock outstanding used in computing basic and diluted net loss per share	A	5,594,880A	A	4,593,733A	A	5,355,806A	A	4,006,527A	Basic and diluted net loss per common stock (\$)	(0.91)	(0.49)	(2.39)	(1.38)	X	Definition Disclosure of accounting policy for cash and cash equivalents, including the policy for determining what items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.	+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1 + Details Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemBalanceType: na Period Type: duration X - DefinitionDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.	+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1 + Details Name: us-gaap ConsolidationPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemBalanceType: na Period Type: duration X - DefinitionDisclosure of accounting policy for its derivative instruments and hedging activities.	+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 815 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(n)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7 + Details Name: us-gaap DerivativesPolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemBalanceType: na Period Type: duration X - DefinitionDisclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.	+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 + Details Name: us-gaap EarningsPerSharePolicyTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemBalanceType: na Period Type: duration X - DefinitionDisclosure of accounting policy for leasing arrangement entered into by lessee.	+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/

RATE A/A September 30, 2024A Lease term (years)A 2.424A Weighted average discount rateA 9.03% SCHEDULE OF RECONCILIATION OF FAIR VALUE OF EMBEDDED CONVERSION FEATURE The following tabular presentation reflects the reconciliation of the fair value of the embedded conversion feature and embedded redemption feature during the period of nine months ended September 30, 2024: A SCHEDULE OF RECONCILIATION OF FAIR VALUE OF EMBEDDED CONVERSION FEATURE A Nine-month period ended September 30, 2024A A (Unaudited)A A A A Open balanceA \$ A A A A A A A A A A Proceeds allocated to embedded redemption feature at initial recognitionA A 35A Revaluation expenses related to embedded redemption feature (Note 5 below)A A 2A Ending balanceA \$37A June Twenty Seven Warrants [Member] A SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JULY 30 NOTES A SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JUNE 27 NOTES A A Nine-month period ended September 30, 2024A A A (Unaudited)A A Open balanceA \$A Total proceeds receivedA A 100A Total proceeds allocated to June 27 Warrants at initial recognitionA A (85) Discount amortization and interest expenses related to June 27 Notes (Note 5 below)A A 16A Partial conversion June 27 Notes and accrued Interest (Note 3I and Note 3J below)A A (26) Ending balanceA \$5A July Eighteen Notes [Member] A SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JULY 30 NOTES A SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JUNE 27 NOTES A A Nine-month period ended September 30, 2024A A A (Unaudited)A A A A Open balanceA \$A Total proceeds allocated to July 18 Notes at initial recognitionA A 360A Interest expenses related to July 18 Notes (Note 5 below)A A 5A Partial conversion July 18 Notes and accrued Interest (Note 3J below)A A (101) Ending balanceA \$264A July Thirteen Notes [Member] A SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JULY 30 NOTES A SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JULY 30 NOTES A A Nine-month period ended September 30, 2024A A A (Unaudited)A A A A Open balanceA \$A Total proceeds receivedA A 4,000A Total proceeds allocated to July 30 Warrants at initial recognitionA A (2,550) Total proceeds allocated to embedded redemption feature at initial recognitionA A (35) Amortization of discount and interest expenses related to July 30 Note (Note 5 below)A A 309A Ending balanceA \$1,724A X - DefinitionSchedule Of Reconciliation Of Carrying Amount Of Notes [Table Text Block] + ReferencesNo definition available. + Details Name: GCTK ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock Namespace Prefix: GCTK Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionSchedule Of Reconciliation Of Fair Value Of Embedded Conversion Feature [Table Text Block] + ReferencesNo definition available. + Details Name: GCTK ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureTableTextBlock Namespace Prefix: GCTK Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionSchedule Of Weighted Average Remaining Lease Terms And Discount Rate [Table Text Block] + ReferencesNo definition available. + Details Name: GCTK ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateTableTextBlock Namespace Prefix: GCTK Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap LeaseCostTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap LesseeOperatingLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - Details Name: us-gaap StatementEquityComponentsAxis=GCTK JuneTwentySevenWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap StatementEquityComponentsAxis=GCTK JulyEighteenNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap StatementEquityComponentsAxis=GCTK JulyThirteenNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 27 R16.htm IDEA: XBRL DOCUMENT v3.24.3 FINANCE (INCOME) EXPENSES, NET (Tables) 9 Months Ended Sep. 30, 2024 Investments, All Other Investments [Abstract] A SCHEDULE OF FINANCE EXPENSES A SCHEDULE OF FINANCE EXPENSES A A A A A A A A A A Three-month period ended September 30,A A Nine-month period ended September 30,A A A 2024A A 2023A A 2023A A A UnauditedA A UnauditedA A A A A A A A A A Discount amortization and interest expenses related to June 27 NotesA \$16A A \$-A A \$16A A \$-A Interest expenses related to July 18 NotesA \$5A A A \$5A A A \$-A Discount amortization and interest expenses related to July 30 NoteA A 309A A A \$309A A A \$-A Revaluation expenses related to derivative financial liabilitiesA \$2A A A \$2A A A \$-A Revaluation expenses incurred from settlement of financial liabilitiesA \$1,505A A A \$1,505A A A \$-A Interest on bank depositsA A (7)A A (1)A A (38)A A (2) Exchange rate differentials, bank commissions and miscellaneousA A 18A A A \$18A A A \$23A A A Finance (income) expenses, netA \$1,848A A (\$1)A A \$1,822A A (\$2) A X - DefinitionTabular disclosure of condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Regulation S-X (SX) -Number 210 -Section 12 -Subsection 04 -Paragraph a - Publisher SECReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3 + Details Name: srt ScheduleOfCondensedFinancialStatementsTableTextBlock Namespace Prefix: srt Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap InvestmentsAllOtherInvestmentsAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.3 GENERAL (Details Narrative) - USD (\$) in Thousands 9 Months Ended 12 Months Ended Apr. 22, 2024 Sep. 30, 2024 Dec. 31, 2023 Subsidiary, Sale of Stock [Line Items] A A Retained Earnings (Accumulated Deficit) A \$ 122,356 \$ 109,853 Cash and cash equivalents A 346,449 Net proceeds from public offering A 8,873 A Unsecured promissory notes A 360 A Debt Securities A 30,000 A Warrant [Member] A A Subsidiary, Sale of Stock [Line Items] A A Unsecured promissory notes A 100 A Secured promissory notes A 4,000 A IPO [Member] A A Subsidiary, Sale of Stock [Line Items] A A A Proceeds from Debt, Net of Issuance Costs A \$ 8,730 Private Placement [Member] A A Subsidiary, Sale of Stock [Line Items] A A A Net proceeds from public offering \$ 500 A A Proceeds from Debt, Net of Issuance Costs A \$ 500 A X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 80 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 80 -Name Accounting Standards Codification -Section 55 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap DebtSecurities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap ProceedsFromDebtNetOfIssuanceCosts Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from entity's first offering of stock to the public. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap ProceedsFromIssuanceInitialPublicOffering Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from borrowings supported by a written promise to pay an obligation that is collateralized (backed by pledge, mortgage or other lien in the entity's assets). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap ProceedsFromSecuredNotesPayable Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from borrowings supported by a written promise to pay an obligation that is uncollateralized (where debt is not backed by the pledge of collateral). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap ProceedsFromUnsecuredNotes

250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(ii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap NetIncomeLoss Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap StatementEquityComponentsAxis=us-gaap CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap StatementEquityComponentsAxis=GCTK PerformanceMilestoneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap StatementEquityComponentsAxis=GCTK OperatingLeaseLiabilityImputedInterest Namespace Prefix: GCTK Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.3 SCHEDULE OF MATURITY ANALYSIS OF LEASE LIABILITY (Details) - USD (\$) \$ in Thousands Sep. 30, 2024 Feb. 19, 2024 Lessee, Lease, Description [Line Items] Å Å Total operating lease payments \$ 73 Å Less: imputed interest 8 Å Present value of lease liabilities 65 \$ 79 Less Than One Year [Member] Å Å Lessee, Lease, Description [Line Items] Å Å Total operating lease payments 30 Å Between 1 - 2 Years [Member] Å Å Lessee, Lease, Description [Line Items] Å Å Total operating lease payments 30 Å More Than 2 Years [Member] Å Å Lessee, Lease, Description [Line Items] Å Å Total operating lease payments \$ 13 Å X - DefinitionLessee operating lease liability imputed interest + ReferencesNo definition available. + Details Name: GCTK LesseeOperatingLeaseLiabilityImputedInterest Namespace Prefix: GCTK Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap LesseeLeaseDescriptionLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap OperatingLeaseLiability Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap LeaseContractualTermAxis=GCTK LessThanOneYearMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap LeaseContractualTermAxis=GCTK MoreThanTwoYearsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.3 SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERMS AND DISCOUNT RATE (Details) Sep. 30, 2024 Significant Transactions Å Lease term (years) 2 years 5 months 1 day Weighted average discount rate 9.03% X - ReferencesNo definition available. + Details Name: GCTK DisclosureSignificantTransactionsAbstract Namespace Prefix: GCTK Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYmMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap Data Type: xbrli:durationItemType Balance Type: na Period Type: instant XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.3 SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JUNE 27 NOTES (Details) - USD (\$) \$ in Thousands 3 Months Ended 9 Months Ended Sep. 2024 Jul. 30, 2024 Jun. 30, 2024 Sep. 30, 2023 Sep. 30, 2023 Sep. 30, 2023 Total proceeds received Å Å Å Å 100 Total proceeds allocated to July 18 Notes at initial recognition Å \$ 1,450 \$ 15 Å Å Å Interest expenses related to July 18 Notes (Note 5 below) Å Å Å \$ 5 June Twenty Seven Warrants [Member] Å Å Å Å Å Open balance Å Å Å Å Å Total proceeds received Å Å Å Å Å 100 Å Total proceeds allocated to June 27 Warrants at initial recognition Å Å Å Å Å (85) Å Discount amortization and interest expenses related to June 27 Notes (Note 5 below) Å Å Å Å Å 16 Å Partial conversion June 27 Notes and accrued interest (Note 3f and Note 3j below) Å Å Å Å Å (26) Å Ending balance Å Å Å Å Å 5 Å July Eighteen Notes [Member] Å Å Å Å Å Open balance Å Å Å Å Å Å Total proceeds allocated to July 18 Notes at initial recognition Å Å Å Å Å 360 Å Interest expenses related to July 18 Notes (Note 5 below) Å 146 Å Å Å Å 5 Å Partial conversion July 18 Notes and accrued interest (Note 3j below) Å Å Å Å Å (101) Å Ending balance Å Å Å Å Å 264 Å Å X - DefinitionDiscount amortization and interest expenses. + ReferencesNo definition available. + Details Name: GCTK DiscountAmortizationAndInterestExpenses Namespace Prefix: GCTK Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPartial conversion and accrued interest. + ReferencesNo definition available. + Details Name: GCTK PartialConversionAndAccruedInterest Namespace Prefix: GCTK Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPartial conversion notes and accrued interest. + ReferencesNo definition available. + Details Name: GCTK PartialConversionNotesAndAccruedInterest Namespace Prefix: GCTK Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionProceeds from allocated warrants at initial recognition. + ReferencesNo definition available. + Details Name: GCTK ProceedsFromAllocatedWarrantsAtInitialRecognition Namespace Prefix: GCTK Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIncluding the current and noncurrent portions, carrying amount of debt identified as being convertible into

another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap ConvertibleDebt Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1 + Details Name: us-gaap InterestExpense Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap ProceedsFromIssuanceOfDebt Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap ProceedsFromIssuanceOfWarrants Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionValue of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap WarrantsAndRightsOutstanding Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap StatementEquityComponentsAxis=GCTK_JuneTwentySevenWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: Period Type: X - Details Name: us-gaap StatementEquityComponentsAxis=GCTK_JulyEighteenNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: Period Type: XML \$3 R23.htm IDEA: XBRL DOCUMENT v3.24.3 SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JULY 30 NOTES (Details) - USD (\$) in Thousands 9 Months Ended Jul. 30, 2024 Jun. 27, 2024 Sep. 30, 2024 Total proceeds received \$ 1,450 \$ 15 A Total proceeds allocated to July 30 Warrants at initial recognition \$ 2,550 \$ 85 A Total proceeds allocated to embedded redemption feature at initial recognition A \$ 35 July 30 Notes [Member] A A Open balance A A Total proceeds received A A 4,000 Total proceeds allocated to July 30 Warrants at initial recognition A A (2,550) Total proceeds allocated to embedded redemption feature at initial recognition A A (35) Amortization of discount and interest expenses related to July 30 Note (Note 5 below) A A 309 Ending balance A A \$ 1,724 X - DefinitionDiscount amortization and interest expenses. + ReferencesNo definition available. + Details Name: GCTK_DiscountAmortizationAndInterestExpenses Namespace Prefix: GCTK Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIncluding the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap ConvertibleDebt Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNet Increase or Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 15 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/815-15/tableOfContent + Details Name: us-gaap EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13 + Details Name: us-gaap FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap ProceedsFromIssuanceOfDebt Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap StatementEquityComponentsAxis=GCTK_JulyThirtyNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML \$3 R24.htm IDEA: XBRL DOCUMENT v3.24.3 SCHEDULE OF RECONCILIATION OF FAIR VALUE OF EMBEDDED CONVERSION FEATURE (Details) \$ in Thousands 9 Months Ended Sep. 30, 2024 USD (\$) Significant Transactions A Open balance Proceeds allocated to embedded redemption feature at initial recognition 35 Revaluation expenses related to embedded redemption feature (Note 5 below) 2 Ending balance \$ 37 X - ReferencesNo definition available. + Details Name: GCTK_RevaluationExpensesRelatedToEmbeddedRedemptionFeature Namespace Prefix: GCTK Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionFair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1

Debt discount rate 28.65% 28.65% Volatility 122.80% 245.00% Risk-free interest rate 4.78%

4.52% Debt description of notice of default (i) failure by the Company to pay the July 30 Note balance on the Maturity Date, (ii) the Company becomes subject to a judgement of more than \$50,000, (iii) voluntary bankruptcy, or (iv) involuntary bankruptcy. Upon the occurrence of an Event of Default specified in clause (iii) above, the July 30 Note balance shall automatically and immediately become due and payable, in all cases without any action on the part of the July 30 Holder. Debt default long term debt amount \$50,000,000 Debt Instrument, Term 10 years Embedded conversion feature percentage 200.00% Fair value of embedded derivative liability \$35,000 Interest expense \$5,000,000 Equity fair value disclosure 1,505,000 \$238,000 Subsequent Event [Member] Short-Term Debt [Line Items] Aggregate gross proceeds offering \$10,000,000 Stock issued during period shares issued for services 19,682,000 Convertible Notes Payable [Member] Short-Term Debt [Line Items] Debt instrument face amount \$360,000 Debt instrument interest rate 8.00% Gross proceeds from notes conversion \$500,000 Conversion price \$1.56 Conversion price \$360 Sale of stock issued price per share \$5.00 Convertible Promissory Notes [Member] Short-Term Debt [Line Items] Debt instrument description (i) is convertible at the discretion of the July 30 Holder at a price equal to the closing price of the Common Stock on the date of conversion and, (ii) if the Closing Price of the Common stock exceeds \$5.00 per share for a period of 5 consecutive trading days, will automatically convert at a price equal to the 5 daily Volume Weighted Average Price (  VWAP  ) of the Common Stock (subject to adjustment for any stock split, stock dividend, reverse stock split, combination or similar transaction). Sale of stock description of transaction (i) cash equal to 200% of the Note balance, or (ii) transaction consideration in the amount to be received by the Holder in such Sale Transaction if the July 30 Note was converted pursuant to an optional conversion.  Sale Transaction   means a merger or consolidation of the Company with or into any other entity, or a sale of all or substantially all of the Company  s assets, or any other transaction or series of related transactions in which the Company  s stockholders immediately prior to such transaction(s) receive cash, securities or other property in exchange for their shares and, immediately after such transaction(s), own less than 50% of the equity securities of the surviving corporation or its parent. Unsecured Promissory Notes [Member] Short-Term Debt [Line Items] Debt instrument face amount \$100,000 Private Placement [Member] Short-Term Debt [Line Items] Short-Term Debt [Line Items] Number of shares issued \$79,366 Common stock share price \$6.30 Aggregate gross proceeds offering \$500,000 Exchange Agreement [Member] Short-Term Debt [Line Items] Lock-up period conditions (a) sell or contract to sell Shares at a price higher than \$0.50 per Share on any trading day up to 10% of the daily volume of Shares or (b) sell or contract to sell Shares at a price higher than \$0.80 per Share on any trading day with no volume limitation. Share price \$1.00 Lease Agreements [Member] Short-Term Debt [Line Items] Monthly rental fee \$2,500 Lessee term of contract 3 years Security deposit \$2,500 Warrants Agreement [Member] Convertible Promissory Notes [Member] Short-Term Debt [Line Items] Debt instrument face amount \$4,000,000 Debt instrument interest rate 8.00% Debt instrument description (i) 12 months anniversary of July 30 Note, or (ii) closing date of a Sale Transaction (defined below) (the   Maturity Date  ) Prefunded Warrants [Member] Prefunded Warrants [Member] Subsequent Event [Member] Short-Term Debt [Line Items] Short-Term Debt [Line Items] Share price \$0.001 Shares of Common Stock 876,391 First Warrant [Member] Short-Term Debt [Line Items] Short-Term Debt [Line Items] Number of shares issued 2,133,334 Exercise price \$1.875 Second Warrant [Member] Exercise price \$2.625 Short-Term Debt [Line Items] Number of shares issued 1,523,810 Exercise price \$2.625 Third Warrant [Member] Short-Term Debt [Line Items] Number of shares issued 1,185,186 Exercise price \$3.375 June Twenty Seven Notes [Member] Interest expense \$113,000 \$20,000 June Twenty Seven Notes [Member] Subsequent Event [Member] Short-Term Debt [Line Items] Stock issued during period shares issued for services 254,226,000 August Twenty Three Warrant [Member] Short-Term Debt [Line Items] Warrants and rights outstanding term 10 years Warrants exercisable Aug. 16, 2025 August Twenty Three Warrant One [Member] Short-Term Debt [Line Items] Class of warrant or right number of securities called by warrants or rights 10,707,000 Exercise price \$1.875 August Twenty Three Warrant Two [Member] Short-Term Debt [Line Items] Class of warrant or right number of securities called by warrants or rights 7,648,000 Exercise price \$2.625 August Twenty Three Warrant Three [Member] Short-Term Debt [Line Items] Class of warrant or right number of securities called by warrants or rights 5,948,000 Exercise price \$3.375 July Eighteen Notes [Member] Short-Term Debt [Line Items] Proceeds from notes \$360,000 Interest expense \$146,000 \$5,000 July Twenty Seven Notes [Member] Short-Term Debt [Line Items] Conversion price \$1.02 September Five Warrants [Member] Warrants exercisable Aug. 16, 2025 September Five Warrants One [Member] Short-Term Debt [Line Items] Class of warrant or right number of securities called by warrants or rights 138,299,000 Exercise price \$1.875 September Five Warrants Two [Member] Short-Term Debt [Line Items] Class of warrant or right number of securities called by warrants or rights 98,785,000 Exercise price \$2.625 September Five Warrants Three [Member] Short-Term Debt [Line Items] Class of warrant or right number of securities called by warrants or rights 76,833,000 Exercise price \$3.375 X - DefinitionEmbedded conversion feature percentage. + ReferencesNo definition available. + Details Name: GCTK_EmbeddedConversionFeaturePercentage Namespace Prefix: GCTK_ Data Type: dtr-types:percentItem Type Balance Type: na Period Type: instant X - DefinitionLock up period description. + ReferencesNo definition available. + Details Name: GCTK_LockUpPeriodDescription Namespace Prefix: GCTK_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionDate the warrants or rights are exercisable, in YYYY-MM-DD format. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightDateFromWhichWarrantsOrRightsExercisable Namespace Prefix: us-gaap_ Data Type: xbrli:dateItem Type Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionIncluding the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_ConvertibleNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of outstanding long-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_DebtDefaultLongtermDebtAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionDescription of the facts pertaining to a notice received from a lender that an event of default has occurred with respect to the long-term debt instrument or borrowing, and a description of the expected financial consequences of receiving such notice, including the effects of a demand for immediate repayment of all amounts due, and the classification of the debt on the balance sheet. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe price per share of the conversion feature embedded in the debt instrument. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5 + Details Name: us-gaap_DebtInstrumentConvertibleConversionPrice1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionIdentification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (

<https://asc.fasb.org/1943274/2147482900/835-30-50-1>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482925/835-30-45-2> + Details Name: us-gaap DebtInstrumentFaceAmount Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionEffective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482949/835-30-55-8>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482900/835-30-50-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482925/835-30-45-2>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-6> + Details Name: us-gaap DebtInstrumentInterestRateEffectivePercentage Namespace Prefix: us-gaap Data Type: dtr-types:percentItem Type Balance Type: na Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481139/470-20-50-1B> + Details Name: us-gaap DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap Data Type: dtr-types:percentItem Type Balance Type: na Period Type: instant X - DefinitionPeriod of time between issuance and maturity of debt instrument, in PnYnMnDnHnMnS format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gaap DebtInstrumentTerm Namespace Prefix: us-gaap Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration X - DefinitionFair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480434/815-10-50-4B> + Details Name: us-gaap EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionFair value of the entity's equity. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2E>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2> + Details Name: us-gaap EquityFairValueDisclosure Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481766/480-10-25-13> + Details Name: us-gaap FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionAmount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 3: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-49>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482964/270-10-50-1>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-24>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483013/835-20-50-1> + Details Name: us-gaap InterestExpense Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionTerm of lessee's operating lease, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479964/842-20-50-3> + Details Name: us-gaap LesseeOperatingLeaseTermOfContract Namespace Prefix: us-gaap Data Type: xbrli:durationItem Type Balance Type: na Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479041/842-20-45-1> + Details Name: us-gaap OperatingLeaseLiability Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479041/842-20-45-5>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478964/842-20-50-4> + Details Name: us-gaap OperatingLeasePayments Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from entity's first offering of stock to the public. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-14> + Details Name: us-gaap ProceedsFromIssuanceInitialPublicOffering Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionThe cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-14> + Details Name: us-gaap ProceedsFromIssuanceOfDebt Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: duration X - DefinitionDescription of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481231/810-10-45-23>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1A -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-1A>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 1B -SubTopic 10 -Topic 810 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-1B> + Details Name: us-gaap SaleOfStockDescriptionOfTransaction Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + ReferencesNo definition available. + Details Name: us-gaap SaleOfStockPricePerShare Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionThe amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap SecurityDeposit Namespace Prefix: us-gaap Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - DefinitionPrice of a single share of a number of saleable stocks of a company. + ReferencesNo definition available. + Details Name: us-gaap SharePrice Namespace Prefix: us-gaap Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionDescription of borrowing classified as short-term upon issuance. Includes, but is not limited to, description of underlying arrangement, repayment terms, interest rate, collateral provided, restriction on use of asset and activity, and compliance with debt covenant. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap ShortTermDebtDescription Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap ShortTermDebtLineItems Namespace Prefix: us-gaap Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionNumber of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders. + ReferencesNo definition available. + Details Name: us-gaap StockIssuedDuringPeriodSharesIssuedForServices Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478448/946-505-50-2>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479886/946-10-S99-3>Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1> + Details Name: us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionValue of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI

+ Details Name: us-gaap StockIssuedDuringPeriodValueConversionOfUnits Namespace Prefix: us-gaap Data Type: xbrl:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDescription of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 - Subparagraph \(SAB Topic 4.C\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 - Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4) + Details Name: us-gaap StockholdersEquityReverseStockSplit Namespace Prefix: us-gaap Data Type: xbrl:stringItemType Balance Type: na Period Type: duration X - DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in "PnYmDtnHmMns" format, for example, "P1Y5M13D" represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2) + Details Name: us-gaap WarrantsAndRightsOutstandingTerm Namespace Prefix: us-gaap Data Type: xbrl:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap SubsequentEventTypeAxis=us-gaap SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap ShortTermDebtTypeAxis=GCTK ConvertiblePromissoryNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap DebtInstrumentAxis=GCTK UnsecuredPromissoryNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap SubsidiarySaleOfStockAxis=us-gaap PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap TypeOfArrangementAxis=GCTK ExchangeAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap TypeOfArrangementAxis=us-gaap LeaseAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap TypeOfArrangementAxis=GCTK WarrantsAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap StatementEquityComponentsAxis=GCTK PrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap StatementEquityComponentsAxis=GCTK SecondWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap StatementEquityComponentsAxis=GCTK ThirdWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap StatementEquityComponentsAxis=GCTK JuneTwentySevenNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap StatementEquityComponentsAxis=GCTK AugustTwentyThreeWarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap StatementEquityComponentsAxis=GCTK AugustTwentyThreeWarrantOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap StatementEquityComponentsAxis=GCTK AugustTwentyThreeWarrantTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap StatementEquityComponentsAxis=GCTK AugustTwentyThreeWarrantThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap StatementEquityComponentsAxis=GCTK JulyEighteenNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap StatementEquityComponentsAxis=GCTK JulyTwentySevenNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap StatementEquityComponentsAxis=GCTK SeptemberFiveWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap StatementEquityComponentsAxis=GCTK SeptemberFiveWarrantsOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap StatementEquityComponentsAxis=GCTK SeptemberFiveWarrantsTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap StatementEquityComponentsAxis=GCTK SeptemberFiveWarrantsThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative) 1 Months Ended 9 Months Ended Oct. 07, 2022 shares Mar. 04, 2004 USD (\$) May 31, 2024 shares Jun. 20, 2023 shares Sep. 30, 2024 USD (\$) shares Sep. 30, 2023 USD (\$) shares Mar. 04, 2004 ILS (₪) Loss Contingencies [Line Items] \$ \$ \$ \$ Restricted shares | shares \$ \$ 30,000,20,000 \$ \$ Research and development expenses | \$ \$ \$ \$ 131,000 \$ \$ Stock based compensation | \$ \$ \$ \$ 239,000 \$ \$ Common Stock [Member] \$ \$ \$ \$ Loss Contingencies [Line Items] \$ \$ \$ \$ Number of common shares issued | shares \$ \$ \$ \$ 79,366 1,075,294 \$ \$ Stock based compensation | \$ \$ \$ \$ 192,000 \$ \$ Discount rate \$ \$ \$ \$ 30.00% \$ \$ Intellectual Property Purchase Agreement [Member] | Common Stock [Member] \$ \$ \$ \$ Loss Contingencies [Line Items] \$ \$ \$ \$ Number of common shares issued | shares 200,000 \$ \$ \$ \$ Israeli Innovation Authority [Member] \$ \$ \$ \$ Loss Contingencies [Line Items] \$ \$ \$ \$ Contingent consideration liability | \$ \$ \$ \$ 73 \$ \$ Minimum [Member] | Intellectual Property Purchase Agreement [Member] | Common Stock [Member] \$ \$ \$ \$ Loss Contingencies [Line Items] \$ \$ \$ \$ Commission as a percentage of aggregate sales price 1.50% \$ \$ \$ \$ Israeli Innovation Authority [Member] \$ \$ \$ \$ Loss Contingencies [Line Items] \$ \$ \$ \$ Contingent consideration liability \$ \$ 93,000 \$ \$ \$ \$ 420,000 Israeli Innovation Authority [Member] | Minimum [Member] \$ \$ \$ \$ Loss Contingencies [Line Items] \$ \$ \$ \$ Royalty percentage maximum \$ \$ 3.00% \$ \$ \$ \$ Israeli Innovation Authority [Member] | Maximum [Member] \$ \$ \$ \$ Loss Contingencies [Line Items] \$ \$ \$ \$ Royalty percentage maximum \$ \$ 5.00% \$ \$ \$ \$ X - DefinitionAggregate sales price of units percentage. + ReferencesNo definition available. + Details Name: GCTK AggregateSalesPriceOfUnitsPercentage Namespace Prefix: GCTK Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionMarketability discount rate + ReferencesNo definition available. + Details Name: GCTK MarketabilityDiscountRate Namespace Prefix: GCTK Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionRoyalty percentage. + ReferencesNo definition available. + Details Name: GCTK RoyaltyPercentage Namespace Prefix: GCTK Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of liability recognized arising from contingent consideration in a business combination. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(2\)\(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(bbb\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(c\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-35-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-35-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6) + Details Name: us-gaap BusinessCombinationContingentConsiderationLiability Namespace Prefix: us-gaap Data Type: xbrl:monetaryItemBalance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1:

[Sub-Topic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 1 - Subparagraph \(a\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147483013/835-20-50-1 & Details](#)

Name: us-gaap_InterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAggregate amount of interest expense on all deposits. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942 - SubTopic 20 - Name Accounting Standards Codification - Section S99 - Paragraph 1 - Subparagraph \(SX 210.9-40\(6\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942 - SubTopic 20 - Name Accounting Standards Codification - Section S99 - Paragraph 1 - Subparagraph (SX 210.9-40(6))) - Publisher FASB - URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 & Details Name: us-gaap_InterestExpenseDeposits Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentsAllOtherInvestmentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense classified as other. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 2 - Subparagraph \(SX 210.5-03\(6\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 2 - Subparagraph (SX 210.5-03(6))) - Publisher FASB - URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 2 - Subparagraph \(SX 210.5-03\(4\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220 - SubTopic 10 - Name Accounting Standards Codification - Section S99 - Paragraph 2 - Subparagraph (SX 210.5-03(4))) - Publisher FASB - URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 & Details Name: us-gaap_OtherExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.3 SUBSEQUENT EVENTS (Details Narrative) - USD (\$) / shares in Units, \$ in Thousands 9 Months Ended Nov. 12, 2024 Sep. 30, 2024 Jun. 27, 2024 Subsequent Event [Line Items] A A Gross proceeds from public offering A \$ 8,873 A Warrant, exercise price A \$ 4.95 Subsequent Event [Member] A A Subsequent Event [Line Items] A A Gross proceeds from public offering \$ 10,000 A Incremental and direct issuance costs 1,127 A A Subsequent Event [Member] | July 30 Notes [Member] A A Subsequent Event [Line Items] A A Debt conversion converted instrument amount \$ 4,089 A Conversion price, per share \$ 1.55 A A Subsequent Event [Member] | IPO [Member] A A Subsequent Event [Line Items] A A Share price \$ 1.389 A A Subsequent Event [Member] | Series A Common Warrant [Member] A A Subsequent Event [Line Items] A A Stock issuance 7,194,240 A A Warrant, exercise price \$ 1.81 A A Subsequent Event [Member] | Series B Common Warrant [Member] A A Subsequent Event [Line Items] A A Stock issuance 7,194,240 A A Warrant, exercise price \$ 1.81 A A Subsequent Event [Member] | Prefunded Warrants [Member] A A A Subsequent Event [Line Items] A A Share price \$ 1.39 A A Subsequent Event [Member] | Common Stock [Member] A A A Subsequent Event [Line Items] A A Stock issuance 2,437,340 A A Subsequent Event [Member] | Common Stock [Member] | July 30 Notes [Member] A A A Subsequent Event [Line Items] A A Stock issuance 2,640,717 A A Subsequent Event [Member] | Prefunded Warrants [Member] A A A Subsequent Event [Line Items] A A Stock issuance 4,756,900 A A Share price \$ 0.001 A A Subsequent Event [Member] | Series A Common Warrant [Member] | July 30 Notes [Member] A A A Subsequent Event [Line Items] A A Stock issuance 2,640,717 A A Subsequent Event [Member] | Series Common Warrant [Member] | July 30 Notes [Member] A A A Subsequent Event [Line Items] A A Stock issuance 2,640,717 A X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 505 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 3 - Publisher FASB - URI https://asc.fasb.org/1943274/214748111/505-10-50-3 & Details> Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemBalance Type: na Period Type: instant X - DefinitionThe value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification - Topic 230 - SubTopic 10 - Section 50 - Paragraph 3 - Publisher FASB - URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification - Topic 230 - SubTopic 10 - Section 50 - Paragraph 5 - Publisher FASB - URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 & Details> Name: us-gaap_DebtConversionConvertedInstrumentAmount1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemBalance Type: credit Period Type: duration X - DefinitionThe price per share of the conversion feature embedded in the debt instrument. + ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 1B - Subparagraph \(c\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 5 - Subparagraph \(a\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481139/470-20-50-5 & Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 1B - Subparagraph (c) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 470 - SubTopic 20 - Name Accounting Standards Codification - Section 50 - Paragraph 5 - Subparagraph (a) - Publisher FASB - URI https://asc.fasb.org/1943274/2147481139/470-20-50-5 & Details) Name: us-gaap_DebtInstrumentConvertibleConversionPrice1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemBalance Type: na Period Type: instant X - DefinitionThe cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification - Topic 230 - SubTopic 10 - Section 45 - Paragraph 15 - Subparagraph \(e\) - Publisher FASB - URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 & Details](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification - Topic 230 - SubTopic 10 - Section 45 - Paragraph 15 - Subparagraph (e) - Publisher FASB - URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 & Details) Name: us-gaap_PaymentsOfDebtIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemBalance Type: credit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from entity's first offering of stock to the public. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification - Section 45 - Paragraph 14 - Subparagraph \(a\) - SubTopic 10 - Topic 230 - Publisher FASB - URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 & Details](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification - Section 45 - Paragraph 14 - Subparagraph (a) - SubTopic 10 - Topic 230 - Publisher FASB - URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 & Details) Name: us-gaap_ProceedsFromIssuanceInitialPublicOffering Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemBalance Type: debit Period Type: duration X - DefinitionPrice of a single share of a number of saleable stocks of a company. + ReferencesNo definition available. + Details Name: us-gaap_SharePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemBalance Type: na Period Type: instant X - DefinitionNumber of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification - Section 50 - Paragraph 2 - SubTopic 10 - Topic 505 - Publisher FASB - URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 & Details> Name: us-gaap_SharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:shareItemBalance Type: na Period Type: instant X - DefinitionDetail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 830 - SubTopic 30 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Publisher FASB - URI https://asc.fasb.org/1943274/2147481674/830-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 855 - SubTopic 10 - Name Accounting Standards Codification - Section 50 - Paragraph 2 - Publisher FASB - URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 & Details> Name: us-gaap_SubsequentEventLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_SubsequentEventEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=GCTK_JulyThirtyNotesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember Namespace Prefix: Data Type: na Balance Type: Period Type: X

[illegible]

[illegible]

[illegible]

E=LLZE970?<#C6XN"/J-K<^S/L .E#^3+P5KJBR)=::\^CZ-%G4W*/\^M-DV+ 1^J;ZGV> ;/N /I P%02P,\$% @ 18%N6=WC(C3)1P #U, ID M
IX;:TW:W&K&ULM9QM:~^X&H, BL6N5K02IN2% MEDIMD=&K3EBUG6K:/>?#ZGQPP85HL(ZIIV1JLR0 M&S^V; .#Y:RZ.
LA(F):JEEO75DHM3K&S=HO10J2L^F7M(0)/>CL SE4KB3.0+4JS2E,MO5R+1)7RZ:N7M MO:=XOE#E6=>JX2.GGXD&HOY:W4AIU^Y19G(JLB,2/%T.ETSR+?+P.JsO^>
MO6NQ19RAE^AYU.^@IGLHN+41*)F^H2P27?BI@625?2=>#0^L=&39UEJX,S-M.SJK+YEY2SL,0QG> =>?>?>5%Y11#9N^9K0+U,7^1_U(9WS9,B^D1>ZD, MATO7A>R#
JP.W0#00(!? BI 8>:U^L#>AIM M4K,Z.I&C X\$#;J P4<#AG7 1^725H^G%9W=WTJIGL9<,7^YS));(LK6GE MDTH05;2^A7%6;0=12?UJK/4^>K3/>WD19>;/3Z0RIN 7^>Z>YS2EW+
JIRK=>TE13NMZPK6=>7D^ZG+J;9Z114H^M^M.A.SEGAFCO19XKOZNC?7J1U= J5G17Z;JA:BA^1GGN-YT^AP^8169EW;?;=<M^DJO1@0IM=#0^IIN?7>=>O SC?<
ANU9>:x;90.^3/57^B1^1%TQA=1J16#M0 MWZG^4F 185XK<9K /BTZVMY^W&AM, Q+3F3 P OC-H@A W^P^I1 @^33%P6Y MJUJ+LIG(K&SHR-
1WN@R9^s6^VM1M4^VLH^JEGGK^CRJ:CHZ-02^/DB.N.2^M2G(SAIXM2\$D B2,(F\$^<ON1L @^5.137VXB0ZU^/XM^R7BJO^S^=)1^ #W1 MKJRL8W6^4
5K6+<^E6.GE1M4^>S1LNW9(9+>2NE&+A1(166^G^&4OH;I?32^M4XK@?^D B+D^M^<1^ MWBQA, @^YTN5\$^=>89J;L3:292^IAG^<9EUF1Z5G6<3^3^5WH**+D2K6IROA^MDB0M@-
(HE,9J M6GE1-W)R300=+2^KC% T4TM>HR7/JI5)ID12NDLKGI1IF2^%5- (4L%[KS M(I=S*42UW/ VWM<IV(?G :2ZCIBADA9 :11^8U1;^*5%)JIUV;1WH6OVK00
M97LH+8#2^3&H+002HM^%#>S>J1U^>XZ9@7M@.7QGQ1M^1.D/2^J3& MH+002HM^%-GSJ1_U^JG022BRFDRS+7183B,N56NORUDG;FGFAJ 106@^E M42B-
062AE1A^>86KZ0 <^S2I00@-(^*U^<00^Z&T^>S4S5=A8S.YI^D0M MO^53;U, R7 6(2ZBIFTO(QV)HHI,MMS&S1&6@J W^K10 M&P%>Y X73& FN=>EX2IMG<I^M^>Q/W;N^ 4AH+0
2J-0&H/20B@MOM^>3=V UN^M^9V^H50&E1A:=A(8E19^1^&9CZ/MK\$V+NU1USWYKJ/MS7WHD<O:E M42B-06DAE1A^>.<I?#I1L<9>5FJI^J5 03G1VGNIDS>BU1?Z
Z^PYVTJO M@B=24L93MAD+16D;DIIIC7UOVE^?H;^>Q:1M^X^T^J40^*V\$TB(I&S=1V8YOG<.<A@QHG M42H I55HC4I(906H6BE^AOCO+<^ZBDBWOM84H=>#% :A=
(8E19^1&^9DJN M15^1^<2AV+E=W10#P5^HU :@)1^*U^T4PM-AZ^1 =0^B^J4%4I1%TAB4 M%D)I8IFJK^O4+SOJ5I:A0CU3(PV V1O)2B 5DJA :EA5I:5-<=<^OI19D
MNC3%T^>HGM^>5 ZU9=;W;ETJ2@^@^F4D1I%5IC4H(144HFBG;OB/QXIZ) M1 5(H+0+1&H/20B@MOM;G24:CI2W^R22V1T^WKAU00VY5 +_K1=>^8 MLO^L.3M78G=VOYP
K91^1^0Q^<0^<Z&T^>S4S5=E9P^<EWS^9CI^J54^K3NH MO^#E42B-06DAE1A^>81&P2%I1J1U&S=Z51^ :51^U1^<2&4^%JHI@JW=J&R;MKF?<
FWZOYSKYK>FWOYIM^L3LVH=>LPN19A^VT^1?2^=>=VTIN^G%<^I^<D^G7E M>B>BS-QS-G [HV7U9Z7.^<@<IXRZ+>>9>Q:NV19LNM(F^YG:=901+OK^MR3H;J M^1KW17?7IRI?
5GOY?>5^Y6GU=>X3.BR@11< 5VT19GP6B\$S^ 51+ P04 M^ #U16G9YQ71A1BS\$ #A& 50^<A1+W=OAHLGN02ZF3I=AS+>+>510)2 M^> Y81A^<B04HWO=R52P\$X,481=0//
IDDLP9IS\$2O1CT^\$I1PN1>(+E^ M4RR^7P/EFIIC.RI=#V2^4%F.^@M1PFHJZ7IT^WWJ+0E)@DG^&L;SZSM^ MBGQC8\$;1F C=YY1%LJ4Z>L<90T^2^>5\$
(5>8^ZYIUC#2S).>QJ1ITZA MF1GN/KIXOS^IZV^R6^<TJD1HA91J^>.<@&X1^4#>WWR1;4#>S^ J31 T28? MVL1^4HJGJZ=>3LE+^%SULO.P^:CIT@VIH5S8B+P&AUB 15^&Q-
6C7I5D1&+1M^>C>@<UIE@91^>VAB18212R^FQ< KK20UMBL.OB^01^>X&HJ^0B1^MY24^J01^>#J 1X>+A+9S3U^/ K^Z\$^1S15I^X10^<A^<@9(7\$@M1^M^<H86<1- JS.)5^Z
W^>EWWO< <-N.OLU+>N2Q0&FW1^>FPB1?7PXP1^R O M1XOCGBT TEGT0<4 16UT0Q581VNVNCJ:JV?E?/1>7>INR^USL^C6OK M1:Y4=+14^6ZS<
NLA7M.CY1^1WIG;62Y1^>2^?P5KU(PB^JQ2=KEO^?H^M MOOZ1^1HO1^@M9%ML<4>=>MT^VJ1^<V^WH^<T2W791MUU+J1P^6F^YRIC;
M^0BROMG=>T1(PRPFE^*)10HH@I=MI&X085L+5S.@+LNTK1Z4HEK1T^>^X MK(3%>R\$TUYG@*9*@%<(7L\$XCXI^XG:V0 :97/1J)DW<\$WT/\$HM/%2HB1|>+N M80>K1CS%
ISFGZJ+HJ54NGP^>8Y7F&F^<4A81N0Z1^>A181GSLF0^>W014KM MU88;|<=<S1^>A-Z6^#&SF8Z<^9TM^E)E8H1YFA^9%5O2^VZ\$>M^>3^01VKK
M6K:7J11^>261V11A:Q1^>9X0818F6Z.P6+7ATOWEPFI0&Z?2 (ASHL>X\$8 M^M^1J2^>T76GLX=12M9=15D11I1\$>:HFE:M31J4@J96ELA/O,K>M^%U:~#
M4X56^<J1J^>G0X14LCI;L1S5=Y17 5RSF1^<A9F6B1J>1%>7D G<#671F^< M&PO=VJR-W-H965T^J(2534196N;J7 6C^M^>A5+01SA&K3L^<9S0F^G;=OI&=<=:9C(MC-
WPR9ANQO14I4ALTCZP/RYH MPN1/|UGX<#<^&XEP1.9+P.1J.B.RMOU1&=31JVRB\$^>B9AEF/-E>=>=IS.P M21Y0G^>SYIO=900EES^G1N^<I4X1ICYCA^>
(YE+A.K7EDYIDN1^>A1?^M%. M68>N+OIH^Y;7:0@BI^32(LOL^>5IO5P08HDD M7M^I=I:0=0%&296P6H&:9R5O1/OE1\$1 9J_2^<N O1^<0^1^%D^>X.%2F%#T\$HPI^F8LW0\$1
156KY1F&E\$JN/L QSGFTFNWHU5G1S;B1FEW^? M7EY 01?>U>L.OOZH^%~\$H.N01S% 5-Z@71M^>M^>O71U1UKY^>Q^KD5^X01=9M+M.69JBY^ZW81H390HF=J2:6RSM1-
L8E1OGIR^1&Z^>1J^>@RVQ1^Y1:HRZHM0BK<1%>47V^IXS;9=U.Y.S\$A&W1~>L^>CQZXRXB1J@3W1^2.K1CQO1^<N&M2^>M\$2GTR&B/3VA^JTBV3Y^IBU+;Y+^*E1LOXC>M^Y1
MI4)00J6<R<1>7WUR.K:4^>#^1K^<VT>13WIG3 BTYBRB^>^>ODK.4K3?S M1(XO6RKL1J.C.MHFW+>4&A5A>DK>3X71 QLYVUR2D>0V3>3(M^>M)7^>D
M\$<09HMI&Y1E6%Q1N.LOJU-092+<^>ACLN^I1U1KW.9^?9&I.W6G.8A1H.M.J1.10&M4EYM+10+@.0^>P>UA0/8.C1.M%2+>2.VPEOW15 MCEUIE(N:AVI\$S)<X-
^I=EE=NLHB3E6^*L\$J.X\$+6^N6DT4^I\$)LXBBB G9 MU^IB>OV^OM.P0^15IID.^>SPI^I@^X-7.7.RITH^H&H1 ME)I1P8)KP=<ID^I E0M@%
(SO=3LX1V1CS0=>R>Q^K10M^TYK&N@) &E9E1B M6<#S1MC6KQVDEK^>OE6F^G^PSU-H\$<10V0-4^*#73:LTWA XDR\$18@IJ M1M^>E1F5Y^Q1^6#^3+I/L4TBC>8<
/O1&O:W4^18OVQK^012:Z8Y& &QM^Y121^I1^%#OI<=<K73%OM@%\$SC=:@3^%ML<0M^>#50N@USPO-7M@.WL<+>W.5P/B9Q^IM2^G(ZLBO1B;~1.225.Q
MP20%\$71^>P^>U^>T8MT1^JM-ODCX4^>LWTK91V1=FZ1(1^5FNJR1 O^>IZOSH MH@:H6@>E9GJ1600781S(GE719@Z33J3S1^D5_@1@.UK^>#8A2J^>UOEGB^~1^>20YT^
8PZW6C^R#I1Z^A501^<62.XW7^>S^*82 @BH M6@>E9GJ1@<O42Q&S^>((IQONP^M2I6/U47R (T0A^>K1S^>H1^>MH_4^>J^>M^>M&6@USR7^>QJ^>E9GJ^>E5I^8%3Q05\$5^V
4C.IU^>CBO015^>BBGVD MUKZ HHJS1I22OE=I=70%<^SUIYW^>I)M^ZPI^WQ.)6C3R^>22OLOKLX\$RBA M2Q7J=>=?^5X^Z^7N2+8N^GV:RE96FRN>+B@/#1I0:ID^>OFKG7R
^G&IR210 M2P.M% @ 18%N67H, (1P 2L T^X^>J5=>EL9^N<S&ULW5C1 M3MLP^>V5R(P1)FTS1J1T5^>B^%VB8D>.>38F>REL=JSCYK7S+?
M.SW:XHL8QM=>AKJ1I5C^>M67B1810S^ZQR(MO2V4N7@7N2^03F2^ASUNET1D1QIK&3CPEH5>1
M.PIQ51>3C9 F^>#F3YK01F^>5^KC^>G@<G;E:XL/KQTIIDE1:YV M^>K2^PTS)=M.CX@V1U9>S2%BSRHX%<@971G(NU) <@_>#<Z<#8:K-6NAJ
MIQW=>3TH0%>HGUY+^>K2+X+ZGI?1B-#@<URIOF^N1X6%CF:7ME-KH1^>M^>K^>NWZP+ZW^>N&K;ZY.64ULDIG2^=>FB19A.9#P3^PH.E17>CBA1 8U1N M&RFG=C.N_K:TIJZ
M13U+>RCXG3(2EG8ZLN1^I KS3^>JOJKK&J7=O=5H48OU>+I>C.F90DO.. MAW3#^>Q9^>WN;4#IE9@>D^>.<=>GVY^>OFA8W&4VY;3<^<_1_3I=YSB33 M5&R;MK7 DE?
YV8ZCWIEN?IMLF 8Z1^>I^YTD U.M^>ID?>LF&J.G1(9A.7J3) M1Z1^Y2=1X(332 LJB?>1336VB31M.E%>K+>N?>G+>6HMOTIM>_FX.>S5=SERE8G1=1/916 MS< V-;Z
1I^>SEGVF21\$>S<8RLZ7F@=>3+1UBVJ1^MAWH^Y8%2^>P16^&IC M^%2^>X61^>EB88%#^>Q&@;16@<C31A1XJM1M+>1P%V1W@>?R^> 3^DY4021 MBGG&GF
<21C1>5KTUV@<Z<L3P1> /A135D\$1XD<1S^N1@RIUO%> ?@>4.B.M^H/KV/PLU1^FS=>S^>31+ P04^>1M^>@6Y9EXJ1_3 @>P M^>1JR96QS^>R9YR96QSG9^Y;P#\$1_Q=>.>?0(8@S9?
\$61D151(V1^>B0D=> MOZ_7J2^>QOEV3P2W1Y1O.TX1+>1J1C1\$>16M6X 4BV0B1S1^>KMOL^>C6^>MTD1SVV~#1HL^>D N&6^>W06061W.D5XA
/E.G;@2=&A(E@6FD7)TZ=>I71=Q_0T^>F08R^T M>EOH^>7H5 J.W&EC^>BM^>XU@LD/TX 4\$1\$!10 /61EG^>PO:~@_M^>T3/
>@>PO=VJR-V10:VLN>+>UOL9A=>YLP&S; BL55^T1CT^>J142) MDU1^>LD6Z1FY\$>S^>N&L.W675^>#^>JS:IVX^>4JV^>F^>X&.>A^>Q9^>O&^>M^>M15T :IM5^>61JOBS6K?<
M9^>B6C6V10^>U23IHGSVXXUDM&S7^>FZL>+I1^>0 M^6^>1^>IM17U/IVP6A6^>S^>2E15AP1M^>N^>MLB>N4M7^>Y1Y1KSNF=>IJO^?>.MOL.R1 4U1^<
1%VZ.0^>T1TB&99(4531)U@U1^>A0^>BC^>K.0.9TV78UBBYG3(T MO1G^>9S.NZ.IK^>J69192767FKO1^>7BLD156PDQ7^>FV73C1Z%PVCVR^>MNPQ05OY1+C&^>UX@4B&L;L.T.MJ
5.0)I&+>@00 R^>M1^>BSHT1F02^>UB81R^>CPAYD.0^>EQ3.0\$^>2(Q^>0^>X^>9Y8POF^>H^>Y M^>N<N352>3>3^>STB^>R^>@A0Q1^>28ZB.J^>GQ24X1^>L^>MHQ1\$66S2(DB^>^>.
IIT.B^>Y1^>YAJD@>1^>Y2H6<11F\$01FEK=>Y.KGEO.(4FB)^>H MA^>2&1)B_&V^>DPOGGU^>#8)3^>F00(&D\$P^>QS.YVO-302FRY18\$>Z^>1S1^>YF1^>U.DE^>^>I&I
M02<#IBB06101:G9PJ1^>F M^>B>B1 O8#>Y1^>ADUX&9#S^>R0W.8Y3&K0 2 M3>=>=>I9F.M6A5F18^>8^>I&I M1+T1Z14B=J8D(5^>YV1O1^>TN^>Y518T16^>CL^>+?
Q125;18.5B)Y1^>L+6A51 MBK31G7^>U1+>P41^>M^>@6Y9+P1^>M55P1IK\$0<@>^>A1^>H^>W&6A5F18^>OR>=>FGD1^>7>ZGY53G(2^>N=64T.MQJ0^>I^>Q2GAXGAF=
I&XAT1EDUA/FWQW96>S^>8^>I&QZFIQO(K^>=>9GRE1M.Y^>M1^>=<K^>J^>C1^>C6>1^>J1Z7^>M^>C^>X2E810S^>CYH14K1\$>#^>JTHA^>T7^>MM1^>@>3B@>03MP6^>
M1@>2^>HABE^>6&D2^>M0^>M1^>DF53<@>DT^>Q^>8DF122838^>V.M^>1^>5^>D&T&X^>84B1^>1^>D^>28^>#>A^>B3^>+T91681>G1S0^>TY1>0^>Z^>K^>O1F^>MUL^>Z^>W^>POOFU^>O^>1^>WH1X10&1&6?<
F=>CM^>XU>AYKO^>5^>O17^>7^>IE&ULS9C+3L.P\$55_1J7 M+>F71D24B@>\$E\$5B-G\$2COS11\$^>HM.WK8>8K8OVL91WJ3D^>OB+90&OLE^>Y ML+A3N^>VDPM>P8%Z62ID
C.C.2N=3693^>4^>6SR1+5ZU^>F7^>K6WUS66X=RPBLZ(C)^>Q^>4Y^>G01OGLH174^>J(MHJL1D-ZD0^KV\$>SF+8.8M\$0<2^>CJVMM200^>F^>E<6&O1HH-0^>#^>ZV(D^>F73
MWG^>LGOQB^>TZFSQ KY1YBL+<1=821M1^>C\$>2D^>HX=>3B1B1LQK1H^>MC=21X^>RFF=DW7^>Y27^>15^>S^>R2^>XK(CFNB>25X(9)C3^>3^>9&=<=1TRW1A)MP4=4@E
A^>J>55Z21J0P^>5^>#D1JG(16.54H.JH)353.N@OE91A^>R^>EDP^>M^>C^>F055^>@JH154^K<=>K^>=>ROCNW^>N^>=>U^>=>GLP91UOXQFGLU+04Q0<1M^>61^>EP^>94UB@>+>0^>+>0^>ID^>Y
0&UL4\$1A0#% @18%N6=1P2N^>P^>1S1M^>1^KP^>108UR:W1S+V^>O&UL4\$1A0#% @18%N69&PO=VJR-W-H965T&UL4\$1A0#% @18%N6=>P^>VYF\$ M1@>AH^>I@>1^>PX
^>AL+W=O&PO=VJR-W-H965T&UL4\$1A0#% @18%N6=14W^>#>=>@>I@>M^>C1^>AT^>AL+W=O&PO=VJR-W-H965T&UL4\$1A0#% @18%N67.N0659\$P^>Y^>@>I@>C^>JG@>
^>AL+W=O M&PO=VJR-W-H965T&UL4\$1A0#% @18%N68BD^>F^>=>@>X^>ID M^>C1^>P1^>AL+W=O&PO=VJR-W-H965T&UL4\$1A0#% @18%N6<+1W\$2^>I@>1A0^>ID^>C1^>N1
^>AL+W=O M&PO=VJR-W-H965T&UL4\$1A0#% @18%N68+K ME^>2^>I@>ID^>C1^>X^>AL+W=O&PO=VJR-W-H965T&UL4\$1A0#% @18%N61^>GY11^>Y00 ID M^>C1^>N1D^>AL+W=O&PO=VJR-W-H965T&UL4\$1A0#% @18%N6; \$S&W@>P08 ID^>C1^>M+8^>AL+W=O&PO=VJR-W-H965T&UL4\$1A0#% M @
18%N6>UX4841^>X1 ID^>C1^>AL+W=O&UL4\$1A0#% @18%N69>^>NQS^>P^>L M^>C1^>D^>18%R96QS^>R9YR96Q\$4L^>A0#% @18%N6<P\$ M^>H2 3^>42^>
10VIN=&5N=>14>7IE&UL4\$1 3I@>D^>0 LPD^>0^>0\$1^>end XML 41 Show.js IDEA:XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and
Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C.
105. var Show=({Show.LastAR=null;Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var
e=a;while(e&e.nodeNamed=TABLE)e=e.nextSibling;if(e.e.nodeNamed=TABLE){var ref=(window)?w.document.document.getElementById(e.ref.cloneNode(10);
e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e.e.style.display='block';Show.LastAR=e;Show.hideAR=function()
{Show.LastAR.style.display='none';Show.toggleNext=function(a){var e=a;while(e.nodeNamed=DIV)e=e.nextSibling;if(e.e.style){e.style.display}{else if(e.e.style.display){e.style
display;if(e.e.style.display='none'){e.d=block;p='^'}else if(e.d='none'p='^'}e.e.style.display=d;if(a.textContent)
f.a.textContent=p+a.textContent.substring(1){else f.a.inerText=p+a.inerText.substring(1)}} XML 42 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */
v2.2.0.24 */ DefRefStyles */ report table.authRefData { background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } report table.authRefData
a { display: block; font-weight: bold; } report table.authRefData p { margin-top: 0px; } report table.authRefData .hide a { background-color: #2F4497; padding: 1px 3px 0px 0px;
text-align: right; } report table.authRefData .hide a: hover { background-color: #2F4497; } report table.authRefData .body { height: 150px; overflow: auto; width: 400px; }
report table.authRefData table { font-size: 1em; } report Styles */ .pl.a .pl.a:visited { color: black; text-decoration: none; } /% table /% report background-color: white;
border: 2px solid #acc; clear: both; color: black; font: normal 0pt Helvetica, Arial, sans-serif; margin-bottom: 2em; } report hr { border: 1px solid #acc; } /% Top labels */ report
th { background-color: #acc; color: black; font-weight: bold; text-align: center; } report th: void { background-color: transparent; color: #000000; font: bold 10pt Helvetica,
Arial, sans-serif; text-align: left; } report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; } report .pl: word-wrap: break-word; } report
td .pl a { cursor: pointer; display: block; width: 200px; overflow: hidden; } report td .pl div a { width: 200px; } report td .pl a: hover { background-color: #ffc; } /% Header
rows... */ report .tr { background-color: #acc; color: black; font-weight: bold; } /% Calendars... */ report .re { background-color: #f0f0f0; } /% Even rows... */ report .re
report .re { background-color: #def; } report .re { border-bottom: 1px solid black; } /% Odd rows... */ report .ro { background-color: white; } report .rou {
border-bottom: 1px solid black; } report .rou { border-bottom: 1px solid black; } /% styles for footnote marker */ report .fn { white-space:
nowrap; } /% styles for numeric types */ report .num { display: block; text-align: right; white-space: nowrap; } report .num { padding-left: 2em; } report .num { padding:
0px 0.4em 0px 2em; } /% styles for text types */ report .text { text-align: left; white-space: normal; } report .text .big { margin-bottom: 1em; width: 17em; } report .text .more
{ display: none; } report .text .note { font-style: italic; font-weight: bold; } report .text .small { font-size: 10em; } report .sup { font-style: italic; } report .outerFootnotes { font-
size: 1em; } XML 44 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3.html 155.213.1 true 49.0 false 5 false false R1.htm 000000001 - Document - Cover Sheet
http://glucotrack.com/role/Cover Cover Cover 1 false false R2.htm 000000002 - Statement - Condensed Consolidated Balance Sheets Sheet
http://glucotrack.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 000000003 - Statement - Condensed Consolidated Balance
Sheets (Parenthetical) Sheet http://glucotrack.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm
000000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet
http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
Statements 4 false false R5.htm 000000005 - Statement - Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited) Sheet
http://glucotrack.com/role/StatementOfChangesInStockholdersEquity Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited) Statements 5 false
false R6.htm 000000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://glucotrack.com/role/StatementsOfCashFlows Condensed
Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 000000007 - Disclosure - GENERAL Sheet http://glucotrack.com/role/General GENERAL
Notes 7 false false R8.htm 000000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet
http://glucotrack.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 000000009 - Disclosure -
SIGNIFICANT TRANSACTIONS Sheet http://glucotrack.com/role/SignificantTransactions SIGNIFICANT TRANSACTIONS Notes 9 false false R10.htm 000000010 - Disclosure -
COMMITMENTS AND CONTINGENT LIABILITIES Sheet http://glucotrack.com/role/CommitmentsAndContingentLiabilities COMMITMENTS AND CONTINGENT LIABILITIES
Notes 10 false false R11.htm 000000011 - Disclosure - FINANCE (INCOME) EXPENSES, NET Sheet http://glucotrack.com/role/FinanceIncomeExpensesNet FINANCE (INCOME)
EXPENSES, NET Notes 11 false false R12.htm 000000012 - Disclosure - SUBSEQUENT EVENTS Sheet http://glucotrack.com/role/SubsequentEvents SUBSEQUENT EVENTS
Notes 12 false false R13.htm 000000013 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet
http://glucotrack.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 13 false false R14.htm
000000014 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesTables
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesTables 14 false false R15.htm 000000015 -
Disclosure - SIGNIFICANT TRANSACTIONS (Tables) Sheet http://glucotrack.com/role/SignificantTransactionsTables SIGNIFICANT TRANSACTIONS (Tables) Tables
http://glucotrack.com/role/SignificantTransactionsTables 15 false false R16.htm 000000016 - Disclosure - FINANCE (INCOME) EXPENSES, NET (Tables) Sheet
http://glucotrack.com/role/FinanceIncomeExpensesNetTables FINANCE (INCOME) EXPENSES, NET (Tables) Tables http://glucotrack.com/role/FinanceIncomeExpensesNet 16

false false R17.htm 00000017 - Disclosure - GENERAL (Details Narrative) Sheet http://glucotrack.com/role/GeneralDetailsNarrative GENERAL (Details Narrative) Sheet http://glucotrack.com/role/General17 false false R18.htm 00000018 - Disclosure - SCHEDULE OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE (Details) Sheet http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails SCHEDULE OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE (Details) Sheet http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails SCHEDULE OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE (Details) Sheet 18 false false R19.htm 00000019 - Disclosure - SCHEDULE OF OPERATING LEASE (Details) Sheet http://glucotrack.com/role/ScheduleOfOperatingLeaseDetails SCHEDULE OF OPERATING LEASE (Details) Details 19 false false R20.htm 00000020 - Disclosure - SCHEDULE OF MATURITY ANALYSIS OF LEASE LIABILITY (Details) Sheet http://glucotrack.com/role/ScheduleOfMaturityAnalysisOfLeaseLiabilityDetails SCHEDULE OF MATURITY ANALYSIS OF LEASE LIABILITY (Details) Details 20 false false R21.htm 00000021 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERMS AND DISCOUNT RATE (Details) Sheet http://glucotrack.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateDetails SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERMS AND DISCOUNT RATE (Details) Details 21 false false R22.htm 00000022 - Disclosure - SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JUNE 27 NOTES (Details) Notes http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJune27NotesDetails SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JUNE 27 NOTES (Details) Details 22 false false R23.htm 00000023 - Disclosure - SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JULY 30 NOTES (Details) Notes http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJuly30NotesDetails SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JULY 30 NOTES (Details) Details 23 false false R24.htm 00000024 - Disclosure - SCHEDULE OF RECONCILIATION OF FAIR VALUE OF EMBEDDED CONVERSION FEATURE (Details) Sheet http://glucotrack.com/role/ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureDetails SCHEDULE OF RECONCILIATION OF FAIR VALUE OF EMBEDDED CONVERSION FEATURE (Details) Details 24 false false R25.htm 00000025 - Disclosure - SIGNIFICANT TRANSACTIONS (Details Narrative) Sheet http://glucotrack.com/role/SignificantTransactionsDetailsNarrative SIGNIFICANT TRANSACTIONS (Details Narrative) Details http://glucotrack.com/role/SignificantTransactionsTables 25 false false R26.htm 00000026 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative) Sheet http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative) Details http://glucotrack.com/role/CommitmentsAndContingentLiabilities 26 false false R27.htm 00000027 - Disclosure - SCHEDULE OF FINANCE EXPENSES (Details) Sheet http://glucotrack.com/role/ScheduleOfFinanceExpensesDetails SCHEDULE OF FINANCE EXPENSES (Details) Details 27 false false R28.htm 00000028 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://glucotrack.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://glucotrack.com/role/SubsequentEvents 28 false false All Reports Book All Reports form 10-q.htm gctk-20240930.xsd gctk-20240930 cal.xml gctk-20240930 def.xml gctk-20240930 lab.xml gctk-20240930 pre.xml http://fasb.org/srt/2024 http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 true true JSON 47 MetaLinks.json IDEA: XBRL DOCUMENT ("version": "2.2", "instance": {"form10-q.htm": {"nsPrefix": "GCTK", "nsuri": "http://glucotrack.com/20240930", "dts": {"local": {"form10-q.htm": {"schema": {"local": {"gctk-20240930.xsd": {"remote": {"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd": {"http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd": {"http://www.xbrl.org/2003/xl-2003-12-31.xsd": {"http://www.xbrl.org/2003/xlink-2003-12-31.xsd": {"http://www.xbrl.org/2005/xbrldt-2005.xsd": {"http://www.xbrl.org/2006/ref-2006-02-27.xsd": {"http://www.xbrl.org/rr/role/negated-2009-12-16.xsd": {"http://www.xbrl.org/rr/role/net-2009-12-16.xsd": {"http://www.xbrl.org/rr/role/reference-2009-12-16.xsd": {"https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd": {"https://www.xbrl.org/dtr/type/2020-01-21/types.xsd": {"https://www.xbrl.org/dtr/type/2022-03-31/types.xsd": {"https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd": {"https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd": {"https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd": {"https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd": {"https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd": {"https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd": {"https://xbrl.sec.gov/country/2024/country-2024.xsd": {"https://xbrl.sec.gov/dei/2024/dei-2024.xsd": {"https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd": {"calculationLink": {"local": {"gctk-20240930 cal.xml": {"definitionLink": {"local": {"gctk-20240930 def.xml": {"labelLink": {"local": {"gctk-20240930 lab.xml": {"presentationLink": {"local": {"gctk-20240930 pre.xml": {"keyStandard": 168, "keyCustom": 45, "axisStandard": 11, "axisCustom": 0, "memberStandard": 12, "memberCustom": 33, "hidden": {"total": 162, "http://fasb.org/us-gaap/2024": 102, "http://glucotrack.com/20240930": 56, "http://xbrl.sec.gov/dei/2024": 4, "contextCount": 155, "entityCount": 1, "segmentCount": 49, "elementCount": 346, "unitCount": 5, "baseTaxonomies": {"http://fasb.org/us-gaap/2024": 525, "http://xbrl.sec.gov/dei/2024": 31, "http://fasb.org/srt/2024": 1, "report": {"R1": {"role": {"http://glucotrack.com/role/Cover": {"longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": {"contextRef": "From2024-01-01to2024-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": {"span": "b", "span": "p", "body": "html"} "reportCount": 1, "baseRef": {"form10-q.htm": {"first": true, "unique": true } "uniqueAnchor": {"contextRef": "From2024-01-01to2024-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": {"span": "b", "span": "p", "body": "html"} "reportCount": 1, "baseRef": {"form10-q.htm": {"first": true, "unique": true } } "R2": {"role": {"http://glucotrack.com/role/BalanceSheets": {"longName": "00000002 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": {"contextRef": "AsOf2024-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": {"td": "tr", "table": "body", "html"} "reportCount": 1, "baseRef": {"form10-q.htm": {"first": true, "unique": true } "uniqueAnchor": {"contextRef": "AsOf2024-09-30", "name": "us-gaap:OtherAssetsCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": {"td": "tr", "table": "body", "html"} "reportCount": 1, "baseRef": {"form10-q.htm": {"first": true, "unique": true } } "R3": {"role": {"http://glucotrack.com/role/BalanceSheetsParentetical": {"longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": {"contextRef": "AsOf2024-09-30", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": {"span": "span", "span": "td", "tr", "table": "body", "html"} "reportCount": 1, "baseRef": {"form10-q.htm": {"first": true, "unique": true } "uniqueAnchor": {"contextRef": "AsOf2024-09-30", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": {"span": "span", "td": "tr", "table": "body", "html"} "reportCount": 1, "baseRef": {"form10-q.htm": {"first": true, "unique": true } } "R4": {"role": {"http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": {"longName": "00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": {"contextRef": "From2024-07-01to2024-09-30", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": {"td": "tr", "table": "body", "html"} "reportCount": 1, "baseRef": {"form10-q.htm": {"first": true, "unique": true } "uniqueAnchor": {"contextRef": "From2024-07-01to2024-09-30", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": {"td": "tr", "table": "body", "html"} "reportCount": 1, "baseRef": {"form10-q.htm": {"first": true, "unique": true } } "R5": {"role": {"http://glucotrack.com/role/StatementOfChangesInStockholdersEquity": {"longName": "00000005 - Statement - Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited)", "shortName": "Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": {"contextRef": "AsOf2022-12-31 us-gaap:CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": {"td": "tr", "table": "body", "html"} "reportCount": 1, "baseRef": {"form10-q.htm": {"first": true, "unique": true } "uniqueAnchor": {"contextRef": "AsOf2022-12-31 us-gaap:CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": {"td": "tr", "table": "body", "html"} "reportCount": 1, "baseRef": {"form10-q.htm": {"first": true, "unique": true } } "R6": {"role": {"http://glucotrack.com/role/StatementsOfCashFlows": {"longName": "00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": {"contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": {"td": "tr", "table": "body", "html"} "reportCount": 1, "baseRef": {"form10-q.htm": {"first": true, "unique": true } "uniqueAnchor": {"contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals

```

"gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "us-gaap:EarningsPerSharePolicyTextBlock": { "us-gaap:SignificantAccountingPoliciesTextBlock": { "body": { "html": "1", "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R15": { "role": "http://glucotrack.com/role/SignificantTransactionsTables", "longName": "00000015 - Disclosure - SIGNIFICANT TRANSACTIONS (Tables)", "shortName": "SIGNIFICANT TRANSACTIONS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "15", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "GCTK:SignificantTransactionsTextBlock": { "body": { "html": "1", "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "GCTK:SignificantTransactionsTextBlock": { "body": { "html": "1", "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R16": { "role": "http://glucotrack.com/role/FinancialIncomeExpensesNetTables", "longName": "00000016 - Disclosure - FINANCE (INCOME) EXPENSES, NET (Tables)", "shortName": "FINANCE (INCOME) EXPENSES, NET (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "16", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "us-gaap:FinancialInstrumentsDisclosureTextBlock": { "body": { "html": "1", "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "srt:ScheduleOfCondensedFinancialStatementsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "us-gaap:FinancialInstrumentsDisclosureTextBlock": { "body": { "html": "1", "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R17": { "role": "http://glucotrack.com/role/GeneralDetailsNarrative", "longName": "00000017 - Disclosure - GENERAL (Details Narrative)", "shortName": "GENERAL (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "17", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "td": "tr", "table": { "body": { "html": "1", "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R18": { "role": "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails", "longName": "00000018 - Disclosure - SCHEDULE OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE (Details)", "shortName": "SCHEDULE OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "18", "firstAnchor": { "contextRef": "From2024-07-01to2024-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "td": "tr", "table": { "body": { "html": "1", "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-09-30", "name": "GCTK:DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "td": "tr", "table": { "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock": { "body": { "html": "1", "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R19": { "role": "http://glucotrack.com/role/ScheduleOfOperatingLeaseDetails", "longName": "00000019 - Disclosure - SCHEDULE OF OPERATING LEASE (Details)", "shortName": "SCHEDULE OF OPERATING LEASE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "19", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "td": "tr", "table": { "body": { "html": "1", "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R20": { "role": "http://glucotrack.com/role/ScheduleOfMaturityAnalysisOfLeaseLiabilityDetails", "longName": "00000020 - Disclosure - SCHEDULE OF MATURITY ANALYSIS OF LEASE LIABILITY (Details)", "shortName": "SCHEDULE OF MATURITY ANALYSIS OF LEASE LIABILITY (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "20", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "td": "tr", "table": { "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "GCTK:SignificantTransactionsTextBlock": { "body": { "html": "1", "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "td": "tr", "table": { "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "GCTK:SignificantTransactionsTextBlock": { "body": { "html": "1", "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R21": { "role": "http://glucotrack.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateDetails", "longName": "00000021 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERMS AND DISCOUNT RATE (Details)", "shortName": "SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERMS AND DISCOUNT RATE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "21", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "p", "td": "tr", "table": { "GCTK:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateTableTextBlock", "GCTK:SignificantTransactionsTextBlock": { "body": { "html": "1", "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "td", "tr", "table": { "GCTK:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateTableTextBlock", "GCTK:SignificantTransactionsTextBlock": { "body": { "html": "1", "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R22": { "role": "http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJune27NotesDetails", "longName": "00000022 - Disclosure - SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JUNE 27 NOTES (Details)", "shortName": "SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JUNE 27 NOTES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "22", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ProceedsFromIssuanceOfWarrants", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "td": "tr", "table": { "body": { "html": "1", "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ProceedsFromIssuanceOfWarrants", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "td": "tr", "table": { "GCTK:ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock", "GCTK:SignificantTransactionsTextBlock": { "body": { "html": "1", "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R23": { "role": "http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJuly30NotesDetails", "longName": "00000023 - Disclosure - SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JULY 30 NOTES (Details)", "shortName": "SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JULY 30 NOTES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "23", "firstAnchor": { "contextRef": "From2024-07-30to2024-07-30", "name": "us-gaap:ProceedsFromIssuanceOfDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "span": "p", "td": "tr", "table": { "GCTK:SignificantTransactionsTextBlock": { "body": { "html": "1", "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ProceedsFromIssuanceOfDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "td": "tr", "table": { "GCTK:ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock", "GCTK:SignificantTransactionsTextBlock": { "body": { "html": "1", "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R24": { "role": "http://glucotrack.com/role/ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureDetails", "longName": "00000024 - Disclosure - SCHEDULE OF RECONCILIATION OF FAIR VALUE OF EMBEDDED CONVERSION FEATURE (Details)", "shortName": "SCHEDULE OF RECONCILIATION OF FAIR VALUE OF EMBEDDED CONVERSION FEATURE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "td": "tr", "table": { "GCTK:ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureTableTextBlock", "GCTK:SignificantTransactionsTextBlock": { "body": { "html": "1", "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "GCTK:RevaluationExpensesRelatedToEmbeddedRedemptionFeature", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": { "td": "tr", "table": { "GCTK:ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureTableTextBlock", "GCTK:SignificantTransactionsTextBlock": { "body": { "html": "1", "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R25": { "role": "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative", "longName": "00000025 - Disclosure - SIGNIFICANT TRANSACTIONS (Details Narrative)", "shortName": "SIGNIFICANT TRANSACTIONS (Details Narrative)", "isDefault": "false", "groupType": "
```

nonowner source." } } }, "auth_ref": { "r14", "r15", "r60", "r111", "r303", "r318", "r319" } }, "us-gaap AccumulatedOtherComprehensiveIncomeMember": { { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": { "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity": { "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": { "r2", "r8", "r15", "r245", "r248", "r286", "r314", "r315", "r483", "r484", "r485", "r494", "r495", "r496", "r497" } } }, "us-gaap AdditionalPaidInCapitalCommonStock": { { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://glucotrack.com/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": { "r54" } } }, "us-gaap AdditionalPaidInCapitalMember": { { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": { "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity": { "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": { "r329", "r495", "r496", "r497", "r526", "r553" } } }, "GCTK AdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted": { { "xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "AdjustmentsToAdditionalPaidInCapitalDeemedDividendResultedFromTriggerOfDownRoundProtectionFeatureOfCertainWarrantsGranted", "crdr": "credit", "presentation": { "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity": { "lang": { "en-us": { "role": { "label": "Deemed dividend resulted from trigger of down round protection feature of certain warrants granted", "documentation": "Adjustments to additional paid-in capital deemed dividend resulted from trigger of down round protection feature of certain warrants granted" } } }, "auth_ref": { } }, "us-gaap AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities" } } }, "auth_ref": { } } }, "GCTK AggregateSalesPriceOfUnitsPercentage": { { "xbrltype": "percentItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "AggregateSalesPriceOfUnitsPercentage", "presentation": { "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Commission as a percentage of aggregate sales price", "documentation": "Aggregate sales price of units percentage." } } }, "auth_ref": { } } }, "GCTK AllocationOfProceedsAndRelatedIssuanceCostsPolicyTextBlock": { { "xbrltype": "textBlockItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "AllocationOfProceedsAndRelatedIssuanceCostsPolicyTextBlock", "presentation": { "http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "label": "Allocation of proceeds and related issuance costs", "documentation": "Allocation Of Proceeds And Related Issuance Costs [Policy Text Block]" } } }, "auth_ref": { } }, "dei AmendmentDescription": { { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": { } }, "dei AmendmentFlag": { { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously filed or accepted submission." } } }, "auth_ref": { } }, "us-gaap AmortizationOffinancingCostsAndDiscounts": { { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOffinancingCostsAndDiscounts", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "lang": { "en-us": { "role": { "label": "Discount amortization and interest expenses related to promissory notes (Note 3E, Note 3G and Note 3H)", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": { "r212", "r433", "r434", "r488", "r536" } } }, "dei AnnualInformationForm": { { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": { "r472" } } }, "us-gaap ArrangementsAndNonarrangementTransactionsMember": { { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": { "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative": { "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative": { "http://glucotrack.com/role/SubsequentEventsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": { "r239" } } } }, "us-gaap Assets": { { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://glucotrack.com/role/BalanceSheets": { "lang": { "en-us": { "role": { "totalLabel": "TOTAL ASSETS", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": { "r80", "r98", "r107", "r136", "r165", "r169", "r172", "r173", "r176", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r240", "r242", "r260", "r300", "r370", "r426", "r427", "r443", "r457", "r521", "r522", "r541" } } }, "us-gaap AssetsAbstract": { { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": { "http://glucotrack.com/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "auth_ref": { } } }, "us-gaap AssetsCurrent": { { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap Assets", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://glucotrack.com/role/BalanceSheets": { "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": { "r104", "r113", "r136", "r176", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r240", "r242", "r260", "r443", "r521", "r522", "r541" } } }, "us-gaap AssetsCurrentAbstract": { { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": { "http://glucotrack.com/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "Current assets" } } }, "auth_ref": { } }, "dei AuditedAnnualFinancialStatements": { { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": { "r472" } } }, "GCTK AugustTwentyThreeWarrantMember": { { "xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "AugustTwentyThreeWarrantMember", "presentation": { "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "August Twenty Three Warrant [Member]", "documentation": "August Twenty Three Warrant [Member]" } } }, "auth_ref": { } }, "GCTK AugustTwentyThreeWarrantOneMember": { { "xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "AugustTwentyThreeWarrantOneMember", "presentation": { "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "August Twenty Three Warrant One [Member]", "documentation": "August Twenty Three Warrant One [Member]" } } }, "auth_ref": { } }, "GCTK AugustTwentyThreeWarrantThreeMember": { { "xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "AugustTwentyThreeWarrantThreeMember", "presentation": { "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "August Twenty Three Warrant Three [Member]", "documentation": "August Twenty Three Warrant Three [Member]" } } }, "auth_ref": { } }, "GCTK AugustTwentyThreeWarrantTwoMember": { { "xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "AugustTwentyThreeWarrantTwoMember", "presentation": { "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "August Twenty Three Warrant Two [Member]", "documentation": "August Twenty Three Warrant Two [Member]" } } }, "auth_ref": { } }, "us-gaap BasisOfAccountingPolicyTextBlock": { { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyTextBlock", "presentation": { "http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "label": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": { } }, "GCTK BetweenOneYearToTwoYearsMember": { { "xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "BetweenOneYearToTwoYearsMember", "presentation": { "http://glucotrack.com/role/ScheduleOfMaturityAnalysisOfLeaseLiabilityDetails": { "lang": { "en-us": { "role": { "label": "Between 1 - 2 Years [Member]", "documentation": "Between 1 - 2 Years [Member]" } } }, "auth_ref": { } }, "us-gaap BusinessCombinationContingentConsiderationLiability": { { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "presentation": { "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Contingent consideration liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": { "r33", "r76", "r236", "r255", "r256", "r257" } } }, "us-gaap CashAndCashEquivalentsAtCarryingValue": { { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://glucotrack.com/role/BalanceSheets": { "http://glucotrack.com/role/GeneralDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": { "r19", "r106", "r420" } } }, "us-gaap CashAndCashEquivalentsPolicyTextBlock": { { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": { "http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies": { "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": { "r20" } } }, "us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents, and restricted cash at beginning of the period", "periodEndLabel": "Cash and cash equivalents, and restricted cash, end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": { "r1", "r66" } } }, "dei CityAreaCode": { { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "City Area

`"Code": "documentation", "Area code of city" } } } }, "auth_ref": { } } }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": { "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" } }, "http://glucotrack.com/role/SubsequentEventsDetailsNarrative" } } }, "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } } }, "auth_ref": { "r94", "r108", "r109", "r110", "r136", "r156", "r157", "r160", "r162", "r167", "r168", "r176", "r188", "r190", "r191", "r192", "r195", "r196", "r214", "r215", "r216", "r217", "r218", "r260", "r324", "r325", "r326", "r327", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r358", "r379", "r396", "r411", "r412", "r413", "r414", "r415", "r478", "r490", "r498" } } }, "us-gaap_ClassOfWarrantOrRightStartDateFromWhichWarrantsOrRightsExercisable": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightStartDateFromWhichWarrantsOrRightsExercisable", "presentation": { "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" } } }, "lang": { "en-us": { "role": { "label": "Warrants exercisable", "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format." } } } }, "auth_ref": { "r219" } } }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights", "presentation": { "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" } } }, "lang": { "en-us": { "role": { "label": "Exercise price", "verboseLabel": "Warrant, exercise price", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } } }, "auth_ref": { "r219" } } }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": { "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" } } }, "lang": { "en-us": { "role": { "label": "Class of warrant or right number of securities called by warrants or rights", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } } }, "auth_ref": { "r219" } } }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } } }, "presentation": { "http://glucotrack.com/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "Commitments and contingent liabilities (Note 4)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } } }, "auth_ref": { "r49", "r83", "r301", "r357" } } }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } } }, "auth_ref": { } } }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": { "http://glucotrack.com/role/CommitmentsAndContingentLiabilities": { "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENT LIABILITIES", "documentation": "The entire disclosure for commitments and contingencies." } } } }, "auth_ref": { "r72", "r180", "r181", "r416", "r513", "r518" } } } }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": { "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" } } }, "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails": { "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity", "http://glucotrack.com/role/SubsequentEventsDetailsNarrative" } } }, "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } } }, "auth_ref": { "r447", "r448", "r449", "r451", "r452", "r453", "r454", "r494", "r495", "r497", "r526", "r551", "r553" } } }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": { "http://glucotrack.com/role/BalanceSheetsParenthetical": { "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" } } }, "lang": { "en-us": { "role": { "label": "Common stock, par value", "verboseLabel": "Common stock share price", "documentation": "Face amount or stated value per share of common stock." } } } }, "auth_ref": { "r52" } } }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": { "http://glucotrack.com/role/BalanceSheetsParenthetical": { "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } } }, "auth_ref": { "r52", "r358" } } } }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": { "http://glucotrack.com/role/BalanceSheetsParenthetical": { "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" } } }, "lang": { "en-us": { "role": { "label": "Common stock, shares issued", "verboseLabel": "Shares of Common Stock", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } } }, "auth_ref": { "r52" } } }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": { "http://glucotrack.com/role/BalanceSheetsParenthetical": { "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } } }, "auth_ref": { "r10", "r52", "r358", "r376", "r553", "r554" } } } }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } } }, "presentation": { "http://glucotrack.com/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "Common Stock of $ 0.001 par value (u201cCommon Stock(u201d)100,000,000 shares authorized as of September 30, 2024 and December 31, 2023, 5,772,190 and 4,178,274 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } } }, "auth_ref": { "r52", "r302", "r443" } } } }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } } }, "presentation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": { "lang": { "en-us": { "role": { "negatedTotalLabel": "Comprehensive loss for the period", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } } }, "auth_ref": { "r16", "r118", "r120", "r125", "r295", "r309", "r310" } } } }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": { "http://glucotrack.com/role/SummaryOfSignificantAccountingPolicies": { "lang": { "en-us": { "role": { "label": "Principles of Consolidation", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } } }, "auth_ref": { "r34", "r422" } } } }, "us-gaap_ConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleDebt", "crdr": "credit", "presentation": { "http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJuly30NotesDetails": { "http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJune27NotesDetails": { "lang": { "en-us": { "role": { "periodStartLabel": "Open balance", "periodEndLabel": "Ending balance", "label": "Convertible Debt", "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company." } } } }, "auth_ref": { "r13", "r82", "r550" } } } } }, "us-gaap_ConvertibleNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleNotesPayable", "crdr": "credit", "presentation": { "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Gross proceeds from notes conversion", "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder." } } } }, "auth_ref": { "r13", "r82", "r550" } } } }, "us-gaap_ConvertibleNotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleNotesPayableCurrent", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } } }, "presentation": { "http://glucotrack.com/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "Convertible promissory notes (Note 3F)", "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder." } } } }, "auth_ref": { "r44" } } } }, "us-gaap_ConvertibleNotesPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConvertibleNotesPayableMember", "presentation": { "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Convertible Notes Payable [Member]", "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder." } } } }, "auth_ref": { "r43", "r81" } } } }, "GCFK_ConvertiblePromissoryNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "ConvertiblePromissoryNotesMember", "presentation": { "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Convertible Promissory Notes [Member]", "documentation": "Convertible Promissory Notes [Member]" } } } }, "auth_ref": { } } }, "GCFK_ConvertiblePromissoryNotesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "ConvertiblePromissoryNotesPolicyTextBlock", "presentation": { "http://glucotrack.com/role/SummaryOfSignificantAccountingPolicies": { "lang": { "en-us": { "role": { "label": "Convertible Promissory Notes", "documentation": "Convertible Promissory Notes [Policy Text Block]" } } } }, "auth_ref": { } } }, "doi_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } } }, "auth_ref": { } } }, "doi_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } } }, "auth_ref": { } } }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format-MM-DD." } } } }, "auth_ref": { } } }, "us-gaap_DebtConversionConvertedInstrumentAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtConversionConvertedInstrumentAmount", "crdr": "credit", "presentation": { "http://glucotrack.com/role/SubsequentEventsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Debt conversion converted instrument amount", "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a non-cash (or part noncash) transaction." } } } }, "auth_ref": { "r21", "r22" } } } }, "us-gaap_DebtDefaultLongtermDebtAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDefaultLongtermDebtAmount", "crdr": "credit", "presentation": { "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Debt default long term debt amount", "documentation": "Amount of outstanding long-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured." } } } }, "auth_ref": { "r135" } } } }, "us-gaap_DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDefaultLongtermDebtDescriptionOfNoticeOfDefault", "presentation": { "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Debt description of notice of default", "documentation": "Description of the facts pertaining to a notice received from a lender that an event of default has occurred with respect to the long-term debt instrument or borrowing, and a description of the expected financial consequences of receiving such notice, including the effects of a demand for immediate repayment of all amounts due, and the classification of the debt on the balance sheet." } } } }, "auth_ref": { "r70" } } } }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": { "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } } }, "auth_ref": { "r13", "r43", "r44", "r81", "r82", "r138", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r430", "r431",`

"r432", "r433", "r434", "r441", "r491", "r514", "r515", "r516", "r535", "r537" }, {"us-gaap_DebtInstrumentConvertibleConversionPrice1": {"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": {"http://glucotrack.com/role/SignificantTransactionsDetailsNarrative": {"lang": {"en-us": {"role": {"label": "Conversion price", "verboseLabel": "Conversion price, per share", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } }}, "auth_ref": {"r73", "r199"}}, "us-gaap_DebtInstrumentDescription": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentDescription", "presentation": {"http://glucotrack.com/role/SignificantTransactionsDetailsNarrative": {"lang": {"en-us": {"role": {"label": "Debt instrument description", "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total." } }}, "auth_ref": {"r13", "r30", "r40", "r43", "r81", "r92", "r270"}}, "us-gaap_DebtInstrumentFaceAmount": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": {"http://glucotrack.com/role/SignificantTransactionsDetailsNarrative": {"lang": {"en-us": {"role": {"label": "Debt instrument face amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } }}, "auth_ref": {"r197", "r270", "r271", "r431", "r432", "r441"}}, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {"xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": {"http://glucotrack.com/role/SignificantTransactionsDetailsNarrative": {"lang": {"en-us": {"role": {"label": "Debt discount rate", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } }}, "auth_ref": {"r46", "r213", "r270", "r271", "r441"}}, "us-gaap_DebtInstrumentInterestRateStatedPercentage": {"xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": {"http://glucotrack.com/role/SignificantTransactionsDetailsNarrative": {"lang": {"en-us": {"role": {"label": "Debt instrument interest rate", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } }}, "auth_ref": {"r46", "r198"}}, "us-gaap_DebtInstrumentNameDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": {"http://glucotrack.com/role/SignificantTransactionsDetailsNarrative": {"lang": {"en-us": {"role": {"documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } }}, "auth_ref": {"r13", "r138", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r430", "r431", "r432", "r433", "r434", "r441", "r491", "r514", "r515", "r516", "r535", "r537"}}, "us-gaap_DebtInstrumentTerm": {"xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTerm", "presentation": {"http://glucotrack.com/role/SignificantTransactionsDetailsNarrative": {"lang": {"en-us": {"role": {"label": "Debt instrument term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDnTnHnMnS format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } }}, "auth_ref": {}}, "us-gaap_DebtSecurities": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecurities", "crdr": "debit", "presentation": {"http://glucotrack.com/role/GeneralDetailsNarrative": {"lang": {"en-us": {"role": {"label": "Debt securities", "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading)."} }}, "auth_ref": {"r175", "r298", "r299", "r445", "r446"}}, "GCTK_DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature": {"xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "DeemedDividendRelatedToTriggerOfDownRoundProtectionFeature", "crdr": "credit", "calculation": {"http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails": {"parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 2.0 }}, "presentation": {"http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails": {"lang": {"en-us": {"role": {"negatedLabel": "Deemed dividend related to trigger of down round protection feature", "documentation": "Deemed dividend related to trigger of down round protection feature." } }}, "auth_ref": {}}, "GCTK_DeemedDividendUponTriggerOfDownRoundProtection": {"xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "DeemedDividendUponTriggerOfDownRoundProtection", "crdr": "credit", "presentation": {"http://glucotrack.com/role/StatementsOfCashFlows": {"lang": {"en-us": {"role": {"label": "Deemed dividend upon trigger of down round protection", "documentation": "Deemed dividend upon trigger of down round protection." } }}, "auth_ref": {}}, "us-gaap_Depreciation": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "calculation": {"http://glucotrack.com/role/StatementsOfCashFlows": {"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 }}, "presentation": {"http://glucotrack.com/role/StatementsOfCashFlows": {"lang": {"en-us": {"role": {"label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } }}, "auth_ref": {"r6", "r29"}}, "us-gaap_DerivativeLiabilities": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilities", "crdr": "credit", "calculation": {"http://glucotrack.com/role/BalanceSheets": {"parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 }}, "presentation": {"http://glucotrack.com/role/BalanceSheets": {"http://glucotrack.com/role/ScheduleOfReconciliationOffFairValueOfEmbeddedConversionFeatureDetails": {"lang": {"en-us": {"role": {"label": "Derivative financial liabilities (Note 3G and Note 3H)", "periodStartLabel": "Open balance", "periodEndLabel": "Ending balance", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } }}, "auth_ref": {"r114", "r115", "r253", "r254", "r258", "r259", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r371", "r373", "r374", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r421", "r529", "r530", "r531", "r552"}}, "us-gaap_DerivativesPolicyTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativesPolicyTextBlock", "presentation": {"http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies": {"lang": {"en-us": {"role": {"label": "Warrants", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } }}, "auth_ref": {"r11", "r36", "r37", "r38", "r39", "r137", "r152"}}, "GCTK_DisclosureSignificantTransactionsAbstract": {"xbrltype": "stringItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "DisclosureSignificantTransactionsAbstract", "lang": {"en-us": {"role": {"label": "Significant Transactions", "verboseLabel": "Schedule Of Operating Lease", "terseLabel": "Schedule Of Weighted Average Remaining Lease Terms And Discount Rate"} }}, "auth_ref": {}}, "GCTK_DiscountAmortizationAndInterestExpenses": {"xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "DiscountAmortizationAndInterestExpenses", "crdr": "debit", "presentation": {"http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJuly30NotesDetails": {"http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJune27NotesDetails": {"lang": {"en-us": {"role": {"label": "Discount amortization and interest expenses related to June 27 Notes (Note 5 below)", "verboseLabel": "Amortization of discount and interest expenses related to July 30 Note (Note 5 below)", "documentation": "Discount amortization and interest expenses." } }}, "auth_ref": {}}, "GCTK_DiscountAmortizationAndInterestExpensesOne": {"xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "DiscountAmortizationAndInterestExpensesOne", "crdr": "debit", "calculation": {"http://glucotrack.com/role/ScheduleOffFinanceExpensesDetails": {"parentTag": "GCTK_FinanceIncomeNet", "weight": -1.0, "order": 1.0 }}, "presentation": {"http://glucotrack.com/role/ScheduleOffFinanceExpensesDetails": {"lang": {"en-us": {"role": {"label": "Discount amortization and interest expenses related to June 27 Notes", "documentation": "Discount amortization and interest expenses one." } }}, "auth_ref": {}}, "GCTK_DiscountAmortizationAndInterestExpensesTwo": {"xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "DiscountAmortizationAndInterestExpensesTwo", "crdr": "debit", "calculation": {"http://glucotrack.com/role/ScheduleOffFinanceExpensesDetails": {"parentTag": "GCTK_FinanceIncomeNet", "weight": -1.0, "order": 3.0 }}, "presentation": {"http://glucotrack.com/role/ScheduleOffFinanceExpensesDetails": {"lang": {"en-us": {"role": {"label": "Discount amortization and interest expenses related to July 30 Note", "documentation": "Discount amortization and interest expenses two." } }}, "auth_ref": {}}, "dei_DocumentAccountingStandard": {"xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": {"http://glucotrack.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing. This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } }}, "auth_ref": {"r471"}}, "dei_DocumentAnnualReport": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": {"http://glucotrack.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } }}, "auth_ref": {"r469", "r471", "r472"}}, "dei_DocumentFiscalPeriodFocus": {"xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": {"http://glucotrack.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } }}, "auth_ref": {}}, "dei_DocumentFiscalYearFocus": {"xbrltype": "yearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": {"http://glucotrack.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } }}, "auth_ref": {}}, "dei_DocumentPeriodEndDate": {"xbrltype": "dateTimeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": {"http://glucotrack.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } }}, "auth_ref": {}}, "dei_DocumentPeriodStartDate": {"xbrltype": "dateTimeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": {"http://glucotrack.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } }}, "auth_ref": {}}, "dei_DocumentQuarterlyReport": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": {"http://glucotrack.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as a quarterly report." } }}, "auth_ref": {"r470"}}, "dei_DocumentRegistrationStatement": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": {"http://glucotrack.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } }}, "auth_ref": {"r458"}}, "dei_DocumentShellCompanyEventDate": {"xbrltype": "dateTimeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": {"http://glucotrack.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } }}, "auth_ref": {"r474"}}, "dei_DocumentShellCompanyReport": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": {"http://glucotrack.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } }}, "auth_ref": {"r471"}}, "dei_DocumentTransitionReport": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": {"http://glucotrack.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } }}, "auth_ref": {"r473"}}, "dei_DocumentType": {"xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": {"http://glucotrack.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } }}, "auth_ref": {}}, "dei_DocumentsIncorporatedByReferenceTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": {"http://glucotrack.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Documents incorporated by reference [Text Block]", "documentation": "Documents incorporated by reference." } }}, "auth_ref": {"r461"}}, "us-gaap_EarningsPerShareBasic": {"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": {"http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": {"lang": {"en-us": {"role": {"label": "Basic net loss per common stock", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } }}, "auth_ref": {"r126", "r144", "r145", "r146", "r147", "r148", "r149", "r153", "r156", "r160", "r161", "r162", "r164", "r234", "r238", "r251", "r252", "r296", "r311", "r423"}}, "us-gaap_EarningsPerShareDiluted": {"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": {"http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": {"lang": {"en-us": {"role": {"label": "Diluted net loss per common stock", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting

period." } } }, "auth_ref": { "r126", "r144", "r145", "r146", "r147", "r148", "r149", "r156", "r160", "r161", "r162", "r164", "r234", "r238", "r251", "r252", "r296", "r311", "r423" } } }, "GCTK_EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones": { "xbrltype": "perShareItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones", "presentation": { "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Diluted net loss per common stock", "documentation": "Earnings per share diluted including warrants and performance milestones.", "label": "EarningsPerShareDilutedIncludingWarrantsAndPerformanceMilestones" } } }, "auth_ref": { "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": { "http://glucotrack.com/role/SummaryOfSignificantAccountingPolicies": { "lang": { "en-us": { "role": { "label": "Basic and diluted loss per share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": { "r24", "r25", "r163" } } }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "lang": { "en-us": { "role": { "label": "Effect of exchange rate changes on cash and cash equivalents, and restricted cash", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": { "r534" } } }, "GCTK_EmbeddedConversionFeaturePercentage": { "xbrltype": "percentItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "EmbeddedConversionFeaturePercentage", "presentation": { "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Embedded conversion feature percentage", "documentation": "Embedded conversion feature percentage." } } }, "auth_ref": { "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability", "crdr": "credit", "presentation": { "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Fair value of embedded derivative liability", "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability." } } }, "auth_ref": { "r79", "r529", "r530", "r531" } } }, "us-gaap_EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet", "crdr": "credit", "presentation": { "http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJuly30NotesDetails": { "http://glucotrack.com/role/ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureDetails": { "lang": { "en-us": { "role": { "label": "Total proceeds allocated to embedded redemption feature at initial recognition", "documentation": "Net increase or decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period." } } }, "auth_ref": { "r525" } } }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": { "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": { "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": { "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": { "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": { "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": { "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": { "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": { "r464" } } }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": { "r460" } } }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument IDomain of the Entity Listings, Instrument." } } }, "auth_ref": { "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate Yes or No whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": { "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": { "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative": { "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": { "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": { "r460" } } }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": { "r477" } } }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": { "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": { "r460" } } }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": { "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": { "r474" } } }, "dei_EntityListingParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityListingParValuePerShare", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Entity Listing, Par Value Per Share", "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: 0.01." } } }, "auth_ref": { "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": { "r472" } } }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": { "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": { "r460" } } }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": { "r460" } } }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": { "r460" } } }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": { "r460" } } }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate Yes or No if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": { "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate Yes or No if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": { "r475" } } }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": {

```

"http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative",
"http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails",
"http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJuly30NotesDetails",
"http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJune27NotesDetails",
"http://glucotrack.com/role/SignificantTransactionsTables",
"http://glucotrack.com/role/StatementOfChangesInStockholdersEquity",
"http://glucotrack.com/role/SubsequentEventsDetailsNarrative" }, { "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } }, "auth_ref": { "r10", "r102", "r121", "r122", "r123", "r139", "r140", "r141", "r143", "r148", "r150", "r152", "r166", "r177", "r178", "r179", "r220", "r229", "r230", "r231", "r232", "r233", "r235", "r237", "r238", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r261", "r263", "r264", "r265", "r266", "r267", "r272", "r273", "r286", "r308", "r314", "r315", "r316", "r329", "r396" } }, "us-gaap": { "EquityFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityFairValueDisclosure", "crdr": "credit", "presentation": { "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Equity fair value disclosure", "documentation": "Fair value of the entity's equity." } }, "auth_ref": { "r527", "r532" } }, "GCTK": { "ExchangeAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "ExchangeAgreementMember", "presentation": { "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Exchange Agreement [Member]", "documentation": "Exchange Agreement [Member]" } }, "auth_ref": { "dei Extension" }, "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": { "http://glucotrack.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } }, "auth_ref": { "us-gaap": { "FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "presentation": { "http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJuly30NotesDetails", "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Total proceeds allocated to July 30 Warrants at initial recognition", "verboseLabel": "Fair value of warrants", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } }, "auth_ref": { "r0", "r6" } }, "GCTK": { "FinanceIncomeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "FinanceIncomeNet", "crdr": "credit", "calculation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap:NetIncomeLoss", "weight": 1.0, "order": 3.0 }, "http://glucotrack.com/role/ScheduleOfFinanceExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://glucotrack.com/role/ScheduleOfFinanceExpensesDetails", "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss" }, "lang": { "en-us": { "role": { "negatedLabel": "Finance (income) expenses, net (Note 5)", "negatedTotalLabel": "Finance (income) expenses, net", "documentation": "Finance income net", "label": "FinanceIncomeNet" } }, "auth_ref": { "us-gaap": { "FinancialInstrumentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentsDisclosureTextBlock", "presentation": { "http://glucotrack.com/role/FinanceIncomeExpensesNet" }, "lang": { "en-us": { "role": { "label": "FINANCE (INCOME) EXPENSES, NET", "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures." } }, "auth_ref": { "GCTK": { "FirstWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "FirstWarrantMember", "presentation": { "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "First Warrant [Member]", "documentation": "First Warrant [Member]" } }, "auth_ref": { "us-gaap": { "GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap:OperatingExpenses", "weight": 1.0, "order": 3.0 }, "presentation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss" }, "lang": { "en-us": { "role": { "label": "General and administrative expenses", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } }, "auth_ref": { "r62", "r381" } }, "us-gaap": { "IPOMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IPOMember", "presentation": { "http://glucotrack.com/role/GeneralDetailsNarrative", "http://glucotrack.com/role/SubsequentEventsDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "IPO [Member]", "documentation": "First sale of stock by a private company to the public." } }, "auth_ref": { "us-gaap": { "IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } }, "auth_ref": { "us-gaap": { "IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap:NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 }, "presentation": { "http://glucotrack.com/role/StatementsOfCashFlows" }, "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } }, "auth_ref": { "r5" } }, "us-gaap": { "IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": { "http://glucotrack.com/role/StatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "Changes in assets and liabilities." } }, "auth_ref": { "us-gaap": { "IncreaseDecreaseInOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherCurrentAssets", "crdr": "credit", "calculation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap:NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 }, "presentation": { "http://glucotrack.com/role/StatementsOfCashFlows" }, "lang": { "en-us": { "role": { "negatedLabel": "Other current assets", "label": "Increase (Decrease) in Other Current Assets", "documentation": "Amount of increase (decrease) in current assets classified as other." } }, "auth_ref": { "r487" } }, "us-gaap": { "IncreaseDecreaseInOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap:NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 }, "presentation": { "http://glucotrack.com/role/StatementsOfCashFlows" }, "lang": { "en-us": { "role": { "verboseLabel": "Other current liabilities", "label": "Increase (Decrease) in Other Current Liabilities", "documentation": "Amount of increase (decrease) in current liabilities classified as other." } }, "auth_ref": { "r487" } }, "GCTK": { "IntellectualPropertyPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "IntellectualPropertyPurchaseAgreementMember", "presentation": { "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Intellectual Property Purchase Agreement [Member]", "documentation": "Intellectual Property Purchase Agreement [Member]" } }, "auth_ref": { "us-gaap": { "InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://glucotrack.com/role/ScheduleOfFinanceExpensesDetails": { "parentTag": "GCTK:FinanceIncomeNet", "weight": 1.0, "order": 2.0 }, "presentation": { "http://glucotrack.com/role/ScheduleOfFinanceExpensesDetails", "http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJune27NotesDetails", "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Interest expenses related to July 18 Notes (Note 5 below)", "verboseLabel": "Interest expense", "terseLabel": "Interest expenses related to July 18 Notes", "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense." } }, "auth_ref": { "r165", "r169", "r170", "r171", "r173", "r269", "r426", "r427" } }, "us-gaap": { "InterestExpenseDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseDeposits", "crdr": "debit", "calculation": { "http://glucotrack.com/role/ScheduleOfFinanceExpensesDetails": { "parentTag": "GCTK:FinanceIncomeNet", "weight": 1.0, "order": 6.0 }, "presentation": { "http://glucotrack.com/role/ScheduleOfFinanceExpensesDetails" }, "lang": { "en-us": { "role": { "label": "Interest on bank deposits", "documentation": "Aggregate amount of interest expense on all deposits." } }, "auth_ref": { "r86" } }, "us-gaap": { "InterestPaidAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidAbstract", "presentation": { "http://glucotrack.com/role/StatementsOfCashFlows" }, "lang": { "en-us": { "role": { "label": "(a) Net cash (received) paid during the year for" } }, "auth_ref": { "us-gaap": { "InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": { "http://glucotrack.com/role/StatementsOfCashFlows" }, "lang": { "en-us": { "role": { "negatedLabel": "Interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } }, "auth_ref": { "r129", "r131", "r132" } }, "us-gaap": { "InvestmentsAllOtherInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "
```

"http://glucotrack.com/role/ScheduleOfMaturityAnalysisOfLeaseLiabilityDetails" }, {"lang": " { "en-us": { "role": { "documentation": "Contractual term of lease arrangement." } } } }, {"auth_ref": " { "r285": "r479" } } }, {"us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostTableTextBlock", "presentation": { "http://glucotrack.com/role/SignificantTransactionsTables" }, {"lang": " { "en-us": { "role": { "label": "SCHEDULE OF OPERATING LEASE", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } } }, {"auth_ref": " { "r539" } } }, {"dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": { "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" }, {"lang": " { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } } }, {"auth_ref": " { "r1": "r1" } } }, {"us-gaap_LegalEntityTypeOfCounterpartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LegalEntityTypeOfCounterpartyDomain", "presentation": { "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" }, {"lang": " { "en-us": { "role": { "documentation": "Nature of the other party participating in a financial transaction." } } } }, {"auth_ref": " { "r1": "r1" } } }, {"GCTK_LessThanOneYearMember": { "xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "LessThanOneYearMember", "presentation": { "http://glucotrack.com/role/ScheduleOfMaturityAnalysisOfLeaseLiabilityDetails" }, {"lang": " { "en-us": { "role": { "label": "Less Than One Year [Member]", "documentation": "Less Than One Year [Member]" } } } }, {"auth_ref": " { "r1": "r1" } } }, {"us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionLineItems", "presentation": { "http://glucotrack.com/role/ScheduleOfMaturityAnalysisOfLeaseLiabilityDetails" }, {"lang": " { "en-us": { "role": { "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } }, {"auth_ref": " { "r278": "r285" } } }, {"us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionTable", "presentation": { "http://glucotrack.com/role/ScheduleOfMaturityAnalysisOfLeaseLiabilityDetails" }, {"lang": " { "en-us": { "role": { "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } } }, {"auth_ref": " { "r278": "r285" } } }, {"us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeasesPolicyTextBlock", "presentation": { "http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies" }, {"lang": " { "en-us": { "role": { "label": "Leases", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } } }, {"auth_ref": " { "r277" } } }, {"GCTK_LesseeOperatingLeaseLiabilityImputedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "LesseeOperatingLeaseLiabilityImputedInterest", "presentation": { "http://glucotrack.com/role/ScheduleOfMaturityAnalysisOfLeaseLiabilityDetails" }, {"lang": " { "en-us": { "role": { "label": "Less: imputed interest", "documentation": "Lessee operating lease liability imputed interest." } } } }, {"auth_ref": " { "r1": "r1" } } }, {"us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": { "http://glucotrack.com/role/SignificantTransactionsTables" }, {"lang": " { "en-us": { "role": { "label": "SCHEDULE OF MATURITY ANALYSIS OF LEASE LIABILITY", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } } }, {"auth_ref": " { "r540" } } }, {"us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "presentation": { "http://glucotrack.com/role/ScheduleOfMaturityAnalysisOfLeaseLiabilityDetails" }, {"lang": " { "en-us": { "role": { "label": "Total operating lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } } }, {"auth_ref": " { "r283" } } }, {"us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": { "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" }, {"lang": " { "en-us": { "role": { "label": "Lessee term of contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDtnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } } }, {"auth_ref": " { "r538" } } }, {"us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "presentation": { "http://glucotrack.com/role/BalanceSheets" }, {"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 }, {"presentation": { "http://glucotrack.com/role/BalanceSheets" }, {"lang": " { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } } }, {"auth_ref": " { "r13": "r43", "r44", "r45", "r47", "r48", "r49", "r50", "r136", "r176", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r241", "r242", "r243", "r260", "r356", "r424", "r457", "r521", "r541", "r542" } } }, {"us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "presentation": { "http://glucotrack.com/role/BalanceSheets" }, {"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 }, {"presentation": { "http://glucotrack.com/role/BalanceSheets" }, {"lang": " { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } } }, {"auth_ref": " { "r58", "r84", "r305", "r443", "r492", "r504", "r533" } } }, {"us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": { "http://glucotrack.com/role/BalanceSheets" }, {"lang": " { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS' EQUITY", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } } }, {"auth_ref": " { "r45", "r105", "r136", "r176", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r241", "r242", "r243", "r260", "r443", "r521", "r541", "r542" } } }, {"us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": { "http://glucotrack.com/role/BalanceSheets" }, {"lang": " { "en-us": { "role": { "label": "Current liabilities", "documentation": "Total current liabilities." } } } }, {"auth_ref": " { "r1": "r1" } } }, {"us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": { "http://glucotrack.com/role/BalanceSheets" }, {"lang": " { "en-us": { "role": { "label": "Non-current liabilities", "documentation": "Linkage difference on principal of loans from stockholders." } } } }, {"auth_ref": " { "r1": "r1" } } }, {"GCTK_LinkageDifferenceOnPrincipalOfLoansFromStockholders": { "xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "LinkageDifferenceOnPrincipalOfLoansFromStockholders", "presentation": { "http://glucotrack.com/role/StatementsOfCashFlows" }, {"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 }, {"presentation": { "http://glucotrack.com/role/StatementsOfCashFlows" }, {"lang": " { "en-us": { "role": { "label": "Linkage difference on principal of loans from stockholders", "documentation": "Linkage difference on principal of loans from stockholders." } } } }, {"auth_ref": " { "r1": "r1" } } }, {"dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": { "http://glucotrack.com/role/Cover", "lang": " { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } } }, {"auth_ref": " { "r1": "r1" } } }, {"GCTK_LockUpPeriodDescription": { "xbrltype": "stringItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "LockUpPeriodDescription", "presentation": { "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative" }, {"lang": " { "en-us": { "role": { "label": "Lock-up period conditions", "documentation": "Lock up period description." } } } }, {"auth_ref": " { "r1": "r1" } } }, {"us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems", "presentation": { "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" }, {"lang": " { "en-us": { "role": { "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } }, {"auth_ref": " { "r182", "r183", "r184", "r187", "r227", "r429", "r519", "r520" } } }, {"us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesTable", "presentation": { "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" }, {"lang": " { "en-us": { "role": { "label": "Loss Contingencies [Table]", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } } }, {"auth_ref": " { "r182", "r183", "r184", "r187", "r227", "r429", "r519", "r520" } } }, {"GCTK_MarketabilityDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "MarketabilityDiscountRate", "presentation": { "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" }, {"lang": " { "en-us": { "role": { "label": "Discount rate", "documentation": "Marketability discount rate." } } } }, {"auth_ref": " { "r1": "r1" } } }, {"us-gaap_MarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketingExpense", "presentation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss", "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 }, {"presentation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss", "lang": " { "en-us": { "role": { "label": "Marketing expenses", "documentation": "Expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services. Costs of public relations and corporate promotions are typically considered to be marketing costs." } } } }, {"auth_ref": " { "r62" } } }, {"sr_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": { "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" }, {"lang": " { "en-us": { "role": { "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } } }, {"auth_ref": " { "r95", "r96", "r97", "r98", "r99", "r100", "r101", "r183", "r184", "r185", "r186", "r222", "r227", "r257", "r292", "r312", "r313", "r320", "r348", "r349", "r399", "r400", "r401", "r402", "r410", "r417", "r418", "r428", "r435", "r436", "r437", "r438", "r439", "r440", "r444", "r523", "r543", "r544", "r545", "r546", "r547", "r548" } } }, {"sr_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "presentation": { "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" }, {"lang": " { "en-us": { "role": { "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } } }, {"auth_ref": " { "r95", "r96", "r97", "r98", "r99", "r100", "r101", "r183", "r184", "r185", "r186", "r222", "r227", "r257", "r292", "r312", "r313", "r320", "r348", "r349", "r399", "r400", "r401", "r402", "r410", "r417", "r418", "r428", "r435", "r436", "r437", "r438", "r439", "r444", "r523", "r543", "r544", "r545", "r546", "r547", "r548" } } }, {"GCTK_ModificationOfEquityClassifiedContractsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "ModificationOfEquityClassifiedContractsPolicyTextBlock", "presentation": { "http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies" }, {"lang": " { "en-us": { "role": { "label": "Modification of equity-classified contracts", "documentation": "Modification Of Equity Classified Contracts [Policy Text Block]" } } } }, {"auth_ref": " { "r1": "r1" } } }, {"GCTK_MoreThanTwoYearsMember": { "xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "MoreThanTwoYearsMember", "presentation": { "http://glucotrack.com/role/ScheduleOfMaturityAnalysisOfLeaseLiabilityDetails" }, {"lang": " { "en-us": { "role": { "label": "More Than 2 Years [Member]", "documentation": "More Than 2 Years [Member]" } } } }, {"auth_ref": " { "r1": "r1" } } }, {"us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "presentation": { "http://glucotrack.com/role/StatementsOfCashFlows" }, {"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 }, {"presentation": { "http://glucotrack.com/role/StatementsOfCashFlows" }, {"lang": " { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } } }, {"auth_ref": " { "r130" } } }, {"us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": { "http://glucotrack.com/role/StatementsOfCashFlows" }, {"lang": " { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } } }, {"auth_ref": " { "r130" } } }, {"us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": { "http://glucotrack.com/role/StatementsOfCashFlows" }, {"lang": " { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } } }, {"auth_ref": " { "r130" } } }, {"us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": { "http://glucotrack.com/role/StatementsOfCashFlows" }, {"lang": " { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } } }, {"auth_ref": " { "r130" } } }, {"us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": { "http://glucotrack.com/role/StatementsOfCashFlows" }, {"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 }, {"presentation": { "http://glucotrack.com/role/StatementsOfCashFlows" }, {"lang": " { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } } }, {"auth_ref": " { "r130" } } } }

cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth ref": { "r66", "r67", "r68" } }, "us-gaap-NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES" } } }, "auth ref": { "r11", "us-gaap-NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap-ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://glucotrack.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails": { "parentTag": "us-gaap-NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails": "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity", "http://glucotrack.com/role/StatementsOfCashFlows": "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss", "lang": { "en-us": { "role": { "negatedTotalLabel": "Net Loss", "label": "Loss for the period", "negatedLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth ref": { "r61", "r68", "r85", "r103", "r116", "r119", "r123", "r136", "r142", "r144", "r145", "r146", "r147", "r148", "r151", "r152", "r158", "r176", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r234", "r238", "r252", "r260", "r307", "r378", "r394", "r395", "r455", "r521" } }, "us-gaap-NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails": { "lang": { "en-us": { "role": { "negatedTotalLabel": "Net loss attributable to common stockholders", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, of income (loss) available to common shareholders." } } }, "auth ref": { "r127", "r144", "r145", "r146", "r147", "r153", "r154", "r159", "r162", "r238" } }, "dei-NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth ref": { "r11", "us-gaap-NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "lang": { "en-us": { "role": { "label": "(B) Non-cash investment and financing activities." } } }, "auth ref": { "r11", "us-gaap-OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap-OperatingIncomeLoss", "weight": -1.0, "order": 1.0 }, "presentation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": { "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth ref": { "r11", "us-gaap-OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap-NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "presentation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": { "lang": { "en-us": { "role": { "negatedTotalLabel": "Operating loss", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth ref": { "r87", "r425", "r499", "r500", "r501", "r502", "r503" } }, "us-gaap-OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": { "http://glucotrack.com/role/StatementsOfCashFlows": { "lang": { "en-us": { "role": { "label": "Recognition of right for use asset against a lease liability (Note 3C)", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth ref": { "r279", "r442" } }, "us-gaap-OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": { "http://glucotrack.com/role/ScheduleOfMaturityAnalysisOfLeaseLiabilityDetails": "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative", "lang": { "en-us": { "role": { "label": "Present value of lease liabilities", "verboseLabel": "Lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth ref": { "r275" } }, "us-gaap-OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "debit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap-LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "presentation": { "http://glucotrack.com/role/BalanceSheets": "http://glucotrack.com/role/ScheduleOfOperatingLeaseDetails", "lang": { "en-us": { "role": { "label": "Operating lease liability, current (Note 3C)", "verboseLabel": "Current operating lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth ref": { "r275" } }, "us-gaap-OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap-Liabilities", "weight": 1.0, "order": 3.0 }, "presentation": { "http://glucotrack.com/role/BalanceSheets": "http://glucotrack.com/role/ScheduleOfOperatingLeaseDetails", "lang": { "en-us": { "role": { "label": "Operating lease liability, non-current (Note 3C)", "verboseLabel": "Non-Current operating lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth ref": { "r275" } }, "us-gaap-OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": { "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Monthly rental fee", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth ref": { "r276", "r280" } }, "us-gaap-OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap-Assets", "weight": 1.0, "order": 2.0 }, "presentation": { "http://glucotrack.com/role/BalanceSheets": "http://glucotrack.com/role/ScheduleOfOperatingLeaseDetails", "lang": { "en-us": { "role": { "label": "Operating lease right-of-use asset, net (Note 3C)", "verboseLabel": "Operating right-of-use asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth ref": { "r274" } }, "us-gaap-OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": { "http://glucotrack.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateDetails": { "lang": { "en-us": { "role": { "label": "Weighted average discount rate", "documentation": "Weighted average discount rate for operating lease calculated at point-in-time." } } }, "auth ref": { "r282", "r442" } }, "us-gaap-OperatingLeaseWeightedAverageRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm", "presentation": { "http://glucotrack.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateDetails": { "lang": { "en-us": { "role": { "label": "Lease term (years)", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth ref": { "r281", "r442" } }, "us-gaap-OrganizationConsolidationAndPresentationOffinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOffinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements Abstract", "documentation": "Organization, Consolidation and Presentation of Financial Statements Disclosure Text Block", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOffinancialStatementsDisclosureTextBlock", "presentation": { "http://glucotrack.com/role/General": { "lang": { "en-us": { "role": { "label": "GENERAL", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth ref": { "r41", "r77", "r321", "r322" } }, "us-gaap-OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap-AssetsCurrent", "weight": 1.0, "order": 2.0 }, "presentation": { "http://glucotrack.com/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "Other current assets", "documentation": "Amount of current assets classified as other." } } }, "auth ref": { "r112", "r443" } }, "us-gaap-OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap-ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 }, "presentation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": { "lang": { "en-us": { "role": { "negatedLabel": "Foreign currency translation adjustment", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term investment nature." } } }, "auth ref": { "r3", "r308" } }, "us-gaap-OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": { "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity": { "lang": { "en-us": { "role": { "label": "Stock-based compensation", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth ref": { "r10", "r12", "r117", "r120", "r124", "r148", "r261", "r262", "r267", "r294", "r308", "r483", "r484" } }, "us-gaap-OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": { "lang": { "en-us": { "role": { "label": "Other comprehensive (income) loss", "documentation": "Amount of other current assets classified as other." } } }, "auth ref": { "r11", "us-gaap-OtherExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherExpenses", "crdr": "debit", "calculation": { "http://glucotrack.com/role/ScheduleOffinancialExpensesDetails": { "parentTag": "GCTK_FinanceIncomeNet", "weight": -1.0, "order": 7.0 }, "presentation": { "http://glucotrack.com/role/ScheduleOffinancialExpensesDetails": { "lang": { "en-us": { "role": { "label": "Exchange rate differentials, bank commissions and miscellaneous", "documentation": "Amount of expense classified as other." } } }, "auth ref": { "r62", "r63" } }, "us-gaap-OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap-LiabilitiesCurrent", "weight": 1.0, "order": 6.0 }, "presentation": { "http://glucotrack.com/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "Other current liabilities", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth ref": { "r44", "r443" } }, "us-gaap-OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://glucotrack.com/role/BalanceSheets": { "parentTag": "us-gaap-Liabilities", "weight": 1.0, "order": 2.0 }, "presentation": { "http://glucotrack.com/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "Loans from stockholders", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth ref": { "r40" } }, "us-gaap-OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap-NetIncomeLoss", "weight": 1.0, "order": 2.0 }, "presentation": { "http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss": { "lang": { "en-us": { "role": { "negatedLabel": "Other income", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth ref": { "r64" } }, "dei-OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "Item 17 or Item 18 specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth ref": { "r471" } }, "us-gaap-OtherResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherResearchAndDevelopmentExpense", "crdr": "debit", "presentation": { "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative": { "lang": { "en-us": { "role": { "verboseLabel": "Research and development expenses", "label": "Other Research and Development Expense", "documentation": "Amount of other research and development expense." } } }, "auth ref": { "r524" } }, "GCTK_PartialConversionAndAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "PartialConversionAndAccruedInterest", "crdr": "debit", "presentation": { "http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJune27NotesDetails": { "lang": { "en-us": { "role": { "label": "Partial conversion July 18 Notes and accrued interest (Note 3f below)", "documentation": "Partial conversion and accrued interest." } } }, "auth ref": { "r11", "GCTK_PartialConversionNotesAndAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "PartialConversionNotesAndAccruedInterest", "crdr": "debit", "presentation": {

```

http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOffune27NotesDetails", "lang": "en-us", "role": "label", "Partial conversion June 27 Notes and accrued Interest (Note 3I and Note 3J below)", "documentation": "Partial conversion notes and accrued interest.", "auth_ref": "I", "us_gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "presentation": "http://glucotrack.com/role/SubsequentEventsDetailsNarrative", "lang": "en-us", "role": "label", "Incremental and direct issuance costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "auth_ref": "r18", "us_gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": "http://glucotrack.com/role/StatementsOfCashFlows", "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0, "presentation": "http://glucotrack.com/role/StatementsOfCashFlows", "lang": "en-us", "role": "negatedLabel", "Purchase of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale, includes cash outflows to pay for construction of self-constructed assets.", "auth_ref": "r65", "GCTK_PerformanceMilestoneMember": { "xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "PerformanceMilestoneMember", "presentation": "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails", "lang": "en-us", "role": "label", "Performance Milestone [Member]", "documentation": "Performance Milestone [Member]", "auth_ref": "I", "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": "http://glucotrack.com/role/Cover", "lang": "en-us", "role": "label", "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "auth_ref": "r465", "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": "http://glucotrack.com/role/Cover", "lang": "en-us", "role": "label", "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "auth_ref": "r467", "GCTK_PrefundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "PrefundedWarrantsMember", "presentation": "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails", "lang": "en-us", "role": "label", "Prefunded Warrants [Member]", "documentation": "Prefunded Warrants [Member]", "auth_ref": "I", "us_gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrivatePlacementMember", "presentation": "http://glucotrack.com/role/GeneralDetailsNarrative", "lang": "en-us", "role": "label", "Private Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "auth_ref": "I", "GCTK_ProceedsFromAllocatedWarrantsAtInitialRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "ProceedsFromAllocatedWarrantsAtInitialRecognition", "crdr": "debit", "presentation": "http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOffune27NotesDetails", "lang": "en-us", "role": "label", "Total proceeds allocated to June 27 Warrants at initial recognition", "documentation": "Proceeds from allocated warrants at initial recognition.", "auth_ref": "I", "us_gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromConvertibleDebt", "crdr": "debit", "calculation": "http://glucotrack.com/role/StatementsOfCashFlows", "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0, "presentation": "http://glucotrack.com/role/StatementsOfCashFlows", "lang": "en-us", "role": "label", "Issuance of convertible promissory notes and bifurcated conversion feature through private placement transaction (Note 3G)", "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "auth_ref": "r17", "GCTK_ProceedsFromConvertibleDebtPrivatePlacementTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "ProceedsFromConvertibleDebtPrivatePlacementTransaction", "crdr": "debit", "calculation": "http://glucotrack.com/role/StatementsOfCashFlows", "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0, "presentation": "http://glucotrack.com/role/StatementsOfCashFlows", "lang": "en-us", "role": "label", "Issuance of convertible promissory note, bifurcated conversion and redemption features and detachable warrants through private placement transaction (Note 3H)", "documentation": "Proceeds from convertible debt private placement transaction.", "auth_ref": "I", "us_gaap_ProceedsFromDebtNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromDebtNetOfIssuanceCosts", "crdr": "debit", "presentation": "http://glucotrack.com/role/GeneralDetailsNarrative", "lang": "en-us", "role": "label", "Proceeds from Debt, Net of Issuance Costs", "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.", "auth_ref": "r129", "us_gaap_ProceedsFromIssuanceInitialPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceInitialPublicOffering", "crdr": "debit", "presentation": "http://glucotrack.com/role/GeneralDetailsNarrative", "lang": "en-us", "role": "label", "Aggregate gross proceeds offering", "terseLabel": "Gross proceeds from public offering", "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "auth_ref": "r4", "us_gaap_ProceedsFromIssuanceOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit", "presentation": "http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOffune30NotesDetails", "lang": "en-us", "role": "label", "Total proceeds allocated to July 18 Notes at initial recognition", "verboseLabel": "Total proceeds received", "terseLabel": "Proceeds from notes", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "auth_ref": "r486", "us_gaap_ProceedsFromIssuanceOfPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfPrivatePlacement", "crdr": "debit", "calculation": "http://glucotrack.com/role/StatementsOfCashFlows", "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0, "presentation": "http://glucotrack.com/role/StatementsOfCashFlows", "lang": "en-us", "role": "label", "Proceeds received from private placement transaction (Note 3D)", "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.", "auth_ref": "r4", "us_gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "calculation": "http://glucotrack.com/role/StatementsOfCashFlows", "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0, "presentation": "http://glucotrack.com/role/StatementsOfCashFlows", "lang": "en-us", "role": "label", "Issuance of promissory notes and detachable warrants through private placement transaction (Note 3E)", "verboseLabel": "Total proceeds received", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "auth_ref": "r4", "us_gaap_ProceedsFromSecuredNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSecuredNotesPayable", "crdr": "debit", "presentation": "http://glucotrack.com/role/GeneralDetailsNarrative", "lang": "en-us", "role": "label", "Secured promissory notes", "documentation": "The cash inflow from borrowings supported by a written promise to pay an obligation that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).", "auth_ref": "r17", "us_gaap_ProceedsFromUnsecuredNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromUnsecuredNotesPayable", "crdr": "debit", "presentation": "http://glucotrack.com/role/GeneralDetailsNarrative", "lang": "en-us", "role": "label", "Unsecured promissory notes", "documentation": "The cash inflow from borrowings supported by a written promise to pay an obligation that is uncollateralized (where debt is not backed by the pledge of collateral).", "auth_ref": "r17", "GCTK_ProceedsReceivedFromUnderwrittenPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "ProceedsReceivedFromUnderwrittenPublicOffering", "crdr": "debit", "calculation": "http://glucotrack.com/role/StatementsOfCashFlows", "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0, "presentation": "http://glucotrack.com/role/StatementsOfCashFlows", "lang": "en-us", "role": "label", "Net proceeds received from underwritten U.S. public offering", "documentation": "Proceeds received from underwritten public offering.", "auth_ref": "I", "GCTK_PromissoryNotesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "PromissoryNotesCurrent", "crdr": "credit", "calculation": "http://glucotrack.com/role/BalanceSheets", "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0, "presentation": "http://glucotrack.com/role/BalanceSheets", "lang": "en-us", "role": "label", "Promissory notes (Note 3G and Note 3H)", "documentation": "Promissory notes current.", "auth_ref": "I", "us_gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": "http://glucotrack.com/role/BalanceSheets", "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0, "presentation": "http://glucotrack.com/role/BalanceSheets", "lang": "en-us", "role": "label", "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "auth_ref": "r27", "r284", "r297", "r306", "r443", "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "lang": "en-us", "role": "label", "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "auth_ref": "r95", "r96", "r97", "r98", "r99", "r100", "r101", "r183", "r184", "r185", "r186", "r221", "r222", "r224", "r225", "r226", "r227", "r257", "r290", "r291", "r292", "r312", "r313", "r320", "r348", "r349", "r399", "r400", "r401", "r402", "r417", "r418", "r428", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r449", "r517", "r523", "r530", "r544", "r545", "r546", "r547", "r548", "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": "http://
```

RetainedEarningsMember", "presentation": "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity", "lang": "en-us", "role": "label", "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit).", "auth_ref": "r102", "r139", "r140", "r141", "r143", "r148", "r150", "r152", "r177", "r178", "r179", "r229", "r230", "r231", "r232", "r233", "r235", "r237", "r238", "r244", "r246", "r247", "r249", "r250", "r272", "r273", "r314", "r316", "r329", "r553", "GCTK RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities": {"xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "RevaluationExpensesIncurredFromSettlementOfFinancialLiabilities", "crdr": "debit", "calculation": "http://glucotrack.com/role/ScheduleOfFinanceExpensesDetails", "parentTag": "GCTK_FinanceIncomeNet", "weight": 1.0, "order": 5.0, "http://glucotrack.com/role/StatementsOfCashFlows": {"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0, "presentation": "http://glucotrack.com/role/ScheduleOfFinanceExpensesDetails", "http://glucotrack.com/role/StatementsOfCashFlows": {"lang": "en-us", "role": "label", "Revaluation expenses incurred from settlement of financial liabilities (Note 3I and Note 3J)", "verboseLabel": "Revaluation expenses incurred from settlement of financial liabilities", "documentation": "Revaluation expenses incurred from settlement of financial liabilities."}}, "auth_ref": "GCTK_RevaluationExpensesRelatedToDerivativeFinancialLiabilities": {"xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "RevaluationExpensesRelatedToDerivativeFinancialLiabilities", "crdr": "debit", "calculation": "http://glucotrack.com/role/ScheduleOfFinanceExpensesDetails", "parentTag": "GCTK_FinanceIncomeNet", "weight": 1.0, "order": 4.0, "http://glucotrack.com/role/StatementsOfCashFlows": {"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0, "presentation": "http://glucotrack.com/role/ScheduleOfFinanceExpensesDetails", "http://glucotrack.com/role/StatementsOfCashFlows": {"lang": "en-us", "role": "label", "Revaluation expenses related to derivative financial liabilities (Note 3H)", "verboseLabel": "Revaluation expenses related to derivative financial liabilities", "documentation": "Revaluation expenses related to derivative financial liabilities."}}, "auth_ref": "GCTK_RevaluationExpensesRelatedToEmbeddedRedemptionFeature": {"xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "RevaluationExpensesRelatedToEmbeddedRedemptionFeature", "crdr": "credit", "presentation": "http://glucotrack.com/role/ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureDetails", "lang": "en-us", "role": "label", "Revaluation expenses related to embedded redemption feature (Note 5 below)", "documentation": "Revaluation expenses related to embedded redemption feature."}}, "auth_ref": "GCTK_RoyaltyPercentage": {"xbrltype": "percentItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "RoyaltyPercentage", "presentation": "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "lang": "en-us", "role": "label", "Royalty percentage maximum", "documentation": "Royalty percentage."}}, "auth_ref": "us-gaap_SaleOfStockDescriptionOfTransaction": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockDescriptionOfTransaction", "presentation": "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative", "lang": "en-us", "role": "label", "Sale of stock description of transaction", "documentation": "Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination."}}, "auth_ref": "us-gaap_SaleOfStockNameOfTransactionDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": "http://glucotrack.com/role/GeneralDetailsNarrative", "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative": "http://glucotrack.com/role/SubsequentEventsDetailsNarrative", "lang": "en-us", "role": "label", "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."}}, "auth_ref": "us-gaap_SaleOfStockPricePerShare": {"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPricePerShare", "presentation": "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative", "lang": "en-us", "role": "label", "Sale of stock issued price per share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."}}, "auth_ref": "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": "http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesTables", "lang": "en-us", "role": "label", "SCHEDULE OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."}}, "auth_ref": "srt_ScheduleOfCondensedFinancialStatementsTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfCondensedFinancialStatementsTableTextBlock", "presentation": "http://glucotrack.com/role/FinanceIncomeExpensesNetTables", "lang": "en-us", "role": "label", "SCHEDULE OF FINANCE EXPENSES", "documentation": "Tabular disclosure of condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows."}}, "auth_ref": "r480", "r493", "GCTK_ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "ScheduleOfReconciliationOfCarryingAmountOfNotesTableTextBlock", "presentation": "http://glucotrack.com/role/SignificantTransactionsTables", "lang": "en-us", "role": "label", "SCHEDULE OF RECONCILIATION OF THE CARRYING AMOUNT OF JULY 30 NOTES", "documentation": "Schedule of Reconciliation of Carrying Amount of Notes [Table Text Block]"}}, "auth_ref": "GCTK_ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "ScheduleOfReconciliationOfFairValueOfEmbeddedConversionFeatureTableTextBlock", "presentation": "http://glucotrack.com/role/SignificantTransactionsTables", "lang": "en-us", "role": "label", "SCHEDULE OF RECONCILIATION OF FAIR VALUE OF EMBEDDED CONVERSION FEATURE", "documentation": "Schedule of Reconciliation of Fair Value of Embedded Conversion Feature [Table Text Block]"}}, "auth_ref": "us-gaap_ScheduleOfShortTermDebtTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShortTermDebtTable", "presentation": "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative", "lang": "en-us", "role": "label", "Short Term Debt [Table]", "documentation": "Disclosure of information about short-term debt arrangement. Includes, but is not limited to, description of arrangement, lender, repayment term, weighted-average interest rate, borrowed amount, and description and amount of refinancing of short-term obligation when obligation is excluded from current liability."}}, "auth_ref": "r43", "GCTK_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateTableTextBlock", "presentation": "http://glucotrack.com/role/SignificantTransactionsTables", "lang": "en-us", "role": "label", "SCHEDULE OF WEIGHTED AVERAGE REMAINING LEASE TERMS AND DISCOUNT RATE", "documentation": "Schedule of Weighted Average Remaining Lease Terms and Discount Rate [Table Text Block]"}}, "auth_ref": "GCTK_SecondWarrantMember": {"xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "SecondWarrantMember", "presentation": "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative", "lang": "en-us", "role": "label", "Second Warrant [Member]", "documentation": "Second Warrant [Member]"}}, "auth_ref": "dei_Security12bTitle": {"xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": "http://glucotrack.com/role/Cover", "lang": "en-us", "role": "label", "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security."}}, "auth_ref": "r459", "dei_Security12gTitle": {"xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": "http://glucotrack.com/role/Cover", "lang": "en-us", "role": "label", "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security."}}, "auth_ref": "r463", "us-gaap_SecurityDeposit": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecurityDeposit", "crdr": "debit", "presentation": "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative", "lang": "en-us", "role": "label", "Security deposit", "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease."}}, "auth_ref": "dei_SecurityExchangeName": {"xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": "http://glucotrack.com/role/Cover", "lang": "en-us", "role": "label", "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered."}}, "auth_ref": "r462", "dei_SecurityReportingObligation": {"xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": "http://glucotrack.com/role/Cover", "lang": "en-us", "role": "label", "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."}}, "auth_ref": "r468", "GCTK_SeptemberFiveWarrantsMember": {"xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "SeptemberFiveWarrantsMember", "presentation": "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative", "lang": "en-us", "role": "label", "September Five Warrants [Member]", "documentation": "September Five Warrants [Member]"}}, "auth_ref": "GCTK_SeptemberFiveWarrantsOneMember": {"xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "SeptemberFiveWarrantsOneMember", "presentation": "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative", "lang": "en-us", "role": "label", "September Five Warrants One [Member]", "documentation": "September Five Warrants One [Member]"}}, "auth_ref": "GCTK_SeptemberFiveWarrantsThreeMember": {"xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "SeptemberFiveWarrantsThreeMember", "presentation": "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative", "lang": "en-us", "role": "label", "September Five Warrants Three [Member]", "documentation": "September Five Warrants Three [Member]"}}, "auth_ref": "GCTK_SeptemberFiveWarrantsTwoMember": {"xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "SeptemberFiveWarrantsTwoMember", "presentation": "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative", "lang": "en-us", "role": "label", "September Five Warrants Two [Member]", "documentation": "September Five Warrants Two [Member]"}}, "auth_ref": "GCTK_SeriesACommonWarrantMember": {"xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "SeriesACommonWarrantMember", "presentation": "http://glucotrack.com/role/SubsequentEventsDetailsNarrative", "lang": "en-us", "role": "label", "Series A Common Warrant [Member]", "documentation": "Series A Common Warrant [Member]"}}, "auth_ref": "GCTK_SeriesBCommonWarrantMember": {"xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "SeriesBCommonWarrantMember", "presentation": "http://glucotrack.com/role/SubsequentEventsDetailsNarrative", "lang": "en-us", "role": "label", "Series B Common Warrant [Member]", "documentation": "Series B Common Warrant [Member]"}}, "auth_ref": "GCTK_SeriesCommonWarrantMember": {"xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "SeriesCommonWarrantMember", "presentation": "http://glucotrack.com/role/SubsequentEventsDetailsNarrative", "lang": "en-us", "role": "label", "Series Common Warrant [Member]", "documentation": "ShareBasedCompensation", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": "http://gluc

represent terms, interest rate, collateral provided, restriction on use of asset and activity, and compliance with debt covenant." } } }, "auth_ref": "r482" } } }, "us-gaap_ShortTermDebtLineItems": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtLineItems", "presentation": { "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Short-Term Debt [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { } }, "us-gaap_ShortTermDebtTypeAxis": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeAxis", "presentation": { "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Short-Term Debt Type [Axis]", "documentation": "Information by type of short-term debt arrangement." } } }, "auth_ref": { "r43", "r514", "r515", "r516" } } }, "us-gaap_ShortTermDebtTypeDomain": { "xbrlType": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeDomain", "presentation": { "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative": { "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "auth_ref": { "r42", "r514", "r515", "r516" } } }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": { "http://glucotrack.com/role/SummaryOfSignificantAccountingPolicies": { "lang": { "en-us": { "role": { "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": { "r69", "r134" } } }, "GCTK_SignificantTransactionsTextBlock": { "xbrlType": "textBlockItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "SignificantTransactionsTextBlock", "presentation": { "http://glucotrack.com/role/SignificantTransactions": { "lang": { "en-us": { "role": { "label": "SIGNIFICANT TRANSACTIONS", "documentation": "Significant Transactions [Text Block]" } } }, "auth_ref": { } }, "dei_SolicitingMaterial": { "xbrlType": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": { "http://glucotrack.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": { "r466" } } }, "us-gaap_StatementOfStockAxis": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": { "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative": "http://glucotrack.com/role/SubsequentEventsDetailsNarrative" } }, "http://glucotrack.com/role/SubsequentEventsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": { "r94", "r108", "r109", "r110", "r136", "r156", "r157", "r160", "r162", "r167", "r168", "r176", "r188", "r190", "r191", "r192", "r195", "r196", "r214", "r215", "r216", "r217", "r218", "r260", "r324", "r325", "r326", "r327", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r358", "r379", "r396", "r411", "r412", "r413", "r414", "r415", "r478", "r490", "r498" } } }, "us-gaap_StatementEquityComponentsAxis": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": { "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative": "http://glucotrack.com/role/GeneralDetailsNarrative" } }, "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails": "http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJuly30NotesDetails", "http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJune27NotesDetails": "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative", "http://glucotrack.com/role/SignificantTransactionsTables": "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity", "http://glucotrack.com/role/SubsequentEventsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": { "r10", "r52", "r56", "r57", "r102", "r121", "r122", "r123", "r139", "r140", "r141", "r143", "r148", "r150", "r152", "r166", "r177", "r178", "r179", "r220", "r229", "r230", "r231", "r232", "r233", "r235", "r237", "r238", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r261", "r263", "r264", "r265", "r266", "r267", "r272", "r273", "r286", "r308", "r314", "r315", "r316", "r329", "r396" } } }, "us-gaap_StatementLineItems": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": { "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails": "http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJuly30NotesDetails", "http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJune27NotesDetails": "http://glucotrack.com/role/SignificantTransactionsTables", "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity": { "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r139", "r140", "r141", "r166", "r273", "r293", "r323", "r340", "r350", "r351", "r352", "r353", "r354", "r355", "r358", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r371", "r372", "r373", "r374", "r375", "r377", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r396", "r450" } } }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": { } }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": { } }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": { } }, "us-gaap_StatementTable": { "xbrlType": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": { "http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails": "http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJuly30NotesDetails", "http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJune27NotesDetails": "http://glucotrack.com/role/SignificantTransactionsTables", "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity": { "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": { "r139", "r140", "r141", "r166", "r174", "r273", "r293", "r323", "r340", "r350", "r351", "r352", "r353", "r354", "r355", "r358", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r371", "r372", "r373", "r374", "r375", "r377", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r396", "r450" } } }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrlType": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": { "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity": { "lang": { "en-us": { "role": { "label": "Exchange of warrants into shares (Note 3B), shares", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": { "r10", "r30", "r52", "r56", "r74", "r207" } } }, "GCTK_StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrantsIntoShares": { "xbrlType": "monetaryItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "StockIssuedDuringPeriodSharesExerciseOfPrefundedWarrantsIntoShares", "crdr": "credit", "presentation": { "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity": { "lang": { "en-us": { "role": { "label": "Exercise of prefunded warrants into shares (Note 3A), shares", "documentation": "Exercise of prefunded warrants into shares, shares." } } }, "auth_ref": { } }, "GCTK_StockIssuedDuringPeriodSharesIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b": { "xbrlType": "monetaryItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "StockIssuedDuringPeriodSharesIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b", "crdr": "credit", "presentation": { "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity": { "lang": { "en-us": { "role": { "label": "Issuance of restricted shares as payment for a previous achievement of milestone pursuant to purchase agreement (Note 4B), shares", "documentation": "Issuance of restricted shares as payment for achievement of milestone pursuant to purchase agreement, shares." } } }, "auth_ref": { } }, "GCTK_StockIssuedDuringPeriodSharesIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities": { "xbrlType": "sharesItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "StockIssuedDuringPeriodSharesIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities", "presentation": { "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity": { "lang": { "en-us": { "role": { "label": "Issuance of Common Stock upon private placement transaction (Note 3D), shares", "documentation": "Stock issued during period shares issuance of shares and warrants as settlement of financial liabilities.", "label": "StockIssuedDuringPeriodSharesIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities" } } }, "auth_ref": { } }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrlType": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname

"monetaryItemType", "nsuri": "http://glucotrack.com/20240930", "localname":
"StockIssuedDuringPeriodValueIssuanceOfRestrictedSharesAsPaymentForAchievementOfMilestonePursuantToPurchaseAgreementNote4b", "crdr": "credit", "presentation":
"http://glucotrack.com/role/StatementOfChangesInStockholdersEquity", "lang": "en-us", "role": "label", "Issuance of restricted shares as payment for a previous
achievement of milestone pursuant to purchase agreement (Note 4B)", "documentation": "Issuance of restricted shares as payment for achievement of milestone pursuant to
purchase agreement.", "auth_ref": "GCTK_StockIssuedDuringPeriodValueIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities", "xbrltype":
"monetaryItemType", "nsuri": "http://glucotrack.com/20240930", "localname":
"StockIssuedDuringPeriodValueIssuanceOfSharesAndWarrantsAsSettlementOfFinancialLiabilities", "crdr": "credit", "presentation":
"http://glucotrack.com/role/StatementOfChangesInStockholdersEquity", "lang": "en-us", "role": "label", "Issuance of shares and warrants as settlement of financial
liabilities (Note 3f and Note 3j)", "documentation": "Stock issued during period value issuance of shares and warrants as settlement of financial liabilities.", "auth_ref":
"GCTK_StockIssuedDuringPeriodValueIssuanceOfWarrant", "xbrltype": "monetaryItemType", "nsuri": "http://glucotrack.com/20240930", "localname":
"StockIssuedDuringPeriodValueIssuanceOfWarrant", "crdr": "credit", "presentation": "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity", "lang": "en-us",
"role": "label", "Issuance of shares and warrants as settlement of financial liabilities (Note 3f and Note 3j)", "documentation": "Stock issued during period
value issuance of warrant", "label": "StockIssuedDuringPeriodValueIssuanceOfWarrant", "auth_ref": "us-gaap_StockIssuedDuringPeriodValueNewIssues",
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation":
"http://glucotrack.com/role/StatementOfChangesInStockholdersEquity", "lang": "en-us", "role": "label", "Issuance of Common Stock upon private placement transaction
(Note 3D)", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public
offering.", "auth_ref": "r10", "r51", "r52", "r74", "r329", "r396", "r412", "r456", "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOffForfeitures",
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOffForfeitures", "crdr": "credit",
"presentation": "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity", "lang": "en-us", "role": "label", "Issuance of restricted shares as compensation
towards directors", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
"auth_ref": "r10", "r74", "GCTK_StockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity", "xbrltype": "monetaryItemType", "nsuri":
"http://glucotrack.com/20240930", "localname": "StockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity", "crdr": "credit", "presentation":
"http://glucotrack.com/role/StatementOfChangesInStockholdersEquity", "lang": "en-us", "role": "label", "Issuance of detachable warrants through private
placement transactions (Note 3f and Note 3H)", "documentation": "Stock issued during period value settlement of liabilities with equity.", "label":
"StockIssuedDuringPeriodValueSettlementOfLiabilitiesWithEquity", "auth_ref": "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation", "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation":
"http://glucotrack.com/role/StatementOfChangesInStockholdersEquity", "lang": "en-us", "role": "label", "Other comprehensive income", "documentation": "Value, after
forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)", "auth_ref": "r31", "r51", "r52", "r74", "us-
gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockIssuedDuringPeriodValueShareBasedCompensationGross", "crdr": "credit", "presentation": "http://glucotrack.com/role/StatementOfChangesInStockholdersEquity",
"lang": "en-us", "role": "label", "Issuance of restricted shares as compensation towards directors", "label": "Shares Issued, Value, Share-Based Payment
Arrangement, before Forfeiture", "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership
plan (ESOP)", "auth_ref": "GCTK_StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross", "xbrltype": "monetaryItemType", "nsuri":
"http://glucotrack.com/20240930", "localname": "StockToBeIssuedDuringPeriodValueRestrictedStockAwardGross", "crdr": "credit", "presentation":
"http://glucotrack.com/role/StatementOfChangesInStockholdersEquity", "lang": "en-us", "role": "label", "Restricted shares to be issued as compensation towards
directors", "documentation": "Stock to be issued during period value restricted stock award gross.", "auth_ref": "us-gaap_StockholdersEquity", "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "calculation", "presentation": "http://glucotrack.com/role/BalanceSheets",
"parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0, "presentation": "http://glucotrack.com/role/BalanceSheets",
"http://glucotrack.com/role/StatementOfChangesInStockholdersEquity", "lang": "en-us", "role": "label", "Total stockholders'2019 (deficit) equity",
"periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent.
Excludes temporary equity and equity attributable to noncontrolling interest.", "auth_ref": "r52", "r56", "r57", "r71", "r360", "r376", "r397", "r398", "r443", "r457",
"r492", "r504", "r533", "r553", "us-gaap_StockholdersEquityAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockholdersEquityAbstract", "presentation": "http://glucotrack.com/role/BalanceSheets", "lang": "en-us", "role": "label", "Stockholders'2019 equity",
"auth_ref": "us-gaap_StockholdersEquityReverseStockSplit", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockholdersEquityReverseStockSplit", "presentation": "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative", "lang": "en-us", "role": "label", "Reverse
stock split", "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance
sheet date but before the release of financial statements.", "auth_ref": "r75", "us-gaap_SubsequentEventLineItems", "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": "http://glucotrack.com/role/SubsequentEventsDetailsNarrative", "lang": "en-
us", "role": "label", "Subsequent Event Line Items", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from
elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
"auth_ref": "r268", "r288", "us-gaap_SubsequentEventMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SubsequentEventMember", "presentation": "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative",
"http://glucotrack.com/role/SubsequentEventsDetailsNarrative", "lang": "en-us", "role": "label", "Subsequent Event [Member]", "documentation": "Identifies event that
occurred after the balance sheet date but before financial statements are issued or available to be issued.", "auth_ref": "r268", "r288", "us-
gaap_SubsequentEventTable", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation":
"http://glucotrack.com/role/SubsequentEventsDetailsNarrative", "lang": "en-us", "role": "label", "Subsequent Event [Table]", "documentation": "Disclosure of
information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued.", "auth_ref":
"r268", "r288", "us-gaap_SubsequentEventTypeAxis", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis",
"presentation": "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative", "http://glucotrack.com/role/SubsequentEventsDetailsNarrative", "lang": "en-us",
"role": "label", "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued
or available to be issued.", "auth_ref": "r268", "r288", "us-gaap_SubsequentEventTypeDomain", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative",
"http://glucotrack.com/role/SubsequentEventsDetailsNarrative", "lang": "en-us", "role": "label", "Event that occurred after the balance sheet date but before
financial statements are issued or available to be issued.", "auth_ref": "r268", "r288", "us-gaap_SubsequentEventsAbstract", "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": "en-us", "role": "label", "Subsequent Events [Abstract]", "auth_ref": "us-
gaap_SubsequentEventsTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation":
"http://glucotrack.com/role/SubsequentEvents", "lang": "en-us", "role": "label", "SUBSEQUENT EVENTS", "documentation": "The entire disclosure for significant events
or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be
issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans
to insiders or affiliates, and transactions not in the ordinary course of business.", "auth_ref": "r287", "r289", "us-
gaap_SubsidaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "presentation": "http://glucotrack.com/role/GeneralDetailsNarrative", "lang": "en-
us", "role": "label", "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]", "documentation": "Disclosure of information about sale of stock made by
subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange
for share of acquired entity.", "auth_ref": "us-gaap_SubsidiarySaleOfStockAxis", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SubsidiarySaleOfStockAxis", "presentation": "http://glucotrack.com/role/GeneralDetailsNarrative", "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative",
"http://glucotrack.com/role/SubsequentEventsDetailsNarrative", "lang": "en-us", "role": "label", "Sale of Stock [Axis]", "documentation": "Information by type of sale of
the entity's stock.", "auth_ref": "us-gaap_SubsidiarySaleOfStockLineItems", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"SubsidiarySaleOfStockLineItems", "presentation": "http://glucotrack.com/role/GeneralDetailsNarrative", "lang": "en-us", "role": "label", "Subsidiary, Sale of Stock
[Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with
domain members defined in one or many axes to the table.", "auth_ref": "us-gaap_SupplementalCashFlowInformationAbstract", "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": "http://glucotrack.com/role/StatementsOfCashFlows",
"lang": "en-us", "role": "label", "Supplemental disclosure of cash flow activities.", "auth_ref": "GCTK_ThirdWarrantMember", "xbrltype": "domainItemType",
"nsuri": "http://glucotrack.com/20240930", "localname": "ThirdWarrantMember", "presentation": "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative",
"lang": "en-us", "role": "label", "Third Warrant [Member]", "documentation": "Third Warrant [Member]", "auth_ref": "dei_TradingSymbol", "xbrltype":
"tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": "http://glucotrack.com/role/TradingCover", "lang": "en-us",
"role": "label", "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange.", "auth_ref": "GCTK_TrueupSharesMember",
"xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "TrueupSharesMember", "presentation":
"http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "lang": "en-us", "role": "label", "Trueup Shares [Member]", "documentation":
"Trueup Shares [Member]", "auth_ref": "us-gaap_TypeOfArrangementAxis", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"TypeOfArrangementAxis", "presentation": "http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative",
"http://glucotrack.com/role/SignificantTransactionsDetailsNarrative", "http://glucotrack.com/role/SubsequentEventsDetailsNarrative", "lang": "en-us", "role": "label",
"Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than
collaborative applicable to revenue-generating activity or operations.", "auth_ref": "r239", "GCTK_UnsecuredPromissoryNotesMember", "xbrltype":
"domainItemType", "nsuri": "http://glucotrack.com/20240930", "localname": "UnsecuredPromissoryNotesMember", "presentation":
"http://glucotrack.com/role/SignificantTransactionsDetailsNarrative", "lang": "en-us", "role": "label", "Unsecured Promissory Notes [Member]", "documentation":
"Unsecured Promissory Notes [Member]", "auth_ref": "us-gaap_UseOfEstimates", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "UseOfEstimates", "presentation": "http://glucotrack.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "lang": "en-us", "role": "label", "Use of
Estimates in the Preparation of Financial Statements", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in
conformity with generally accepted accounting principles.", "auth_ref": "r26", "r27", "r28", "r90", "r91", "r92", "r93", "us-gaap_WarrantMember", "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": "http://glucotrack.com/role/GeneralDetailsNarrative",
"http://glucotrack.com/role/SignificantTransactionsDetailsNarrative", "lang": "en-us", "role": "label", "Warrant [Member]", "documentation": "Security that gives the
holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "auth_ref": "r447", "r448",
"r451", "r452", "r453", "r454", "GCTK_WarrantsAgreementMember", "xbrltype": "domainItemType", "nsuri": "http://glucotrack.com/20240930", "localname":
"WarrantsAgreementMember", "presentation": "http://glucotrack.com/role/SignificantTransactionsDetailsNarrative", "lang": "en-us", "role": "label", "Warrants
Agreement [Member]", "documentation": "Warrants Agreement [Member]", "auth_ref": "us-gaap_WarrantsAndRightsOutstanding", "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation":
"http://glucotrack.com/role/ScheduleOfReconciliationOfCarryingAmountOfJune27NotesDetails", "lang": "en-us", "role": "label", "periodStartLabel": "Open balance",
"periodEndLabel": "Ending balance", "label": "Warrants and Rights Outstanding", "documentation": "Value of outstanding derivative securities that permit the holder the right
to purchase securities (usually equity) from the issuer at a specified price.", "auth_ref": "r529", "r530", "r531", "us-gaap_WarrantsAndRightsOutstandingTerm",
"xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingTerm", "presentation":
"http://glucotrack.com/role/SignificantTransactionsDetailsNarrative", "lang": "en-us", "role": "label", "Warrants and rights outstanding term", "documentation": "Period
between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable
date or upon event certain to occur, in PnYnMnDtnHnMnS format, for example, P1Y5M13D represents reported fact of one year, five months, and thirteen days.",

```

http://aef.ref:1529,"r530","r531"}},{"us-gaap-WeightedAverageNumberOfDilutedSharesOutstanding":{"xbrltype":"sharesItem","nsuri":"http://fasb.org/us-gaap/2024","localname":"WeightedAverageNumberOfDilutedSharesOutstanding","presentation":{"http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails":{"http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss"},"lang":{"en-us":{"role":{"label":"Weighted average number of common stock outstanding used in computing diluted net loss per share"},"documentation":"The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."}}},"auth_ref":{"r155","r162"}},{"us-gaap-WeightedAverageNumberOfSharesOutstandingBasic":{"xbrltype":"sharesItem","nsuri":"http://fasb.org/us-gaap/2024","localname":"WeightedAverageNumberOfSharesOutstandingBasic","presentation":{"http://glucotrack.com/role/ScheduleOfAntidilutiveNetLossAndWeightedAverageDetails":{"http://glucotrack.com/role/StatementsOfOperationsAndComprehensiveLoss"},"lang":{"en-us":{"role":{"label":"Weighted average number of common stock outstanding used in computing basic net loss per share"},"documentation":"The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."}}},"auth_ref":{"r153","r162"}},{"us-gaap-WeightedAverageNumberOfSharesRestrictedStock":{"xbrltype":"sharesItem","nsuri":"http://fasb.org/us-gaap/2024","localname":"WeightedAverageNumberOfSharesRestrictedStock","presentation":{"http://glucotrack.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative"},"lang":{"en-us":{"role":{"label":"Restricted shares"},"documentation":"Number of shares of restricted stock determined by relating the portion of time within a reporting period that restricted shares have been outstanding to the total time in that period. Restricted shares are subject to sales, contractual, regulatory or other restrictions that prevent or inhibit the holder from freely disposing of them before the restriction ends."}}},"auth_ref":{"r23"},"dei-WrittenCommunications":{"xbrltype":"booleanItem","nsuri":"http://xbrl.sec.gov/dei/2024","localname":"WrittenCommunications","presentation":{"http://glucotrack.com/role/Cover"},"lang":{"en-us":{"role":{"label":"Written Communications"},"documentation":"Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."}}},"auth_ref":{"r476"},"std_ref":{"r0"},"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Section":"25","Paragraph":"13","SubTopic":"10","Topic":"480","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147481766/480-10-15-13"},"r1":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Section":"45","Paragraph":"14","SubTopic":"230","Topic":"830","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147477401/830-230-45-1"},"r2":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Section":"45","Paragraph":"104","SubTopic":"10","Topic":"220","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147482790/220-10-45-10A"},"r3":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Section":"45","Paragraph":"10A","Subparagraph":"(a)","SubTopic":"10","Topic":"220","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147482790/220-10-45-10A"},"r4":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Section":"45","Paragraph":"14","Subparagraph":"(a)","SubTopic":"10","Topic":"230","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147482740/230-10-45-14"},"r5":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Section":"45","Paragraph":"28","Subparagraph":"(a)","SubTopic":"10","Topic":"230","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147482740/230-10-45-28"},"r6":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Section":"45","Paragraph":"28","Subparagraph":"(b)","SubTopic":"10","Topic":"230","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147482740/230-10-45-28"},"r7":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Section":"50","Paragraph":"14","SubTopic":"10","Topic":"360","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147482099/360-10-50-1"},"r8":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Section":"50","Paragraph":"14","Subparagraph":"(c)(3)","SubTopic":"10","Topic":"810","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147481203/810-10-50-1A"},"r9":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Section":"50","Paragraph":"1B","SubTopic":"10","Topic":"810","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147481203/810-10-50-1B"},"r10":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Section":"50","Paragraph":"2","SubTopic":"10","Topic":"505","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147481112/505-10-50-2"},"r11":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Section":"50","Paragraph":"2","SubTopic":"10","Topic":"815","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147480434/815-10-50-2"},"r12":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Section":"55","Paragraph":"15","SubTopic":"10","Topic":"220","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147482739/220-10-55-15"},"r13":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Section":"S99","Paragraph":"1","Subparagraph":"(SX 210.5-02(22))","SubTopic":"10","Topic":"210","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147480566/210-10-S99-1"},"r14":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Section":"45","Paragraph":"14","Subparagraph":"(a)","SubTopic":"10","Topic":"220","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147482790/220-10-45-14"},"r15":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Section":"220","SubTopic":"10","Section":"45","Paragraph":"14A","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147482790/220-10-45-14A"},"r16":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Section":"220","SubTopic":"10","Section":"45","Paragraph":"5","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147482790/220-10-45-5"},"r17":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Section":"230","SubTopic":"10","Section":"45","Paragraph":"14","Subparagraph":"(b)","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147482740/230-10-45-14"},"r18":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Section":"230","SubTopic":"10","Section":"45","Paragraph":"15","Subparagraph":"(c)","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147482740/230-10-45-15"},"r19":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Section":"230","SubTopic":"10","Section":"45","Paragraph":"4","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147482740/230-10-45-4"},"r20":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Section":"230","SubTopic":"10","Section":"50","Paragraph":"14","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147482913/230-10-50-1"},"r21":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Section":"230","SubTopic":"10","Section":"50","Paragraph":"3","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147482913/230-10-50-3"},"r22":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Section":"230","SubTopic":"10","Section":"50","Paragraph":"5","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147482913/230-10-50-5"},"r23":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Section":"260","SubTopic":"10","Section":"45","Paragraph":"13","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147482689/260-10-45-13"},"r24":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Section":"260","SubTopic":"10","Section":"50","Paragraph":"1","Subparagraph":"(c)","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147482662/260-10-50-1"},"r25":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Section":"260","SubTopic":"10","Section":"50","Paragraph":"2","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147482662/260-10-50-2"},"r26":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Section":"275","SubTopic":"10","Section":"50","Paragraph":"4","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147482661/275-10-50-4"},"r27":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Section":"275","SubTopic":"10","Section":"50","Paragraph":"8","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147482661/275-10-50-8"},"r28":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Section":"275","SubTopic":"10","Section":"50","Paragraph":"9","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147482661/275-10-50-9"},"r29":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Section":"360","SubTopic":"10","Section":"50","Paragraph":"1","Subparagraph":"(a)","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147482099/360-10-50-1"},"r30":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Section":"505","SubTopic":"10","Section":"50","Paragraph":"3","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147481112/505-10-50-3"},"r31":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Section":"718","SubTopic":"10","Section":"50","Paragraph":"2","Subparagraph":"(d)(1)","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147480429/718-10-50-2"},"r32":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Section":"805","SubTopic":"20","Section":"55","Paragraph":"31","Subparagraph":"(c)","Publisher":"FASB","URI":"https://asc.fasb.org/1943274/2147479876/805-20-55-31"},"r33":{"role":{"http://fasb.org/us-gaap/role/ref/legacyRef","Name":"Accounting Standards Codification","Section":"805","SubTopic":"30","Section":"2
```

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

```

http://www.xbrl.org/2003/role/exampleRef, "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103", "r438": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r439": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r440": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r441": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/214748006/944-40-55-29" }, "r442": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r443": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r444": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/214748006/944-40-55-29" }, "r445": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/214748007/944-80-55-14" }, "r446": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/214748007/944-80-55-9" }, "r447": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-4" }, "r448": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r449": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-4" }, "r450": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1(a)))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r454": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r455": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r456": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r457": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/194
```

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

QZBL1..TOZ>WGGFVJ(C)~?#4IQ/CK~#KJLJL?~M~JW7~K%7LNEJUVU..JLJE9KM~1MK75M~^L(CUR~P8..HIA..9:K11~KJ8?~JEL~6UI:HB..MPUJ?~+?EQUGJ#~:~
~5L~5G~9L~U~&A~Y1FX~(C~>48J?~?GJHK..3%~M~RKY>M8~V~J~MUXP10R?5~1~%HIA?~L~T0SKM~^~DE~#Z?~PM~+EPX~MBS..PH..0~
~8V?~CJ~2~H~&~4~E~H~106K~5~P~G~H~6U~L~T~Z~T~D~BNKYQ~P~H~G~U~C~F~Z~9~I~W~3K~G~N~D~H~O~A~T~0~76~G~P~G~2..R0~>~M~^~Y~Y~&~M~X~U~L~P~H~F~U~H~O~Y~B~L~R~D~Q~A~
~M~M~V~U~?~Q~S~B~>~+~X~H~R~M~7~>H~7~C~H~3~?~(Z~Y89V~G~G~E~I~B~3~&~L~E~X~I~(Z~M~7~4~3~>~&~1~F~D~N~2~7~G~(C~C~>M~B~S~D~9~7~>~T~F~H~3~Y~P~P~&~&~
(RV..6B~(UK?~(O~I~L~K~M~I~V~Z~C~2~63S..CUC~&~W~M~M~8~5~X~T~P~&~G~&~A~+~I~N~&~W~C~D~Y~O~D~I~G~W~Y~F~L~?~I~OC~M~R~Y>~2~S~(Z~Y~U~H~I~K~X~&~D~M~>~X~Z~M~F~O~I~J~X~W~S~|~T~M~N~H~O~>~
<~%~V~I~.58~7~I~+~A~4~3~V~R~>~?~Y~5~C~U~5~Z~O~A~I~&~O~I~N~U~&~R~4~S~8~V~>~%~V~G~M~7~I~G~M~C~N~3~8~X~>~(Z~I~V~L~2~H~N~I~4~>~&~T~G~>~5~\$~L~M~I~>~D~#~>~2~E~\$~Z~>~%~+~6~U~
M~O~>~D~I~+~E~I~U~5~M~E~W~S~2~6~G~9~K~O~>~&~J~4~5~D~>~I~W~+~Z~D~>~>~&~&~A~H~B~I~7~L~M~&~F~R~I~F~?~(T~H~D~>~2~G~M~&~I~D~B~R~T~D~I~6~I~F~O~S~C~>~>~2~P~O~6~5~U~>~2~S~V~I~+~B~S~R~
M~2~3~O~H~S~G~H~G~T~P~>~I~X~F~U~M~&~O~C~O~I~G~O~J~O~S~C~>~O~R~N~K~J~2~8~J~3~6~X~>~&~&~&~M~K~D~F~2~I~D~Z~M~W~B~Z~A~H~N~I~9~>~I~J~3~9~I~5~(Z~T~H~D~>~6~F~T~7~\$~X~4~7~>~S~R~M~V~4~+~Y~>~\$~2~B~>~
%~P~V~5~3~(R~I~S~I~>~R~P~O~>~I~F~I~F~I~U~&~U~C~>~V~5~2~&~I~S~G~>~N~P~>~F~M~P~2~G~I~7~>~O~P~M~K~T~I~N~>~H~O~J~D~P~Z~S~&~I~N~9~>~A~J~S~>~A~>~I~>~&~6~W~N~I~B~D~>~U~B~W~I~O~5~I~4~
M~/M~W~M~>~X~F~Y~>~I~>~L~S~K~H~3~P~D~N~&~P~Y~S~>Q~W~S~Z~B~M~>P~6~D~X~I~(5~>~T~I~F~I~Y~T~B~>~M~S~E~F~2~O~W~N~L~Z~M~P~>~6~O~I~K~7~9~M~I~V~>~6~O~T~>~H~O~S~B~O~2~A~>~5~V~W~>~&~R~>~G~C~Y~R~6~(H~I~F~C~O~?~I~K~
M~6~>~3~S~O~E~X~R~>~5~M~S~Y~I~Z~A~R~O~>~3~C~X~5~L~N~G~U~S~I~G~P~Z~W~K~O~M~Z~W~>~I~R~C~I~>~>~G~I~>~I~Y~Z~E~V~I~>~Z~I~G~O~>~%~K~O~>~X~W~R~L~U~>~C~Z~W~I~Z~A~Z~O~N~S~2~R~>~I~M~E~M~B~S~C~O~I~K~Z~U~I~N~W~>~
6~Y~S~Y~8~+~U~K~?~Q~X~O~S~>~I~S~M~9~U~5~+~H~Y~E~U~J~E~>~I~O~I~9~B~U~>~T~I~M~P~5~E~>~T~A~H~7~I~J~W~I~N~9~3~M~J~Z~Y~I~>~N~G~O~>~I~>~I~N~H~I~N~E~H~F~X~?~I~6~V~T~>~O~>~I~>~K~O~>~M~N~T~>~E~T~&~L~A~E~9~H~2~I~W~>~I~>~V~T~>~>~Z~>~>~
I~>~3~K~O~>~O~O~W~N~I~>~%~G~I~>~6~#~>~O~9~W~>~W~>~M~O~#~B~I~K~X~6~N~P~>~5~P~7~>~O~>~D~R~U~A~>~I~V~T~W~I~N~J~>~B~6~S~>~A~L~S~H~P~S~W~N~E~3~K~I~V~W~S~>~>~&~O~>~
M~2~>~W~V~D~I~2~8~I~5~N~P~E~I~C~M~R~>~>~I~R~W~>~O~W~L~%~V~K~I~?~>~Y~>~>~I~D~>~5~O~O~P~>~#~F~X~W~M~I~E~>~S~>~6~W~Y~K~>~O~P~L~M~F~E~S~>~I~X~I~L~W~O~W~Z~I~5~N~K~O~>~N~W~>~6~O~X~6~I~>~G~W~>~9~>~T~E~M~
M~7~M~W~M~>~>~M~>~Q~I~>~6~>~?~>~V~5~>~I~O~>~6~B~Y~M~I~Z~O~2~O~P~X~S~>M~N~I~A~I~>~P~>N~C~5~>~I~W~I~O~I~M~I~F~I~W~I~O~>~I~Z~>~I~8~X~>~I~H~>~5~S~3~>~V~R~K~O~I~5~R~I~I~>~I~>~5~2~>~S~M~J~N~I~>~I~X~W~U~X~F~N~I~>~M~>~O~W~>~M~J~
M~>~W~>~X~>~7~6~T~O~>~H~W~T~>~9~F~8~I~V~I~>~U~P~W~O~H~E~>~S~Q~W~4~Z~X~W~K~M~O~>~I~V~N~E~I~>~I~>~M~N~I~&~K~>~Z~I~3~>~O~T~V~>~A~I~H~V~O~>~>~>~I~W~I~G~>~I~W~4~Z~3~G~K~G~>~T~U~J~S~>~>~I~4~L~G~G~N~>~A~G~%~L~6~>~>~M~%?~
>~>~O~Z~I~A~>~6~2~6~T~O~>~Z~Y~N~>~V~N~%~I~Z~I~V~>~>~>~P~G~I~B~>~T~I~E~K~>~X~N~2~A~>~M~R~N~M~2~6~C~F~K~I~G~5~I~N~Y~>~C~>~I~>~7~I~>~C~I~V~I~>~M~G~I~K~>~U~5~2~N~O~>~U~E~P~T~I~O~>~H~W~Z~>~E~P~M~7~I~M~>~V~Y~>~>~
X~S~9~O~V~R~>~7~>~9~N~>~D~>~I~O~36~>~>~E~>~H~I~>~I~>~>~X~4~I~?~>~W~>~V~Y~T~>~C~G~H~>~>~>~V~O~M~>~>~S~L~>~8~X~E~W~>~G~I~7~N~I~5~P~R~O~>~M~W~I~R~I~G~C~I~N~G~>~#~>~R~5~K~A~9~I~O~>~X~>~I~>~O~K~I~Y~N~>~Z~I~>~E~>~6~V~?~
>~>~6~2~>~I~O~>~Q~D~Z~I~>~>~U~M~V~>~O~>~W~>~Y~K~>~7~>~I~>~Y~K~O~N~E~>~W~I~T~Y~C~W~O~9~W~K~F~I~Z~>~I~U~K~>~K~H~K~>~>~I~P~>~>~>~I~4~B~Z~G~L~M~I~>~I~>~W~L~W~>~>~7~I~6~I~T~O~V~W~K~9~T~L~5~M~Z~R~9~B~I~>~I~>~4~?~>~A~2~>~I~V~>~>~S~8~B~R~?~
U~>~S~>~>~>~I~O~V~>~I~R~G

!BHJL<\$3PG>Q=4J<551Y,8EUA+VVM*249M, RNT0*B8-YU*27=>EK8B0 ML/>@SQ0-1\$W51<43+Q+08X*VC0HII, PC 03<K&>EXIN*1=HLW4-I@%#Q M/H;U,2,9-22
!B%7N%K<HUT>M<2>171C!#6,2J(OJ7UV@Q8L)3G,PIYU MK4LL,U3\$NT,23<&XKFC@IHL7*ENKIDJ3YNJ,":KJ-26%Q<""763YNPJ+SIKU" M8=+M13(4+3+K0C2@)
!QMYY1*6W<=>R8=>06Y91C!>FP0XMSXSNP6A(I,M9-U)H6NN1KXRO+IE 84-S+KBB%R",":KJ-W99,U,D6-A3U(I3BFE&MFTFD1@IPLVD@ FE6HJ,CL&H<=<
<1\$5>Y<X&T129R!>M599&03#<72,3-L 0%>+P/H#<=>LXLOK@<""S05>+H,":N2!>W\$VQYOT,M6+VLF65M6*ABHJ>Z,K/M
SB=>U)0%&A14!<G702-N&A*G702!L!P5+3,":M80%<K&4\$ND8R2!<1-2%>DJ!<=>8,J5A!<MSCI26I+GJXINZ!>+J!<07A1ZDV<IVB?>+YUX9T%0,5Y,C7H6Z7H!>=J
M<K!<WSDC,UEEGIDIGRNP23I3FB&+I2G6S2<3M!<Q&L%\$<D,W<JYQLO0%2YGM6GAD&@WO%>+G'KJ!<6@!<2PFEE0YK<@%K3R!<YD<=>5Y,C!<FF5ZH?M2&Q/D?I
!C95U+YJYTK97EHPN3(3%<H!<UEF&2=>+A!<39+<+<1,":0X5AS&B8 MCTP!<P@CXI\$>+F!<+K,":A6ZD9L&H(HUO2Y"3A38)169*4GLP+J!<M?D?>R>=>+WM=>
!OX<+!<+L,":70LE,":22VY<+L,":34K,OBQVYV M&D?<ISR,0A:J\$1+5 5HGR<HBU?XHW,":A10H,":J&KMHU,M!<IDP,V,5%JGT@<M&=>#R0?I
?<SFKOJ1U+I,":TEDEE1NHG@<+L<M!<P&X/F?<7ILLRSK&54WG<H<+4!<B%<SZ!<=>6Q2T,50I!<7N059UG!<P,":MAZHC!<7L+675TF@<40!<I7K7HTFL!<HFEG<+L
Z=>=>0!<0T?<G&(<C02&K MIE,Y+HUFK!<I?<F&K2&S774=>+<1W<S,":(9/23I5M0<=<7R2&50I!<7L+<H!<M!<V9!<B015R-W!<9"3!<M!<U!<=>S1,B,7?<M
!<8!<C77,4Y,":NM,WM,WM,WM,WZ!<B=>+JN!<V&A0H!<=>E!<A=>T(H,MOI,IR2R1X!<F+H!<H1PC&4!<=>B4N,":W(H!<A!<=>#E<44 MUO2<=>97!<4!<C^<N!<D!<P!<M&R\$<=>+<R/ZTO-
<=>BB-W<Y,":758Y<=>DUIM?<H<4Y<=>M&DPRB<@<(<U,":0<=>47Z<U,":47&M<?<C<7+V3BKFTMVSE+V05Z,90>H<K-Y2EG<=<K9G<V!<YS
*6=>SRMF<=>LMO<0=>8H0N<8%<IAZ\$<=>#<G,":H27&6-9?<7,":M!<M!<C4JD3<=<+<QUYK<=>#<61VY>9#<R<H<=>H!<=<F<N<=>FIABNH87!<2AL M\$<=>U<H!<4,7,N2#<X!
(<=>F?<D?<T<ANM!<5NP<=>FURJ@<0P!<5I!<VQ2U9Q&H MMZ3&E!<G&E,N94D&B%<BRYG3!<+7K<=>3BIEG!<H!<=>Z(9V!<I7X020<D<=<X!<M!<M4R05!<9S<=<+!<U<KHP0<I
(<=>S&E<=>ELP<N&SFTUO!<7&S<=<8<=>+<V<R>Z<=>I!<MS<(<1P9I!<I!<2 6IP<@<=>+<4/956&80<=>J!<U8!<B03Z!<147UVY!<10A!<+T?<OR0S!<I M-V,":V15!<UE7&SBAV0
!<=>F!<F!<U!<V!<XZ?<R!<=<+5Z3<KX01<=>+P=>=>X,M!<I7<6!<ZCF,6WMOOR!<N-R!<8&GJKA!<2&9I,3IV<=>4HY8ZD?<=>+H<K<K,P,M,":B!<9!<29EAN<=>YUH>+JNZSV!<X&B<=>
!<GG!<F!<F!<B!<F!<JH!<NKP20<B4<0A3!<L M!<=>H!<V!<V8Z87@<=>+IOOH!<F4B>=>9,9D2!<=>H!<EN,":0G<=>GM>ZZQ<4A<=>ZP8KME<=>Y(SG9 M2CHNWK&XB>+A*RU>+<@E?<=>
EG,":H6=>=>F!<D&K,":A5!<74&K<=>+H!<6!<D!<U!<V!<V8V!<M3R<K!<GU5HS!<F&SWK,2YK!<J!<U>+X!<=>F!<2W!<69EW<A>N,":5!<K!<R3E!<P!<E2!<M!<C!<N!<D&C5!<14V!<M!<N&Q&D!<L?<=>
+<A!<+!<F!<V!<2!<D!<F!<3,":G!<4!<W!<24 AUCW&B?<F M<C!<=>U&B!<X!<M!<=>B?<75F!<U,":0<X!<N!<R?<=>+<P!<X!<T,":5!<5<=>K<=>H6,8!<I0<4!<24RM,":K!<+V!<N!<4K0!<=>+!<U,":2,":N<=>5RZ<3(C!<UE!<+!<=<1!
!<4=>=>M3C2!<D!<D!<F!<1+X!<7C4!<P!<35!<R!<J!<D!<=>+!<6!<5<=>5,":2A&S,":3JH PR3<=<+!<U!<T!<R!<F!<J!<N!<G,":<A!<AGG\$<S!<0ZHBZ?<=>7!<=>+G87&B<=>P5K!<40E60Z!<M!<=>+M,":60 M0&#<=>
!<H!<G!<Y,ERIN,":H!<M,":6<=>6!<P!<=>=>+H!<S!<O!<7H!<T!<H!<1W&X0!<+!<=>H!<F!<B4 MMT!<=>+A!<=>X!<=>C!<Q!<07RE,M!<Y!<MPQ,":6!<S!<J!<U!<5!<OZC!<U,":165D2!<4D&3!<FGH!<=>
=>O!<F!<X!<=>+S!<T!<3!<A!<A!<Y!<4&S8!<=>M!<RCSH!<H!<U!<V!<70X&R,":B,WD<+B&C!<6!<M!<=>+J!<G!<A!<17R&A!<H!<C!<=>+!<Z!<W,":<Y!<Y!<M!<=>H!<PK!<E!<F!<V!<E!<=>+!<C!<=>+!<72=>=>6WV!<=>
!<S,":ZB8U!<ZBU+MFTS0",":M5P!<U!<M!<D?<6"JS9Z!<@<=>+!<M!<16P,":4!<J!<F!<N!<P!<B!<6 M!<=>6L=>Q!<S!<W!<T!<N02!<H!<LO!<KZOP?<WH?<Z!<I?<=>
M6<=>8X<=>S,":M!<5!<M!<P!<M!<C!<4!<1!<O!<B,":B!<W08!<IE!<F!<M,":7!<+>Q?<=>+!<U!<G!<B!<Q!<LSS!<22Q!<Q!<W!<E!<M!<N!<X!<F!<S!<

[illegible]

[illegible]

[illegible]

Use of Estimates—The accompanying unaudited condensed interim consolidated financial statements and related notes should be read in conjunction with the Company's consolidated financial statements and related notes included in the Company's annual report on Form 10-K for the fiscal year ended December 31, 2023, as was filed with the Securities and Exchange Commission ("SEC") on March 28, 2024. The unaudited condensed interim consolidated financial statements have been prepared in accordance with the rules and regulations of the SEC related to interim financial statements. As permitted under those rules, certain information and footnote disclosures normally required or included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The financial information contained herein is unaudited; however, management believes all adjustments have been made that are considered necessary to present fairly the results of the Company's financial position and operating results for the interim periods. All such adjustments are of a normal recurring nature.

The results for the period of three and nine months ended September 30, 2024 are not necessarily indicative of the results to be expected for the year ending December 31, 2024 or for any other interim period or for any future period.

Use of Estimates in the Preparation of Financial Statements—The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts of expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these interim financial statements, the most significant estimates and assumptions include identification and measurement of financial instruments.

Principles of Consolidation—The consolidated interim consolidated financial statements include the accounts of the Company and its subsidiary. Significant intercompany balances and transactions have been eliminated in consolidation.

Cash and Cash Equivalents—Cash and cash equivalents include identification and measurement of financial instruments.

Modification of equity-classified contracts—The modification or exchange of equity-classified contracts, such as warrants that were classified as equity before the modification or exchange and remained eligible for equity classification after the modification, is accounted for in a similar manner to a modification of stock-based compensation. Accordingly, the incremental fair value from the modification or exchange (the change in the fair value of the instrument before and after the modification or exchange) is recognized as a reduction of retained earnings of increase of accumulated deficit as a deemed dividend. Modifications or exchanges that result in a decrease in the fair value of an equity-classified share-based payment awards are not recognized. In addition, the amount of the deemed dividend is also recognized as an adjustment to earnings available to common shareholders for purposes of calculating earnings per share.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)—(in thousands of US Dollars)

NOTE 2—SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)

Convertible Promissory Notes—Upon initial recognition of convertible promissory notes and similar instruments, the Company considers the provisions of ASC 815-40, "Derivatives and Hedging—Contracts in Entity's Own Equity" ("ASC 815-40") in order to determine whether the conversion features embedded within the convertible instrument should be separated from the host instrument.

When it is determined that an embedded conversion feature qualifies for equity classification (such when the embedded conversion option, if it were freestanding, is not qualified as a derivative in accordance with the provisions of ASC 815-10, "Derivatives and Hedging" since its terms did not require or permit net settlement or when the embedded conversion option is indexed to the entity's own stock), the conversion option is not bifurcated. When bifurcation is not required, the Company considers whether the debt instrument involves a significant premium (i.e. when the proceeds received or allocated upon issuance exceed the principal amount that will be paid at maturity). When it is determined that a substantial premium exists, the entire premium is allocated to paid-in capital and when it is determined, otherwise no additional accounting is required and the convertible promissory note is accounted for at amortized cost using effective interest method over the term of the note until its stated maturity.

Allocation of proceeds and related issuance costs—When multiple instruments are issued in a single transaction (package issuance), the total net proceeds from the transaction are allocated among the individual freestanding instruments identified. The

allocation occurs after identifying all freestanding instruments and the subsequent measurement basis for those instruments.

Financial instruments that are required to be subsequently measured at fair value (such as derivative liabilities) are measured at fair value and the remaining consideration is allocated to other financial instruments that are not required to be subsequently measured at fair value (such as liabilities measured at amortized cost, common shares and warrants eligible for equity classification), based on the relative fair value basis for such instruments.

GLUCOTRACK INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

(in thousands of US Dollars)

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)

Warrants

Certain warrants that were issued to several holders are classified as a component of permanent equity since they are freestanding financial instruments that are legally detachable and separately exercisable, do not embody an obligation for the Company to repurchase its own shares, and permit the holders to receive a fixed number of Ordinary Shares upon exercise for a fixed exercise price and thus, are considered as indexed to the Company's own shares. As such warrants were issued together with financial instruments that are not subsequently measured at fair value and the warrants were measured based on allocation of the proceeds received by the Company in accordance with the relative fair value basis. When applicable, direct issuance expenses that were allocated to certain warrants were deducted from additional paid-in capital.

Leases

Right of Use ("ROU") assets and liabilities are recognized on the commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company's leases do not provide an implicit rate, the Company uses its Incremental Borrowing Rate ("IBR") based on the information available on the commencement date in determining the present value of lease payments. The Company's IBR is estimated to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic environments where the leased asset is located. The ROU asset also includes any lease payments made prior to commencement and is recorded net of any lease incentives received. Moreover, the ROU asset may also include initial direct costs, which are incremental costs of a lease that would not have been incurred if the lease had not been obtained. The Company uses the long-lived assets impairment guidance in ASC 360-10, "Property, Plant, and Equipment - Overall", to determine whether a ROU asset is impaired, and if so, the amount of the impairment loss to recognize. Certain leases include options to extend or terminate the lease. An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain that the Company will exercise that option. An option to terminate is considered unless it is reasonably certain that the Company will not exercise the option.

GLUCOTRACK INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

(in thousands of US Dollars)

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)

Earnings Per Share

Basic and diluted loss per share

Basic loss per share is computed by dividing the loss for the period applicable (after considering the effect of deemed dividend related to trigger of down round protection feature) for Common Stockholders by the weighted average number of shares of Common Stock outstanding and shares of Common Stock to be issued upon achievement of certain performance milestones during the period.

background-color: white

and upon exercise of pre-funded warrants. In computing, diluted loss per share, basic earnings per share are adjusted to reflect the potential dilution that could occur upon the exercise of options or warrants issued or granted using the "treasury stock method" and using the if-converted method with respect to certain convertible promissory notes and bifurcated redemption feature accounted for as derivative financial liability, if the effect of each of such financial instruments is dilutive. In computing diluted loss per share, the average stock price for the period is used in determining the number of Common Stock assumed to be purchased from the proceeds to be received from the exercise of stock options or stock warrants.

SCHEDULE OF ANTIDILUTIVE NET LOSS AND WEIGHTED AVERAGE

US dollars (except share data)

US dollars (except share data)

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Ending balance</td><td style="padding-bottom: 2.5pt)></td>
<td style="border-bottom: Black 2.5pt double;text-align:left">\$</td><td style="border-bottom: Black 2.5pt double;text-align:right">264</td><td style="padding-
bottom: 2.5pt;text-align:left"></td></tr></table> 3600005000_10100026400040000000.00(ii) 12 months anniversary of July 30 Note, or (ii) closing date of a Sale
Transaction (defined below) (the “Maturity Date”)(i) is convertible at the discretion of the July 30 Holder at a price equal to the closing price of the Common Stock on the
date of conversion and, (ii) if the Closing Price of the Common stock exceeds \$5.00 per share for a period of 5 consecutive trading days, will automatically convert at a
price equal to the 5 daily Volume Weighted Average Price (“VWAP”) of the Common Stock (subject to adjustment for any stock split, stock dividend, reverse stock split,
combination or similar transaction).5.00(i) cash equal to 200% of the Note balance, or (ii) transaction consideration in the amount to be received by the Holder in such
Sale Transaction if the July 30 Note was converted pursuant to an optional conversion.“Sale Transaction” means a merger or consolidation of the Company with or into
any other entity, or a sale of all or substantially all of the Company’s assets, or any other transaction or series of related transactions in which the Company’s stockholders
immediately prior to such transaction(s) receive cash, securities or other property in exchange for their shares and, immediately after such transaction(s), own less than
50% of the equity securities of the surviving corporation or its parent.(i) failure by the Company to pay the July 30 Note balance on the Maturity Date, (ii) the Company
becomes subject to a judgement of more than \$50,000, (iii) voluntary bankruptcy, or (iv) involuntary bankruptcy.Upon the occurrence of an Event of Default specified in
clause (iii) above, the July 30 Note balance shall automatically and immediately become due and payable, in all cases without any action on the part of the July 30
Holder.50000000P10Y21333341.87515238102.62511851863.3752145000025500000.28651.2280.0478350001415000 <p id=“xdx_898_ecustom--
ScheduleOfReconciliationOffCarryingAmountOfNotesTableTextBlock_hus_gaap--StatementEquityComponentsAxis_custom_JulyThirteenNotesMember_zYCOP3ckmT7h”
style=“font: 10pt Times New Roman, Times, Serif;margin: 0pt;text-align: justify”><span
style=“font-family: Times New Roman, Times, Serif;font-size: 10pt”>SCHEDULE OF RECONCILIATION
OF THE CARRYING AMOUNT OF JULY 30 NOTES</p><table cellpadding=“0” cellspacing=“0” style=“font: 10pt Times New Roman,
Times, Serif;border-collapse: collapse;width: 93%;margin-left: 0.5in”><tr style=“vertical-align: bottom”><td></td><td style=“font-weight: bold;padding-bottom:
1pt”></td><td colspan=“2” id=“xdx_493_20240101_20240930_us-gaap--StatementEquityComponentsAxis_custom-JulyThirtyNotesMember_zdScKnDfucKZ”
style=“border-bottom: Black 1pt solid;font-weight: bold;text-align:center”>Nine-month period ended
September 30, 2024</td><td style=“padding-bottom: 1pt;
font-weight: bold”></td></tr><tr style=“vertical-align: bottom”><td></td><td style=“font-weight: bold;padding-bottom: 1pt”></td><td colspan=“2” style=“border-
bottom: Black 1pt solid;font-weight: bold;text-align:center”(Unaudited)</td><td style=“padding-bottom: 1pt;font-weight: bold”></td></tr><tr style=“vertical-align:
bottom”><td></td><td></td><td colspan=“2” style=“text-align:center”></td></td></tr><tr id=“xdx_408_eus-gaap-ConvertibleDebt_iS_pn3n3_z5ZmxnOzkuZ”
style=“vertical-align: bottom;background-color: rgb(204,238,255)”><td style=“text-align:left”>Open balance</td><td></td><td style=“text-align:left”>\$</td><td></td><td style=“text-align:right”></td></tr><tr id=“xdx_400_eus-gaap--
ProceedsFromIssuanceOfDebt_pn3n3_zF8inGKRWPb” style=“vertical-align: bottom;background-color: White”><td style=“width: 80%;text-align:left”>Total proceeds
received</td><td style=“width: 2%”></td><td style=“width: 1%”;text-align:left”></td><td style=“width: 16%;text-align:right”>4,000</td><td style=“width: 1%;text-al-
ign:left”></td></tr><tr id=“xdx_401_eus-GAAP-FairValueAdjustmentOfWarrants_pn3n3_zqFWVLlIyTe” style=“vertical-align: bottom;background-color:
rgb(204,238,255)”><td style=“text-align:left”>Total proceeds allocated to July 30 Warrants at initial recognition</td><td></td><td style=“text-align:left”></td><td></td><td style=“text-align:right”>(2,550</td><td style=“text-align:left”></td></tr><tr id=“xdx_407_eus-gaap--
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_pn3n3_zvB2Po9ffcc” style=“vertical-align: bottom;background-color: White”><td style=“text-align:left”>Total
proceeds allocated to embedded redemption feature at initial recognition</td><td></td><td style=“text-align:left”></td><td style=“text-align:right”>(35</td><td></td><td style=“text-align:left”></td></tr><tr id=“xdx_404_ecustom-DiscoutAmortizationAndInterestExpenses_pn3n3_zWiPtRHKbZxf” style=“vertical-align: bottom;
background-color: rgb(204,238,255)”><td style=“text-align:left;padding-bottom: 1pt”>Amortization of discount and interest expenses related to July 30 Note (Note 5
below)</td><td style=“padding-bottom: 1pt”></td><td style=“border-bottom: Black 1pt solid;text-align:left”></td><td style=“border-bottom: Black 1pt solid;text-
align:right”>309</td><td style=“padding-bottom: 1pt;text-align:left”></td></tr><tr id=“xdx_402_eus-gaap-ConvertibleDebt_iE_pn3n3_zC5jf7GSR526”
style=“vertical-align: bottom;background-color: White”><td style=“padding-bottom: 2.5pt”><span style=“display: none;font-family: Times New Roman, Times, Serif;
font-size: 10pt”>Ending balance</td><td style=“padding-bottom: 2.5pt”></td><td style=“border-bottom: Black 2.5pt double;text-align:left”>\$</td><td></td><td style=“border-bottom: Black 2.5pt double;text-align:right”>1,724</td><td style=“padding-bottom: 2.5pt;text-align:left”></td></tr></table> 3600002550000_
3500030990001724000 <p id=“x dx_89F_ecustom--ScheduleOfReconciliationOffFairValueOfEmbeddedConversionFeatureTableTextBlock_zXF9TFc66BgQ” style=“font: 10pt
Times New Roman, Times, Serif;margin: 0pt 0pt 0pt 0.5in;text-align: justify”>The following
tabular presentation reflects the reconciliation of the fair value of the embedded conversion feature and embedded redemption feature during the period of nine months
ended September 30, 2024.</p><p style=“font: 10pt Times New Roman, Times, Serif;margin: 0pt;text-align: justify”><span style=“font-family: Times New
Roman, Times, Serif;font-size: 10pt”>SCHEDULE OF RECONCILIATION OF FAIR VALUE OF EMBEDDED
CONVERSION FEATURE</p><table cellpadding=“0” cellspacing=“0” style=“font: 10pt Times New Roman, Times, Serif;border-collapse: collapse;width:
93%;margin-left: 0.5in”><tr style=“vertical-align: bottom”><td></td><td style=“font-weight: bold;padding-bottom: 1pt”></td><td colspan=“2”
id=“xdx_49F_20240101_20240930_zt5N59dkXs8” style=“border-bottom: Black 1pt solid;font-weight: bold;text-align:center”>Nine-month period ended

September 30, 2024</td><td style=“padding-bottom: 1pt;font-weight: bold”></td></tr><tr style=“vertical-align: bottom”><td></td><td style=“font-weight: bold;
padding-bottom: 1pt”></td><td colspan=“2” style=“border-bottom: Black 1pt solid;font-weight: bold;text-align:center”(Unaudited)</td><td style=“padding-bottom:
1pt;font-weight: bold”></td></tr><tr style=“vertical-align: bottom”><td></td><td></td><td colspan=“2” style=“text-align:center”></td></td></tr><tr id=“xdx_403_eus-gaap-DerivativeLiabilities_iS_zozdHfaCn3yp4” style=“vertical-align: bottom;background-color: rgb(204,238,255)”><td style=“text-align:left”>Open
balance</td><td></td><td style=“text-align:left”>\$</td><td></td><td style=“text-align:right”></td></tr><tr id=“xdx_40E_eus-gaap-EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet_pn3n3_zP200s6gmurD” style=“vertical-align:
bottom;background-color: White”><td style=“width: 80%;text-align:left”>Proceeds allocated to embedded redemption feature at initial recognition</td><td></td><td style=“width: 2%”></td><td style=“width: 1%;text-align:left”></td><td style=“width: 16%;text-align:right”>35</td><td style=“width: 1%;text-align:left”></td></tr><tr id=“xdx_40B_ecustom-RevaluationExpensesRelatedToEmbeddedRedemptionFeature_pn3n3_zihVxNPa8Od1” style=“vertical-align: bottom;background-color:
gb(204,238,255)”><td style=“text-align:left;padding-bottom: 1pt”>Revaluation expenses related to embedded redemption feature (Note 5 below)</td><td style=“padding-bottom: 1pt”></td><td style=“border-bottom: Black 1pt solid;text-align:left”></td><td style=“border-bottom: Black 1pt solid;text-align:
right”>2</td><td style=“padding-bottom: 1pt;text-align:left”></td></tr><tr id=“xdx_40L_eus-gaap-DerivativeLiabilities_iE_zkchStUzvHMV1” style=“vertical-align:
bottom;background-color: White”><td style=“padding-bottom: 2.5pt”>Ending
balance</td><td style=“padding-bottom: 2.5pt”></td><td style=“border-bottom: Black 2.5pt double;text-align:left”>\$</td><td></td><td style=“border-bottom: Black
2.5pt double;text-align:right”>37</td><td style=“padding-bottom: 2.5

[illegible]

[illegible]

SubsequentEventMember_us-gaap--StatementClassOfStockAxis_custom--PrefundedWarrantsMember_zzpcZaXFd25" title="Shares issued, per share">1.39, and the public offering price for each Pre-Funded Warrant and accompanying Common Warrants was \$1.389 (the "Offering Price").</p><p style="font: 10pt Times New Roman, Times, Serif; font-size: 10pt"></p><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify">The Pre-Funded Warrants have an exercise price of \$0.001 per share, are exercisable immediately and expire when exercised in full. Each Series A Common Warrant will have an exercise price per share of \$1.81 and will be exercisable beginning on the date on which Stockholder Approval (as defined below) is received and deemed effective (the "Initial Exercise Date" or the "Stockholder Approval Date"). The Series A Warrants will expire on the five-year anniversary of the Initial Exercise Date. The Series B Warrants will have an exercise price per share of \$1.81 and will be exercisable beginning on the Initial Exercise Date. The Series B Warrants will expire on the two and one-half year anniversary of the Initial Exercise Date. The issuance of Common Warrant Shares upon exercise of the Common Warrants is subject to stockholder approval under applicable rules and regulations of The Nasdaq Stock Market LLC ("Nasdaq") ("Stockholder Approval" and the date on which Stockholder Approval is received and deemed effective, the "Stockholder Approval Date").</p><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify">The exercise price of Series A Warrants and Series B Warrants is subject to certain adjustments. If at the time of exercise there is no effective registration statement registering, or the prospectus contained therein is not available for the issuance of the Series A Warrants Shares and Series B Warrant Shares to the holders, then the Series A Warrants and Series B Warrants may also be exercised, in whole or in part, at such time by means of a "cashless exercise". In addition, the holders are entitled to an option to require the Company to purchase the Series A Warrants and Series B Warrants for cash in an amount equal to their Black-Scholes Option Pricing Model value, in the event that certain fundamental transactions (which some of them are not considered solely within the control of the Company) as defined in the Series B Warrants agreement, occur. Additionally, holders of Series B Warrants may also effect an "alternative cashless exercise" at any time while the Series B Warrants are outstanding following the Initial Exercise Date. Under the alternate cashless exercise option, the holder of the Series B Warrant has the right to receive an aggregate number of shares equal to the product of (i) the aggregate number of shares of Common Stock that would be issuable upon a cashless exercise of the Series B Warrant and (ii) 3.0.</p><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify">Total incremental and direct issuance costs are estimated at the total amount of \$1.127.</p><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify">The closing of the public offering occurred on November 14, 2024 (the "Closing Date").</p><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin: 0pt 0pt 0pt 0.5in; text-align: justify">In a private placement offering completed concurrently with the completion of the public offering, the July 30 Investor voluntarily converted approximately \$4,089 of Debt, which represents the outstanding minimal amount of principal and accrued interest under the July 30 Note as of November 12, 2024, on substantially the same terms as the public offering, resulting in the issuance of 2,640,717 shares of Common Stock (plus 2,640,717 accompanying Series A Warrants and 2,640,717 accompanying Series B Common Warrants), based on a conversion price of \$1.55 per share.</p><p>10000000243734047569004756900719424071942401.391.3890.0011.811.811127000408900002640717264071726407171.55 Represents amount lower than \$1.